Conditional T and NK cell antagonism by a giant and highly conserved orthopoxvirus virulence factor

Conditional T and NK cell antagonism by a giant and highly conserved orthopoxvirus virulence factor | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Conditional T and NK cell antagonism by a giant and highly conserved orthopoxvirus virulence factor Laurence Eisenlohr, Stephen Carro, Emma Hedgepeth, Candy Lucero-Sanchez, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8672980/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Orthopoxviruses, including variola and monkeypox, have long ravaged human populations for reasons that remain unclear. Members of the highly conserved B22 protein family are notable for their extreme virulence via targeting of multiple host defenses. C15, the B22 protein of ectromelia (murine model for smallpox), is known to target NK cells and CD4+ T cells, and, as shown here, also CD8+ T cells. Unexpectedly, in C57Bl/6 mice, T cell responses were larger, more functional, and phenotypically enhanced in the face of C15 expression. cDC1-mediated cross-presentation contributed to enhanced CD8+ T cell responses, but the primary contributor was C15-mediated antagonism of NK cell-dependent viral control, and single cell analysis identified a potential signaling scaffold downstream of C15 inhibitory activity. Conversely, in BALB/c mice, which mount suboptimal NK cell responses, T cells were more prominently inhibited. These studies introduce the concept of conditional immunomodulation dictated by the immunocompetence profile of the host. Biological sciences/Microbiology/Virology/Pox virus Biological sciences/Immunology/Infectious diseases/Viral infection Biological sciences/Immunology/Adaptive immunity/Cellular immunity Biological sciences/Immunology/Lymphocytes/NK cells Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Main Orthopoxviruses (OPXVs) are a genus of mammalian-tropic viruses that exhibit a broad host range, induce severe pathology, and are a significant public health burden 1 , 2 . Although the most prominent OPXV, variola (the causative agent of smallpox), was eradicated in 1980, the global human-to-human spread of mpox (MPXV) 3 as well as the emergence of novel OPXV species 4 – 6 highlight the substantial risk OPXVs continue to pose to the general population. Furthermore, the 2022-23 outbreak of Clade IIB mpox revealed significant limitations of current anti-OPXV therapeutics, including sub-optimal vaccine efficacy 7 – 10 and ineffectiveness of current FDA-approved antivirals 11 – 14 . Generally, OPXV virulence is attributed to the abundant immunomodulatory proteins encoded within their genomes, but many of these proteins are understudied and are also not shared across the entire genus, creating barriers to the establishment of general principles of OPXV virulence. Notable among OPXV immunomodulatory proteins is the B22 family of proteins 15 – 19 . Encoded by the largest open reading frames (ORFs) in OPXV genomes, B22 proteins are highly conserved in all OPXVs except for vaccinia 15 , which was used to develop the smallpox and mpox vaccines due to its dampened virulence 20 . Initial in vitro studies found that B22 proteins, including those from monkeypox, cowpox (CPXV), and variola, are potent inhibitors of T cell receptor (TCR)-dependent activation 15 . Furthermore, studies in non-human primates demonstrated that infection with MPXV lacking its B22 homolog (MPXVΔ197) was severely attenuated in its pathogenesis, both in viral replication over time as well as morbidity and mortality 15 . These findings as well as the large size and high conservation of B22 family members strongly imply a major and indispensable role in OPXV biology. In line with this, studies using ectromelia (ECTV) infection in mice found that the insertion of a stop codon before its B22 ORF (corresponding protein termed “C15” in ECTV) largely prevents mortality in BALB/c mice 16 , which are highly susceptible to wild-type (WT) ECTV infection 21 . Together, these studies demonstrated conserved and prominent contributions to virulence by B22 proteins in diverse mammalian hosts and highlight their strong candidacy as potential targets for anti-OPXV therapeutics. However, the immunological consequences of B22 protein expression in vivo have been poorly defined. ECTV infection of mice exemplifies a natural host-pathogen relationship with notable similarities to the disease progression of smallpox 22 , and alongside the high conservation of its B22 protein with those of MPXV and variola 17 , this model offers a broadly relevant avenue to study the critical contributions of B22 proteins to OPXV virulence. Using ECTV, we previously demonstrated that C15 is capable of potently inhibiting mouse CD4 + T cells, but not CD8 + T cells, post-peptide loading onto antigen-presenting cells (APCs) 17 , in contrast to other B22 family members, which had been demonstrated to inhibit both CD4 + and CD8 + T cells 15 . Furthermore, preliminary in vitro findings suggested that C15 functions by inhibiting the formation of APC-T cell synapses 17 . Further complicating the picture is the discovery that C15 contributes to viral dissemination in vivo as early as two days post-infection in C57Bl/6 (B6) mice 16 , 19 , well before the establishment of an adaptive immune response. Whole lymph node imaging revealed that C15 inhibits natural killer (NK) cell engagement of infected cells, resulting in much greater viral replication and dissemination at early time points in WT ECTV infection compared to ECTVΔC15 19 . These findings place C15, and B22 proteins by extension, into an extremely limited category of viral virulence factors that can inhibit both the innate and adaptive immune system through the targeting of separate immune cell populations 23 . Nevertheless, the consequences of C15 on the development of antiviral T cell responses and the dynamic interplay between C15 and NK cells in vivo has not been explored. Furthermore, whether C15 is capable of unequivocally inhibiting CD8 + T cells, like other B22 proteins, has not been thoroughly investigated. Here, using a novel in vitro expression system, we demonstrate that, indeed, C15 potently inhibits CD8 + T cells, uncovering a third inhibitory activity of this enigmatic virulence factor. Counterintuitively, during in vivo infection of C57Bl/6 (B6) mice, in the face of C15, WT ECTV induced larger and more functional CD8 + T cell responses compared to ECTVΔC15, with phenotypic and transcriptomic analyses indicating stronger TCR signaling in WT-derived CD8 + T cells. Experiments in Batf3 -/- mice identified cDC1-mediated cross-presentation as the primary host workaround to CD8 + T cell inhibition by C15, but CD4 + T cell responses were similarly enhanced with C15 expression. Considering previous findings that NK cells heavily restrict ECTVΔC15 replication early in the draining lymph node, we determined that antigen load differences, driven by C15-mediated antagonism of NK cells, were the defining factors in the T cell responses to WT and ECTVΔC15. Using single cell RNA sequencing, we identified a candidate signaling scaffold that may be upstream of C15-mediated NK cell inhibition. Finally, we demonstrated that in BALB/c mice, which bear deficiencies in NK cell responses against ECTV, C15 more prominently targets CD4 + and CD8 + T cell responses, establishing the principle of conditional immune antagonism by C15. Results The ECTV C15 protein inhibits both CD4 + and CD8 + T cells To evaluate the breadth of T cell inhibition by C15, we established an inducible expression system that utilizes the Sleeping Beauty transposase to deliver a doxycycline-controlled C15-(HA tag) gene cassette into C57Bl/6 (B6)-derived skin fibroblasts (B6-C15) (Fig. 1 A) 24 . We validated the expression and membrane trafficking of C15 via flow cytometry, demonstrating dose-dependent increases in HA-tag+ cells (Fig. 1 A). In previous work, we demonstrated that C15 inhibits CD4 + T cell activation 17 . To confirm this activity in our inducible expression system, we transduced B6-C15 cells with lentivirus encoding the class II transactivator (CIITA) (Figure S1 A), induced overnight, and performed a T cell hybridoma assay (Fig. 1 B) 25 . As controls, we included an uninduced condition and an inducible cell line expressing the comparably large transmembrane protein guanylyl cyclase C (GC-C) (Figure S1 B) 26 . In line with our previous findings, C15 expression significantly reduced activation of MHCII-restricted T cell hybridomas (Fig. 1 B). Initial publications on B22 family proteins reported that these proteins inhibit both CD4 + and CD8 + T cell activation 15 . In contrast, we previously demonstrated that C15 inhibits only CD4 + T cells 17 . We speculated this selective effect was due to low C15 expression levels in our previous systems, and, indeed, this is supported by the demonstration that inhibition of CD4 + T cell hybridomas by C15 is reduced when expression is driven by a weaker promoter (UbC) (Figure S1 C). We investigated the inhibition of various CD8 + T cell hybridomas using our inducible cell line, finding that C15 inhibited all CD8 + T cell hybridomas similarly to CD4 + T cell hybridomas (Fig. 1 C). To ensure inhibition was not an artifact of our in vitro system, we infected FMS-like tyrosine kinase 3 ligand (Flt3l)-derived type 1 conventional dendritic cells (cDC1s) (Figures S1 D-G) with ECTV-eGFP (WT) 27 or ECTVΔC15 (ΔC15) 17 (Figure S1 H-I) for co-culture with ECTV-specific primary CD8 + or CD4 + T cells (Fig. 1 D). Restimulation of CD8+ (Fig. 1 E) and CD4+ (Fig. 1 F) T cells by ΔC15-infected cDC1s was significantly greater compared to WT-infected cDC1s, although the relative inhibition was much more potent in the CD4 + T cell co-culture. Furthermore, CD4 + T cell IFNγ spots were significantly larger when co-cultured with ΔC15-infected cDC1s compared to WT-infected cDC1s (Fig. 1 F). C15-mediated inhibition was not due to downregulation of any MHC or co-stimulatory molecule (Figure S1 J), suggesting that the mechanism of C15 inhibition is either MHC-independent or fundamental to all antigen-specific APC-T cell interactions. Previous data indicated that C15 functions post-peptide loading 17 , but it has not yet been shown whether C15 modulates the number of peptide-MHC (pMHC) complexes on the cell surface. Using TCR-like antibodies that recognize either pMHCI (H-2K b -SIINFEKL) or pMHCII (I-A b -Ea 52-68 ) complexes, we found that C15 does not alter the abundance of pMHC complexes on the cell surface, derived from either mRNA lipid nanoparticle-encoded protein (Figures S1 K-M) or pulsed peptide (Figures S1 N-O). Taken together, our data indicate that, in addition to its impact on NK cells, C15 can inhibit CD4 + and CD8 + T cells without disrupting pMHC complex presentation at the cell surface. To gain additional insights into C15 inhibitory activity, we asked whether C15 could inhibit T cell hybridoma activation from a “bystander” cell. To accomplish this, we induced MHCII-negative C15-HA-tag cells (bystander) and co-incubated them with MHCII+ B6 fibroblasts (APCs) in the presence CD4 + T cell hybridomas and exogenous peptide. Here, C15 inhibited hybridoma activation in a dose-dependent manner (Fig. 1 G), but this was not mediated by a secreted fragment since supernatant from high density cell cultures did not have an inhibitory effect (Figure S1 P). To ask whether C15 antagonizes TCR-independent calcium flux or intracellular signaling, we treated hybridomas with ionomycin and phorbol 12-myristate 13-acetate (PMA). In this context, C15 was unable to inhibit hybridoma activation (Fig. 1 H), suggesting TCR-dependent inhibition like other B22 protein members 15 . Thus, our data indicate that C15 is cell-associated and can inhibit TCR-dependent CD4 + and CD8 + T cell activation without necessarily being expressed by the APC. CD8 + T cell responses are enhanced in the face of C15 Given the importance of CD8 + T cells in protective immunity against ECTV 28 , 29 , we footpad infected B6 mice with either WT or ΔC15 and evaluated splenic CD8 + T cell responses (Fig. 2 A). Contrary to expectations, CD8 + effector T cell (CD8 + T eff ) responses to infection were significantly greater as a percentage of total CD8 + T cells during WT infection, with differences being apparent as early as 7 days post-infection (dpi) (Fig. 2 B). To probe antigen-specific CD8 + T eff , we stained splenic CD8 + T cells with an H-2K b tetramer loaded with the immunodominant B8R 20-27 epitope (B8R+) (Figure S2 A). Notably, at 6 dpi, WT-derived B8R+ T eff had greater expression of the activating markers CD69 and CD25, which persisted through 7 dpi (Fig. 2 C). Furthermore, PD-1, perforin, and granzyme B (GzmB) were upregulated starting at 7 dpi, and PD-1 expression was maintained through 10 dpi (Figs. 2 C-D). Together, these data suggest that WT infection (C15-expressing), counterintuitively, induced a larger and more activated CD8 + T cell response to infection compared to ΔC15. To further investigate whether CD8 + T cell responses are, in fact, enhanced in the face of C15, we assessed cytokine production by and cytolytic potential of CD8 + T cells from either WT or ΔC15-infected mice at 7 or 9 dpi. This was done via restimulation of splenocytes with ΔC15-infected DC2.4 cells or B8R peptide (Figure S2 B). While there were no significant differences in the proportion of cytokine-producing CD8 + T cells with either restimulation condition at 7 dpi (Figs. 2 E-F), by 9 dpi, a substantially greater proportion of WT-derived CD8 + T cells were cytokine-producing and exhibited higher cytotoxic potential compared to ΔC15-infected mice from both restimulation conditions (Figs. 2 G-I). The greater functionality of WT-derived total CD8 + T cells can be attributed to the larger population of CD8 + T eff in WT-infected mice at 9 dpi (Fig. 2 B), but the lower functionality of B8R peptide-stimulated T cells in ΔC15-infected mice indicate less cytokine-producing capacity on a per cell basis, as the proportion of B8R+ CD8 + T cells is equivalent between WT and ΔC15 at this timepoint (Fig. 2 J). In line with decreased functionality, a significantly greater proportion of ΔC15-derived B8R+ T eff highly expressed CX3CR1 (CX3CR1 hi ) (Figs. 2 K and S2 C-D), a marker of terminal differentiation that has been negatively associated with polyfunctionality 30 , 31 . Furthermore, at 9 dpi, there were more CX3CR1 int B8R+ T eff in WT-infected mice compared to in ΔC15-infected mice (Fig. 2 L). Together, these data indicate that B8R+ T eff in WT-infected mice are more polyfunctional and less terminally differentiated than those from ΔC15 infection. Lastly, to couple phenotypic and functional differences with transcriptional changes, we performed bulk RNA-sequencing on splenic CD8 + T eff at 7 and 10 dpi (Figs. 2 M and S2 E and Table S1 ). At 7 dpi, differentially expressed genes (DEGs) within CD8 + T eff from WT-infected mice were enriched for targets of MYC – a prominent regulator downstream of T cell activation (Figure S2 F) 32 , IL-2 signaling (Figure S2 G), and zinc ion binding (Figure S2 H), which has been positively associated with TCR engagement 33 , 34 . Gene ontology (GO) analysis further demonstrated enrichment in genes related to mRNA processing, RNA localization, ribosome biogenesis, and DNA metabolism (Figure S2 I). In contrast, ΔC15-derived CD8 + T eff were strongly enriched for genes downstream of type I interferon (IFN) (Figure S2 J), genes associated with an NK cell-like phenotype (Figure S2 K), and genes implicated in negative regulation of TCR signaling ( Cd37 , Cish , Klr1g , Nrp2 , Ptpn6 , Tnk2 ) 35 – 40 . At 10 dpi, WT-derived CD8 + T eff maintained greater expression of several AP-1-associated factors ( Fos , Jun , Egr1 ) 41 , 42 while ΔC15-derived CD8 + T eff had greater expression of Bach2 and Zbtb20 , which restrain chromatin accessibility of AP-1 factors 43 , 44 and limit the metabolic capacity of CD8 + T cells 45 , indicating the persistence of T cell phenotypes from earlier infection timepoints (Figures S2 L-M and Table S1 ). These transcriptional data support the findings that WT infection drives larger and functionally enhanced CD8 + T eff compared to ΔC15-derived CD8 + T eff , in line with our direct assessments of CD8 + T cell phenotype. CD8 + T cells have higher avidity during WT infection We speculated that WT infection induced larger CD8 + T eff responses than ΔC15 infection due to broader T cell priming from a more diverse array of epitopes. Consistent with this, by 10 dpi, there were significantly less B8R + T cells among T eff during WT infection compared to ΔC15 (Figure S3 A). This suggests that antigen-specific responses during WT infection are more antigenically diverse and less dominated by the B8R epitope than those during ΔC15 infection. Conversely, a significantly greater proportion of B8R+ T eff during ΔC15 infection suggests that there may be differences in clonal diversity among B8R+ CD8 + T cells. To investigate this, we performed bulk TCR sequencing on B8R+ T eff cells from WT- or ΔC15-infected mice at 7 and 10 dpi (Figure S3 B). However, there were no differences in clonal diversity between WT- or ΔC15-infected mice at either timepoint (Fig. 3 A). Furthermore, there were not major differences in either V or J gene usage between infection conditions (Figures S3 C-D). Therefore, C15 expression does not alter the TCR repertoire of B8R + T cells, and there is no evidence for selective clonal expansion in either infection condition. An alternative explanation for the enhanced CD8 + T eff responses during WT infection is greater T cell avidity, as higher avidity T cells have been shown to proliferate more efficiently in vivo 46 . Therefore, we tested the relative avidity of B8R+ CD8 + T eff from WT- or ΔC15-infected mice using a tetramer decay assay (Figure S3 E) 47 . We found no differences in the rate of tetramer decay between infection conditions, suggesting similar avidities (Figure S3 F), but the B8R tetramer-TCR affinity may be too high for a meaningful investigation of T cell avidity. As an orthogonal approach, we evaluated the phenotype of WT- or ΔC15-derived CD8 + T eff over time in a model of chronic antigen stimulation, as high avidity T cells have been shown to undergo greater exhaustion in these contexts 47 – 50 . To generate a model of chronic antigen stimulation during ECTV infection, we depleted B6 mice of CD4 + T cells prior to infection with WT and ΔC15 (Fig. 3 B), as previous work suggested CD4 + T cells are required to promote efficient CD8 + T cell contraction post-infection 28 . WT-infected mice began succumbing to infection by approximately 35 dpi, with 80% deceased by 70 dpi, whereas ΔC15-infected mice largely survived throughout this timeline (80% survival) (Fig. 3 C). By 30 dpi, CD8 + T eff in CD4-depleted mice generally had elevated PD-1 expression, but WT-derived CD8 + T eff exhibited higher expression of the terminal exhaustion markers CD39, TOX, and LAG-3 compared to those from ΔC15-infected mice (Fig. 3 D) 51 – 53 , which were enriched within B8R + T cells (Fig. 3 E). CD8 + T cell exhaustion was highly progressive, with systemic upregulation of terminal exhaustion markers in the days prior to death (Figure S3 G). Together, these findings suggest that WT-derived CD8 + T eff have greater avidity that drives enhanced proliferation and functionality in vivo . CD8 + T cells exhibit similar memory trajectories during WT and ΔC15 infection Greater avidity of CD8 + T eff during WT infection suggests that CD8 + T cell memory may be enhanced compared to ΔC15 infection 54 . To investigate this, we tracked B8R + T cells over the course of 6 months post-WT or -ΔC15 infection and monitored short-lived effector cells (SLEC), memory precursor effector cells (MPEC), and “double positive” (KLRG1 + CD127+) effector cells (DPEC) (Fig. 3 F), which are thought to be the primary source of “exKLRG1” long-lived memory cells 55 – 57 . SLEC and DPEC were the dominant populations at 14 dpi in all mice (Fig. 3 G), while DPEC and MPEC were dominant at 181 dpi, with roughly equal proportions. Notably, the trajectories of memory development were similar following WT and ΔC15 infection (Fig. 3 G). Therefore, despite C15 expression substantially enhancing the magnitude and function of the acute CD8 + T cell response, there does not appear to be long-term effects on the development of CD8 + T cell memory against the B8R epitope. Cross-presentation compensates for C15-mediated inhibition of direct presentation to CD8 + T cells The juxtaposition of potent CD8 + T cell inhibition by C15 in vitro and the greater CD8 + T cell responses during WT infection suggests compensatory mechanisms in vivo . While C15 can effectively block antigen presentation from a bystander cell (Fig. 1 G), we speculated that cross-presentation drives enhanced CD8 + T cell responses during WT infection compared to ΔC15. Therefore, we used the Batf3 -/- mouse model, which is deficient in the development of CD8α + cDC1s – the primary mediators of cross-presentation during poxviral infections 58 , 59 – while allowing for ECTV viral replication 60 . We infected either B6 or Batf3 -/- mice with WT or ΔC15 and investigated their splenic CD8 + T cell responses at 7 dpi (Fig. 4 A). Similar to other reports 61 , we found that the ratio of splenic CD4+/CD8 + T cells 7 dpi was significantly higher in Batf3 -/- mice compared to B6 counterparts, highlighting an intrinsic deficit in CD8 + T cell proliferation independent of infection condition (Figure S4 A). However, the development of CD8 + T eff was significantly reduced in WT-infected Batf3 -/- mice compared to their B6 counterparts, while CD8 + T eff were unchanged in ΔC15-infected mice (Fig. 4 B). While CD8 + T eff did not differ in their expression of CD25 or CX3CR1 between B6 and Batf3 -/- mice (Figs. 4 C-D), the proportion of B8R+ T eff was significantly upregulated in Batf3 -/- mice independent of infection condition (Fig. 4 E), suggesting that B8R is more abundantly presented when cross-presentation is stunted. CD8 + T eff also trended towards or exhibited greater expression of TIM-3 in Batf3 -/- mice (Figure S4 B), which may explain the lower capacity for Batf3 -/- CD8 + T eff to proliferate 62 . CD40-CD40L signaling between cDC1s and CD4 + T cells has been suggested as critical in the “licensing” of cDC1s for CD8 + T cell priming 63 . To exclude the possibility that the differences observed with WT and Batf3 -/- mice could be explained by differences in CD40-CD40L signaling, we treated B6 and Batf3 -/- mice with αCD40L blocking antibody during WT infection (Fig. 4 F). CD70 expression, a response downstream of CD40 ligation 64 , on cDC1s was downregulated in B6 mice treated with αCD40L, indicating successful blockade (Figures S4 C-D). Batf3-independent cDC1s responded with limited CD70 upregulation but greater overall CD40 expression (Figures S4 E), and αCD40L treatment expanded cDC1s in Batf3 -/- mice (Figure S4 F). CD40L blockade did not dampen CD8 + T eff responses to WT infection in B6 mice, but it increased the induction of CD8 + T eff in Batf3 -/- mice (Figs. 4 G-H), implicating non-canonical CD40L signaling in negatively regulating CD8 + T cell responses in Batf3 -/- mice during ECTV infection 65 , 66 . In B6 mice, there was a decrease in CD4 + T eff following αCD40L treatment (Figs. 4 I), which was expected given the role for CD40L in activation of CD4 + T eff 67,68 . Together, these data demonstrate that phenotypes in WT-infected Batf3 -/- mice are not due to a lack of CD40-CD40L engagement, and that T cell responses during WT infection are more sensitive to deficits in cross-presentation compared to ΔC15 infection, in line with inhibition of direct presentation to CD8 + T cells by C15. CD4 + T cell responses are similarly enhanced during WT infection compared to ΔC15 Inhibition of CD4 + T cells by C15 has been previously reported in vitro and ex vivo 17 . Furthermore, here, C15 demonstrated enhanced potency against CD4 + T cells ex vivo compared to CD8 + T cells (Fig. 1 F). We therefore speculated that CD4 + T cell responses may be more sensitive to C15 inhibition in vivo . However, like CD8 + T cells, we found that the induction of CD4 + T eff (CD62L-CD44+) was greater during WT infection compared to ΔC15 (Fig. 5 A). Furthermore, the development of antigen-experienced CD4 + T cells (CD11a+CD49d+) 69,70 , which correlate with CD4 + T eff (Figure S5A), and antigen-specific (I-A b -I1L 7-21 -specific, I1L+) 69 CD4 + T cells was greater in spleens of WT-infected mice by 7 dpi (Figs. 5 B-C), without an impact to immunodominance over time (Figure S5B). A hallmark of ECTV infection is the development of cytotoxic CD4 + T cells (CD4-CTLs, GzmB + and/or perforin+) 69,71 . As previously described 69 , 71 , WT infection induced a substantial population of CD4-CTLs (Figs. 5 D-E). In contrast, there was little to no CD4-CTL induction during ΔC15 infection (Fig. 5 E). To determine whether CD4-CTL induction is strictly dependent on C15, we compared CD4-CTL development during ΔC15 infection of β2m -/- mice, as the absence of CD8 + T cells in these mice (Figure S5C) induces a compensatory increase in CD4-CTLs 72 . Notably, the induction of CD4-CTLs was rescued in β2m -/- mice following ΔC15 infection (Fig. 5 F), suggesting that CD4-CTL responses are not intrinsically linked to C15 expression. To gain broader insights into the impact of C15 on CD4 + T eff cell responses, we performed bulk RNA-sequencing on sorted splenic CD4 + T eff 7 dpi (Figs. 5 G, S5 D and Table S2 ). WT-derived CD4 + T eff , like CD8 + T eff , had increased expression of transcriptional modules downstream of IL-2 signaling (Figure S5E) and MYC expression (Figure S5F), as well as upregulation of genes related to oxidative phosphorylation (Figure S5G) and the unfolded protein response (Figure S5H). GO term enrichment further identified an upregulation of genes associated with the cell cycle in WT-derived CD4 + T eff (Fig. 5 H). The transcriptional phenotype of CD4 + T eff during ΔC15 infection was similar to that of CD8 + T eff (Figs. 5 G and S5 I-J), but there was also greater expression of regulatory T cells (T reg )-associated genes ( Runx1, Foxo1, Foxo3, Foxp3, Gpr83, Ikzf4, Nrp1 ) 73 – 77 (Fig. 5 G), suggesting that ΔC15-derived CD4 + T eff are more skewed towards immunosuppressive phenotypes. Lastly, we asked whether CD4 + T follicular helper cell (T fh ) responses recapitulated our findings in CD4 + T eff , examining the balance of T fh and CD4 + T follicular regulatory cells (T fr ), as antibodies are a critical determinant of protection against ECTV 28 . We measured the induction of T fh and T fr cells in the spleen and inguinal lymph node (iLN) at 7 and 10 dpi (Figure S5K). WT-infected mice had a significantly greater proportion of T fh within both splenic CD4 + T eff and total CD4 + T cells 7 dpi, but this difference was not apparent at 10 dpi (Fig. 5 I). In contrast, ΔC15-infected mice had greater proportions of T fr in splenic CD4 + T eff at 7 and 10 dpi and within total CD4 + T cells 10 dpi (Fig. 5 J). Between infection conditions, we found no significant differences in the induction of T fh or T fr cells within the iLN (Figures S5L-M). Notably, these differences in T fh did not change anti-ECTV IgG antibody titers 28 dpi (Figure S5N). Overall, as with CD8 + T cell responses, CD4 + T cell responses to ECTV infection are enhanced in the presence of C15 – at odds with the potent inhibition observed in vitro and ex vivo (Fig. 1 ). Cross-protective immunity is maintained in the absence of C15 Given WT- and ΔC15-infected mice displayed similar CD8 + T cell memory trajectories and equivalent anti-ECTV IgG development, we asked whether significant deficits in acute T cell responses during ΔC15 infection impacted the establishment of cross-protective immunity. Therefore, we challenged WT- or ΔC15-immunized mice 30 dpi with a lethal dose of the related orthopoxvirus, cowpox (CPXV) (Figure S5O). All ECTV-immunized (WT or ΔC15) mice survived (Figure S5P), with increases in the CD8 + T eff population following challenge (Figure S5Q). Together, these data demonstrate that the transcriptional, phenotypic and functional differences in CD8 + and CD4 + responses during WT or ΔC15 infection, under the specified conditions, do not hinder the establishment of cross-protective immunity. T cell differences between WT and ΔC15 infection are driven by antigen load While cDC1-mediated cross-presentation explains the enhanced CD8 + T cell responses in the face of C15 expression, this mechanism does not explain the deficiencies in CD8 + and CD4 + T cell responses during ΔC15 infection, which should be significantly enhanced compared to WT according to in vitro and ex vivo findings (Fig. 1 ) 17 . We next considered the possibility that the interaction between C15 and its third cellular target, NK cells, impacts T cell responses. We have previously demonstrated that ΔC15 replication in B6 mice is heavily restricted in the draining lymph node due to NK cell-mediated control, which is effectively antagonized by C15 19 . Therefore, we hypothesized that decreased antigen load during ΔC15 infection may underlie the differences in T cell responses described above, and this notion is further supported by the association between CD4-CTL induction and viral replication 71 , both of which are markedly reduced during ΔC15 infection. The finding that ΔC15 infection of β2m -/- mice rescued the induction of CD4-CTLs (Fig. 5 F) implies that ΔC15 infection replication is enhanced in the absence of a functional CD8 + T cell compartment. Indeed, B6 mice pretreated with anti-CD8 depleting antibody succumbed to both WT and ΔC15 infection (Figure S6A). To directly quantify viral burden in β2m -/- mice ex vivo , we used an anti-MPXV A35R (A33R in ECTV) monoclonal antibody 78 , which displayed strong cross-reactivity with ECTV (Figures S6B-C). Notably, inflammatory monocytes (iMOs, Figure S6D) from ΔC15-infected β2m -/- mice were more highly infected than their B6 counterparts (Fig. 6 A). Thus, differences in viral load may explain the impairment of T cell responses during ΔC15 infection. To explicitly test the relationship between antigen load and T cell phenotype, we first infected B6 mice with WT ECTV and treated with cidofovir (CDV) 3 dpi to limit late viral replication (Fig. 6 B) 79 , 80 . In line with previous reports 71 , CDV treatment significantly dampened the induction of CD4-CTLs (Fig. 6 C). Furthermore, CDV treatment also increased the proportion of CX3CR1 + and CX3CR1 int CD8 + T eff (Fig. 6 D) and reduced PD-1 + CD25+ CD8 + T eff (Fig. 6 E). CDV treatment did not impact the magnitude of CD8 + T eff generation among total CD8 + T cells (Fig. 6 F), but the expression of granzyme B and perforin was reduced to a level equal to ΔC15 infection (Figs. 6 G-H). To directly implicate NK cells as the mediator of key antigen restrictions during ΔC15 infection, we compared T cell responses to WT or ΔC15 infection in untreated mice with that of NK-depleted, ΔC15-infected mice (Fig. 6 I). NK cell depletion restored CD8 + T eff induction to levels equivalent to WT infection (Fig. 6 J) and increased CD25 and PD-1 expression above that of WT infection (Fig. 6 K). Furthermore, NK cell depletion rescued CD4-CTL induction (Fig. 6 L). Together, these data demonstrate that NK cell-infected cell interactions and their subsequent impact on antigen load are the defining factors in the CD4 + and CD8 + T cell response to WT and ΔC15 infection in B6 mice. As a proof-of-principle, we revisited ΔC15 infection of Batf3 -/- mice, where the proportion of CD8 + T cells that developed into T eff by 7 dpi was equivalent to B6 counterparts (Fig. 4 B). In this model, we speculated that lower antigen load in combination with deficiencies in cross-presentation synergize to ablate CD8 + T eff expansion during ΔC15 infection in Batf3 -/- mice, and this notion is supported by the finding that the proportion of CD8 + T eff at 9 dpi is unchanged during ΔC15 infection compared to WT infection, which underwent a modest expansion (Figures S6E). Given findings thus far, we reasoned that increases in antigen load during ΔC15 infection of Batf3 -/- mice should propel CD8 + T eff expansion beyond that of WT infection, as direct presentation is more efficient than cross-presentation 81 . We depleted NK cells in Batf3 -/- mice prior to ΔC15 infection, and in line with our hypothesis, NK cell depletion pushed CD8 + T eff expansion beyond that of WT-infected Batf3 -/- mice (Fig. 6 M) and enhanced CD25 (Fig. 6 N) and TIM-3 expression (Fig. 6 O). Thus, restoration of antigen load during ΔC15 infection of Batf3 -/- mice, which has unobstructed direct priming due to the absence of C15, led to enhanced CD8 + T eff responses compared to WT infection. This further supports early antigen load restriction of ΔC15 by NK cells as the critical bottleneck in the establishment of robust antiviral T cell responses. NK and T cells undergo distinct transcriptional changes in the dLN during ΔC15 infection Early engagement and antagonism of NK cell-mediated control by C15 is critical to permit efficient viral replication in the dLN 19 , ultimately driving enhanced CD8 + and CD4 + T cell responses to infection. To investigate the mechanistic basis, we first assessed the transcriptional differences in the dLN during WT and ΔC15 infection at 48 hpi, a time point prior to measurable differences in viral titer 19 . We performed bulk RNA sequencing on dLNs harvested 48 hpi (Figures S7A-B and Table S3 ). GO term enrichment of DEGs identified a handful of terms that were different between infection conditions (Figure S7C). Most notable terms were production of reactive oxygen species in WT-infected and macroautophagy in ΔC15-infected dLNs. To more precisely identify transcriptional differences, we performed single cell RNA sequencing (scRNA-seq). To ensure we captured the earliest points of divergence between WT and ΔC15 infection, we performed qPCR for viral RNA at 24 and 32 hpi as well as probed NK cell phenotypes at 48 hpi. There was significantly more viral RNA by 32 hpi in WT-infected dLNs (Fig. 7 A). Additionally, by 48 hpi, NK cells from WT-infected dLNs had significantly greater expression of KLRG1 (Fig. 7 B), CD137 (Fig. 7 C), GzmB (Fig. 7 D), and IFNγ (Fig. 7 E), suggesting that the initial impact of C15 on NK function occurs prior to 48 hpi. Therefore, we chose 24 and 48 hpi as timepoints for scRNA-seq, specifically probing transcriptional changes within T and NK cell (CD19-negative) populations (Figure S7D). We recovered eight Leiden clusters, named according to key marker genes (Figs. 7 F and S7 E). Across timepoints, IFN-responsive T cells and NK cells increased in proportion for both infection conditions (Figures S7F-G). Notably, a cluster of T cells (annotated “Activated T cells”) defined by TCR-associated genes ( Nfkb1 , Nr4a3 , Egr3 , Relb , Dnmt3a , Myc ) 32 , 82 – 85 had greater representation in ΔC15-infected dLNs at 48 hpi (Figure S7G). Cluster-specific expression analysis did not identify DEGs 24 hpi infection across T cell clusters, but by 48 hpi, several genes downstream of TCR engagement ( Tox, Cd44, Tnf, Egr1 ) 42 , 86 , 87 and those associated with cytoskeleton remodeling ( Prag1, Tmsb10 ) 88 , 89 were upregulated during ΔC15 infection (Fig. 7 G). In contrast, T cell clusters from WT-infected mice mainly upregulated genes associated with IFN signaling ( Mx1 , Ifit3b , Socs3 ). Together, these data are consistent with earlier TCR engagement in ΔC15-infected dLNs. When investigating NK cells at 24 hpi, only a single DEG, Gab2 (a signaling scaffold) 90 , was upregulated in ΔC15 dLNs (Fig. 7 H), and there were no DEGs at 48 hpi (Figure S7H), in contrast with phenotypic differences seen by flow cytometry (Fig. 7 B-E). Therefore, we performed sub-clustering on NK cells to investigate key NK cell subsets. This yielded two primary clusters (NK-1 and NK-2) (Fig. 7 I), with NK-1 enriched for conventional NK cell marker genes ( Ncr1 , Klrk1 , Gzma , Itga2 ) and NK-2 enriched for genes associated with transcriptional regulation as well as NKT-like markers ( Tcf7 , Lef , Bcl11b ) 91 – 94 (Fig. 7 J). At 48 hpi, DEGs were only found within NK-2 (Fig. 7 K). WT-derived NK-2 cells had greater expression of Klrg1 as well as several genes related to MAPK-ERK signaling ( Ksr1 , Map3k5 , Ndrg3 ) 95 – 97 , regulation of apoptosis ( Hipk2 , Wwox ) 98 , 99 and vesicle transport ( Vps37b ) 100 . In contrast, ΔC15-derived NK-2 cells had increased expression of three genes associated with regulation of calcium signaling ( Ahnak ) 101 , glycerol-3-phosphate shuttling ( Gpd2 ), and actin bundling ( Lcp1 ) 102 . Together, these data identify transcriptional differences in NK cells from WT- and ΔC15-infected dLNs that may point to the key function of C15 during early infection, including a potential signaling scaffold ( Gab2 ) downstream of C15-associated inhibition of NK cell function. C15 antagonizes NK or T cells depending on host immunocompetence The genetic factors underlying the resistance of B6 mice to lethal ECTV infection, compared to other mouse strains, have been directly mapped to the natural killer complex (NKC) 103 , 104 . The essential role of C15-mediated NK cell inhibition to permit enhanced viral dissemination suggests that C15-NK cell engagement is the predominant NK-dependent host-pathogen interaction governing ECTV pathogenesis in B6 mice. To directly test this notion, we evaluated mortality of B6 mice infected with WT or ΔC15 that had been pre-treated with anti-NK1.1 depleting antibody, a treatment that induces significant mortality during WT infection 27 . By 9 dpi, 60% of WT-infected mice succumbed to infection (Fig. 8 A). However, NK-depleted mice had significantly less mortality following ΔC15 infection, with only a single mouse succumbing to infection 9 dpi (Fig. 8 A). Thus, NK cell-mediated control of infection in B6 mice is significantly less critical for protection in the absence of C15. Other mouse strains, such as BALB/c mice, are not protected from lethal ECTV infection, with differences in susceptibility thought to be strongly driven by deficiencies in NK cell responses to infection 105 , 106 . This suggests that C15 engagement of NK cells may have less importance in driving pathogenesis, as NK cell responses are naturally impaired. Furthermore, previous work in BALB/c mice demonstrated that at 4 dpi, which is past the critical timepoints of early NK cell engagement, viral loads of WT and ΔC15 are equivalent in the dLN, spleen, and liver 16 . To evaluate the importance of C15-NK cell interactions to ECTV pathogenesis, we similarly treated BALB/c mice with anti-NK1.1 antibody prior to infection with ΔC15. Here, in contrast to B6 mice, NK cell depletion prior to infection of BALB/c mice with ΔC15 resulted in 100% mortality (Fig. 8 B), indicating that, in this case, NK cell engagement by C15 is not the primary form of antagonism to host immunity. We therefore hypothesized that C15 may have a more pronounced inhibitory impact on the development of T cell responses in BALB/c mice compared to B6 mice. To test this, we infected BALB/c mice with either WT or ΔC15 and quantified infected cells within the spleen at 5 and 7 dpi as well as T cell responses at 7 dpi (Fig. 8 C). In line with previous reports demonstrating lower viral titers by 6 and 8 dpi during ΔC15 infection 16 , inflammatory monocytes (iMOs), DCs, and B cells were either trending or significantly less infected 7 dpi in ΔC15-infected mice (Figs. 8 D and S6 D). However, the magnitude of CD8 + T eff responses were comparable between infection conditions at 7 dpi (Figs. 8 E), with some ΔC15-infected mice having levels of CD8 + T eff greater than WT-infected mice. While proliferation among CD8 + T eff was similar as measured via %Ki67+ (Fig. 8 F), ΔC15-derived CD8 + T eff had lower CD25 expression (Fig. 8 G). Within the CD4 + T cell compartment, T eff as well as CD4-CTL responses were similar between infection conditions at 7 dpi (Figs. 8 H-I). Collectively, these data indicate that in hosts where C15-mediated antagonism of NK cells is not the primary mode of immunomodulation, C15 does, in fact, meaningfully inhibit T cell responses, as evidenced by the equal (trending towards greater) magnitude of T eff responses during ΔC15 infection but lower viral load at 7 dpi. Furthermore, these data demonstrate the ability of C15 to exhibit “conditional antagonism”, where different inhibitory activities are exhibited, depending upon the immunological capabilities of the host. Discussion The continued global persistence of OPXVs, post-eradication of variola, highlights an incomplete understanding of their biology and a critical need for innovative antiviral strategies 107-112 . The immunomodulatory proteins encoded by OPXVs ultimately determine pathogenesis 113 , but there is much to be learned about how these proteins contribute to pathogenesis. To date, there have been limited studies on both the function and in vivo significance of B22 proteins 15-17,19 , despite their conservation, extreme size notwithstanding, in all highly virulent OPXVs. Our studies on the ECTV B22 protein, C15, have demonstrated its capacity to antagonize three immune cell populations: CD4+ T cells 17 , NK cells 19 , and, as shown here, CD8+ T cells. While C15 potently inhibited CD4+ and CD8+ T cells in vitro and ex vivo (Figure 1), in B6 mice, WT (C15-expressing) ECTV infection generated significantly more robust T cell responses, as indicated by phenotypic, functional and transcriptomic analyses (Figures 2, 3 and 5). We determined this was partially explained by compensatory cDC1-mediated cross-presentation (Figure 4) but primarily driven by antigen load differences from differential restriction of viral replication by NK cells (Figure 6). Specifically, early restriction of DC15 viral replication by NK cells, which is antagonized by C15, dampened T cell responses, and this deficiency could be restored through the depletion of NK cells prior to DC15 infection. Single cell RNA sequencing analysis identified a candidate signaling adapter, Gab2 , that may be downstream of C15-mediated antagonism of NK cells (Figure 7). Lastly, we found that in BALB/c mice, which have genetic deficiencies in NK cell responses to ECTV, C15 more prominently inhibited T cell responses (Figure 8). Unlike other viral virulence factors that have been described to inhibit both T cells and NK cells 23,114 , C15 does not appear to modulate the expression of key ligands critical for effector cell engagement (e.g., MHC molecules) 23,114-116 , setting it apart. All current evidence suggests that C15 inhibits cell-cell contacts 17,19 , though this has yet to be explicitly demonstrated. While parallels can be drawn between the function of synaptic events for CD8+ T cells and NK cells 117-119 , CD4+ T cells are more distinct, both kinetically 120-123 and in post-synaptic function 124 . This raises the question of whether C15 inhibitory functions map to a single domain or are spatially separated. B22 proteins are unusually large (e.g., C15 is 1924 amino acids), and previous studies have identified two cleavage-dependent fragments 15,18 , leading to speculation that one fragment mediates each respective inhibitory activity (i.e., NK cells and T cells). Our lab is actively investigating the molecular mechanisms and structure-function relationships of C15. Many viral virulence factors have been described to have multiple functions, and in many cases, multi-functionality is a necessity due to limited genome size. However, OPXVs are some of the largest mammalian viruses by genome size (~170-230 kb). The integration of multiple immune-targeting functions coupled with the maintenance of a very large ORF raises key questions about the evolutionary benefit of B22 proteins. Here, our findings in B6 and BALB/c mice offer a potential explanation. In B6 mice, the NK cell-targeting function of C15 is the critical host-pathogen interaction, which permits enhanced viral replication and dissemination. However, the consequence to this replication is more robust antiviral T cell responses. In BALB/c mice, where NK cells have intrinsic deficits in control of viral replication, C15 more prominently antagonizes the early development of T cell responses, which likely underlies its enhanced replication at later timepoints during infection 16 . These points suggest that the conditional antagonism of NK cells or T cells allows ECTV to robustly replicate in genetically diverse hosts, using differences in host immunocompetence to enhance viral fitness. Furthermore, our data imply that enhanced T cell responses during WT infection in B6 mice is a “trade-off” for the virus, where early viral replication is more critical for spread to uninfected hosts rather than having enhanced fitness during the adaptive immune responses. In BALB/c mice, where early viral replication is not heavily restricted by NK cells, antagonism of T cells is likely more critical for viral fitness. Thus, the evolutionary benefit of B22 proteins may stem from their adaptability against host immune defenses, though this topic requires further exploration. Our previous work highlighting the relationship between C15 and NK cells was inferential, using whole lymph node imaging to quantify the proximity of infected cells and NK cells 19 . Here, using scRNA-seq, we were able to identify a signaling scaffold, Gab2, that may be associated with C15 antagonism of NK cells. Gab2 (Grb2-associated binder 2) or its binding partner, Grb2, are involved in the regulation of lymphocyte PI3K signaling downstream of various receptors 125 , including Fcg receptors 126 , activating receptors 127 , and cytokine receptors 90 . Gab2 expression has been demonstrated in both mouse and human NK cells 126,128 , but its role in NK cell signal transduction is largely unknown. Prior work suggested that Gab2 is not required for NK cell function in mice 126 , but additional studies in human NK92MI cells implicate Gab2 as a primary regulator of NK cell PI3K signaling 128 . Thus, further studies on the role of Gab2 and PI3K signaling in NK cell activation during ECTV infection and its relationship with C15 antagonism are required. At 48 hpi, DC15-derived NK-2 cells had greater expression of three genes of interest: Ahnak , Gpd2 , and Lcp1 . Previous work in T cells has identified a critical role for AHNAK in regulating calcium signaling, specifically maintaining the membrane expression of calcium channels and permitting NFAT translocation into the nucleus 101 . Given that calcium flux is required for functional NK cell cytotoxicity 129 , DC15-derived NK-2 cells may have an enhanced capacity for cytolysis. Further supporting this notion is the greater expression of Lcp1 , which encodes for the actin cross-linker L-plastin (LPL) 102,130 . LPL plays a significant role in the regulation of T cell activation through the stabilization of immunological synapses 131 as well as transport of activating receptors 132 . Together, these upregulated genes suggest that DC15-derived NK-2 cells may be functionally enhanced at this timepoint relative to WT-derived cells, in line with an inhibition of NK cells by C15. Overall, our findings underscore the complexity of B22 proteins and their diverse engagement of the host immune response. The significant homology between C15 and the mpox B22 protein 17 , as well as other human-tropic OPXVs, necessitates investigation into the conservation of function across homologs, which could reinforce the establishment of B22 proteins as next-generation OPXV antiviral targets. Moreover, the differences in host response to infection in B6 and BALB/c mice suggest that in a genetically diverse human population, the presence or absence of potential B22 protein targets in individuals (e.g., NK receptors) may significantly impact the outcome to infection, defining whether B22 proteins primarily function to inhibit innate or adaptive immune responses. Methods Mice Female and male C57Bl/6J (strain #000664) and BALB/cJ (strain #000651) (8-10 weeks old) were purchased from The Jackson Laboratory. Batf3 -/- mice (strain #013755) were initially purchased form The Jackson Laboratory and subsequently bred in-house. In all experiments, mice were age and sex-matched across infection groups, and mice ranged between 8-12 weeks old in all infection experiments. Mice were maintained in a specific pathogen-free facility at the Children’s Hospital of Philadelphia (CHOP). All experiments and procedures were approved by the Institutional Animal Care and Use Committees at CHOP. ECTV and CPXV Infections ECTV-eGFP (Strain Moscow) was a kind gift from Dr. Luis Sigal 27 . ECTVDC15 was previously constructed using standard homologous recombination 17 . CPXV strain Brighton Red cell lysate was ordered from BEI Resources (NR-88) and approved under USDA Veterinary Permit #611-24-185-96159. All viruses were propagated and titered as previously described 16-18 . Briefly, ECTV viruses were seeded on 143B (TK - ) osteosarcoma cells at a multiplicity of infection (MOI) of 3 for 72 hours. Cells were then harvested and subjected to 3x freeze-thaw-vortex cycles prior to re-seeding. After scaling up (8 x T175 flask), virus was purified by ultracentrifugation at 20,000 rpm x 1 hour on a 36% sucrose cushion. Viral stocks were resuspended in 10 mM Tris pH 9.0. CPXV was purified similarly, except viral stocks were grown using BS-C-1 cells. Purified virus was titered by plaque assay on BS-C-1 cells under an overlay of 1% methylcellulose/complete DMEM media. For mouse infection with ECTV, C57Bl/6J and Batf3 -/- mice were infected with 3 x 10 3 plaque-forming units (PFU) by injection of 15 ml volume in PBS into the hind footpad. Alternatively, BALB/cJ mice were infected with 3 x 10 2 PFU into the hind footpad. For mouse infection with CPXV, C57Bl/6J mice were infected intraperitoneally (i.p.) with 2 x 10 5 PFU. All infections were performed in the morning between 8-10 AM. Cellular analyses during infection were performed in the spleen, liver or popliteal lymph node, as indicated. Cell lines All fibroblast (e.g., B6-C15, B6-GCC, UbC-C15) cell lines were derived from in-house C57Bl/6 (B6) skin fibroblasts. B6 parental fibroblasts (MHCII-) were used to generate inducible cell lines. B6 fibroblasts expressing human CIITA and BALB/c-derived I-E d were used to generate the UbC-C15 cell line. These cell lines and derivative cell lines (see below) were maintained in Dulbecco’s modified eagle medium (DMEM) containing 5% (D5) or 10% (D10) fetal bovine serum, 2 mM L-glutamine, and 1x penicillin and streptomycin. 143B and BS-C-1 cell lines were cultured in D5 and D10, respectively. Where applicable, cell lines were also cultured in the presence of 2 mg/ml blasticidin to maintain purity of inducible cell lines. The generation and characterization of T cell hybridomas (NP 366-374 , OVA 257-264 , M-SL9, and NA 437-451 ) was previously described 133,134 . Briefly, antigen-specific T cells were fused with the partner cell line, BWZ.36/CD8a, which contained an NFAT-inducible lacZ cassette to readout activation. T cell hybridomas were maintained in Roswell Park Memorial Institute (RPMI) medium containing 10% FBS, 2 mM L-glutamine, 1x penicillin and streptomycin and 50 mM 2-mercaptoethanol (R10). Similarly, DC2.4 cells were grown and maintained in R10 medium. All cells were grown at 37 o C in a 5% CO 2 incubator. Lentivirus generation and transduction The C15-HAtag encoding lentiviral vector was generated by performing fragmented in-fusion cloning to insert the C15-HAtag cassette in between the XbaI and SalI restriction sites of the pUltra lentiviral vector (Addgene, plasmid #24129), downstream of an eGFP reporter. The CIITA-encoding lentiviral vector was generated by removing the eGFP cassette from the pUltra vector by restriction digest and inserting a gene block for human CIITA (Uniprot P33076) with an N-terminal FLAG (DYKDDDDK) tag between the AgeI and SalI restriction sites. For lentivirus production, 6 x 10 6 293T cells were plated in a 10-cm dish in D5 media overnight. The following day, 22 mg total of endotoxin-free plasmid preparations of the glycoprotein (VSV-G, Addgene plasmid #8454), packaging components (psPAX2, Addgene plasmid #12260), and transfer vector (pUltra-derived vector) were transfected with Lipofectamine 2000 (Invitrogen) at a 0.2:1:1 ratio. To generate lipid complexes, 50 ul of Lipofectamine 2000 was added to the plasmid mixture and complexed for 15 minutes. Five ml of pre-warmed antibiotic-free D5 media was add to cells prior to complexes. After complex addition, cells were cultured for 16 hours. The next day, media was replaced with 10 ml of complete D5 media and left for 24 hours. Lentivirus was collected at 24 and 48 hours, pooled, filtered through a 0.22-mm filter, precipitated using Lenti-X Concentrator (Takara Bio) according to manufacturer protocols, and resuspended in 50 ml aliquots. To transduce cells, 1 x 10 5 cells were resuspended in 3 ml of D5 media containing 8 mg/ml polybrene (Sigma-Aldrich). One 50 ml aliquot of lentivirus was then added to the cell suspension, mixed by gentle pipetting, and left to complex for 5 minutes at room temperature (RT). After 5 minutes, cells were plated in individual wells of a 6-well plate and cultured overnight. Transductants were expanded up to a T75 flask prior to cell sorting for either eGFP+ (UbC-C15) or MHCII+ (CIITA) cells. A total of three sorts were performed to recover a pure, but polyclonal, population. Generation of stable cell lines and induction To generate inducible expression vectors, codon-optimized C15 17 and guanylyl cyclase C (GC-C, kind gift from Dr. Scott Waldman) were subcloned into the pSBtet-Bla vector (Addgene, plasmid #60510) between the SfiI restriction sites. For stable cell line generation, 2 x 10 6 B6 parental fibroblasts were plated into a 10-cm dish with D5 media and cultured overnight. The next day, 1 mg of inducible, gene-of-interest vectors (C15 or GC-C) were co-transfected alongside 2 mg of the pCMV(CAT)T7-SB100 vector (Addgene plasmid #34879) using 9 ml of X-tremeGENE HP DNA transfection reagent (Roche). Complexes were formed at room temperature for 30 minutes, replacing culture media before addition to cells. Transfections were left in the incubator for 48 hours. After incubation, cells were trypsinized, spun down, and resuspended in 10 ml of D10-Bla (D10 + 2 mg/ml blasticidin) media. For each cell line, either 1 ml, 400 ml, 200 ml, 100 ml, 50 ml, or 20 ml of cell suspension was plated in a final volume of 2 ml D10-Bal in a 6-well plate. Cells were left in the incubator for 1-2 weeks, replacing every 2-3 days and monitoring the development of cell “islands”. Individual cell islands were marked using a light microscope and subsequently scraped using a p200 tip into 1 ml of D10-Bla media in individual wells of a 24-well plate. Colonies were expanded from a 24-well plate into a 6-well plate and subsequently screened by flow cytometry for protein expression. To screen clones for protein expression, clones were trypsinized and duplicated into another 6-well plate. The duplicate plate media was supplemented with 1 mg/ml doxycycline hyclate (Sigma-Aldrich), and cells were induced overnight. The following day, cells were recovered from each well using a calcium-magnesium free medium and scraping, followed by gentle resuspension. Clones were then stained, using an antibody specific for the HAtag expression, either by surface staining (C15) or intracellular staining (GC-C) and analyzed using a flow cytometer. The top clone(s) from the original plate were expanded and frozen down for further use. To induce cells for T cell hybridoma assays (see below), cell lines were trypsinized, spun down, and resuspended in complete D5 media (no blasticidin). Between 2-3 x 10 6 cells of each cell line were transferred into two duplicate 15-ml conical vials and topped up with D5 media to ~14.5 ml. To both tubes, 150 ml of 1M HEPES pH 7.4 (Gibco) was added, but to only one tube, 150 ul of 100 mg/ml doxycycline (diluted 1:100 from a 10 mg/ml stock) was added for the induced condition. Conicals were then parafilmed and rotated at 37 o C end-over-end for 16-20 hours. Viral genome sequencing To prepare DNA from ECTV viruses for sequencing, genomic DNA was isolated from 0.5 ml of sucrose-cushion purified viral stock using the DNeasy Blood and Tissue Kits (Qiagen) according to manufacturer protocols. Two mg of genomic DNA was sent to Genewiz for library preparation and short read whole genome sequencing, collecting a total of 1 GB sequencing data for each viral sample. Reads were mapped to the ECTV Moscow (GenBank AF012825.2) genome. Genomic variants were visualized using the Integrative Genomics Viewer (IGV Version 2.19.1) 135 . ECTV-eGFP and ECTVDC15 were determined to be >99.997% identical to the reference genome. Whole virion ELISA and anti-A33R antibody validation To quantify the development of anti-ECTV antibodies, high-capacity ELISA plates were coated with 2 x 10 5 PFU ECTV Moscow in 100 ml PBS overnight at 4 o C. The following day, the plates were blocked (3% goat serum, 0.5 % dehydrated milk powder, 0.1% Tween-20 in PBS) for 1.5 hours at RT with 150 rpm shaking. Plates were washed with PBS-T (PBS + 0.05% Tween-20) and 100 ml of serum serial dilutions were added for 2 hours at RT with 150 rpm shaking. Serial dilutions of the human anti-A35R antibody were also added to test cross-reactivity with ECTV. After removing and washing serum/antibody dilutions, plates were stained with 100 ml goat anti-mouse IgG (H+L) HRP secondary antibody at 1:5000 or goat anti-human IgG (H+L) HRP secondary antibody at 1:2500 in blocking buffer for 1 hour at RT with 150 rpm shaking. Afterwards, plates were washed and 100 ml of TMB SureBlue substrate (1:1 mixture of solutions A and B, SeraCare) were added to each well without shaking for 10 minutes at RT in the dark. After 10 minutes, 50 ml of 2M hydrochloric acid (HCl) was added to each well, and plates were gently tapped to distribute HCl. Immediately after neutralization, plate absorbance was measured at 450 nm. To validate cross-reactivity of anti-A35R monoclonal with ECTV A33R, B6 parental fibroblasts were infected in vitro with ECTV-eGFP. Briefly, two aliquots of 5 x 10 5 cells were spun down in 1.7-ml microfuge tubes and resuspended in 100 ul PBS + 1% FBS. To one tube, 5 x 10 5 PFU of ECTV-eGFP were added, and the tubes were left to incubate at 37 o C for 1 hour, gently resuspending with a p200 every 20 minutes. After the incubation, tubes were topped up with D5 media and spun down. Cells were resuspended in 1 ml of D5 media and subsequently plated in a 6-well plate in a final volume of 2 ml of D5 media overnight. The next day, cells were trypsinized, spun down, and transferred to a 96-well U-bottom plate for flow cytometry staining. Synthetic peptides The following synthetic peptides were used: OVA 257-264 (SIINFEKL), M-SL9 (SLQGRTLIL) 136 , NP 366-374 (ASNENMETM), NA 437-451 (TVDWSWPDGAELPFT) 134 , B8R 20-27 (TSYKFESV), and EVM153 46-60 (VKNKYMWCYSQVNKR) 137 . All peptides were obtained lyophilized from Genscript at >85% purify. Stock concentrations were made to 10 mg/ml in DMSO. T cell hybridoma assay The day before a T cell hybridoma assay, cells were induced as described above. In some instances, 1 mg of mRNA-LNP/1 x 10 6 cells was added to the 15-ml conical prior to end-over-end rotation overnight. The following day, fibroblasts (APCs) were spun down and resuspended to 2.5 x 10 5 cells/ml in R10 media. T cell hybrids were harvested from their respective flasks and resuspended to 2.78 x 10 5 cells/ml in R10 media. To a 96-well black flat-bottom plate, 100 ul of APCs and 90 ul of T cell hybrids were plated into respective wells. When adding peptide, 10 ul of 200 mg/ml synthetic peptide diluted in 0.1% BSA/PBS was added to each corresponding well (10 mg/ml final concentration). In negative control wells, 10 ul of 0.1% BSA/PBS was added in absence of peptide. Co-cultures were incubated at 37 o C for 16-20 hours. After incubation, co-cultures were lysed with a substrate buffer containing 1.25% Triton X-100, 22 mg/ml 4-methyl-umbelliferyl-b-D-galactopyranoside (Sigma-Aldrich), 38.5 mM 2-mercaptoethanol and 9 mM MgCl 2 in PBS for 3 hours at 37 o C. After incubation, fluorescence was quantified at 365/445 nm using a microplate reader. Hybridoma assays consisted of at least three technical replicates and were performed several independent times where indicated. For hybridoma assays with phorbol 12-myristate 13-acetate (PMA) and ionomycin, APC-hybrid co-cultures in the presence of exogenous peptide were allowed to incubate for 1 hour at 37 o C prior to addition of 50 ng/ml PMA and 1 mg/ml ionomycin. Trans and supernatant inhibition assay Trans inhibition assays were performed the same as other T cell hybridoma assays with a few modifications. Briefly, bystander cells (MHCII-negative, B6-C15 or B6-GC-C) were spun down and resuspended to 1 x 10 6 in R10 media. A serial dilution of bystander cells was made such that concentrations were 5 x 10 4 cells/50 ml, 2.5 x 10 4 cells/50 ml, and 1.25 x 10 4 cells/50 ml. To corresponding wells, 50 ml of diluted bystanders or 50 ml R10 medium alone were added. APCs (MHCII-positive, B6-CIITA) were resuspended to 5 x 10 5 cells/ml, and 50 ml were added to each well. Peptide was added to a final concentration of 10 mg/ml, as above, and co-cultures were incubated at 37 o C for 16-20 hours. Assay readout was performed according to standard protocols. To test inhibitory capacity of supernatant, 5 x 10 6 B6-C15-CIITA or B6-GC-C-CIITA cells were induced overnight in a 15-ml conical vial. The next day, induced cells were spun down and supernatant isolated. B6-CIITA cells were then resuspended to 2.5 x 10 5 cells in either R10, B6-C15-CIITA supernatant, or B6-GC-C-CIITA supernatant. A standard T cell hybridoma assay was then setup and readout the following day. Generation of mRNA-LNPs OVA mRNA-LNPs were a kind gift of Dr. Mohamed-Gabriel Alameh and are described elsewhere. 138 Preclinical-grade mRNA encoding the a and b chains of I-E d were made using previously published methods. 139,140 The b chain was modified to encode a covalently linked epitope (“S1”, FERFEIFPK) to ensure proper folding of I-E d . To maximize translation of mRNA molecules, the sequence was codon-optimized to enrich for GC content. Optimized DNA sequences were inserted into an mRNA expression vector that was a kind gift of Dr. Drew Weissman. Expression vectors were first linearized prior to in vitro transcription using the MEGAscript T7 Transcription Kit (ThermoFisher), substituting N1-methylpsuedouridine (TriLink) in place of uridine and co-translationally capping with the CleanCap reagent (TriLink). Synthesized mRNA was purified using cellulose to remove dsRNA byproducts, and the quality evaluated by agarose gel electrophoresis. Equal molar ratios of I-E d a and b chains were co-encapsulated into LNPs. The lipid mixture was composed of the SM-102 (BroadPharm), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, Avanti), cholesterol (Avanti), and 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG-2000, Avanti) at a 50:38.5:10:1.5 molar ratio. Lipids were dissolved in ethanol and buffered in 10% v/v citric acid, pH 4.0. Subsequently, 150 mg of total mRNA were diluted in citric acid buffer. The total lipid mass to RNA mass ratio was 17.5:1. Lipids were then added into diluted mRNA and rapidly mixed via P1000 pipet 15-17 times. LNPs were then immediately neutralized with an equal volume of PBS and dialyzed in PBS overnight using a 10 kDa dialysis cassette (Thermo). The following day, mRNA-LNPs were concentrated using a 10 kDa centrifugal filter (Amicon) to 0.2-0.3 mg/ml. Synthesis of recombinant Flt3l For recombinant Flt3l generation, a codon-optimized (Twist Biosciences) DNA sequence for the ectodomain of human Flt3l (Met1-Ala181, Uniprot P49771) fused to a C-terminal 6x-His tag was inserted into a CMV promoter-driven expression vector via in-fusion cloning. Endotoxin-free plasmid preparations were then transfected into Expi293 cells (ThermoFisher) according to manufacturer recommendations. Briefly, 20 mg of pCMV-hFtl3l-6xHis and 80 ml of Expifectamine 293 were diluted into 1.5 and 1.4 ml of Opti-MEM I Reduced Serum Media, respectively (Gibco). After incubation for 5 minutes at RT, the diluted Expifectamine 293 was added into the diluted DNA, gently mixing with a p1000 pipet. Complexes were allowed to form at RT for 15 minutes. During complexation, Expi293 cells were diluted to 3 x 10 6 cells/ml in 25 ml of Expi293 Expression Medium (Gibco). After the incubation, formed complexes were added dropwise to Expi293 cells while gently shaking to distribute. Cells were placed back into the incubator at 37 o C while shaking on an orbital shaker at 125 rpm for 18-20 hours. The following day, 150 ml of Enhancer 1 and 1.5 ml of Enhancer 2 were added to the transfected cells. The cells were then placed back into the incubator and grown for an additional 4 days (5 days total expression). To purify recombinant protein, cell cultures were spun down at 2500 x g for 10 minutes at 4 o C. The supernatant was subsequently filtered through a 0.22 mm filter and concentrated down to ~10 ml using a 10 kDa centrifugal filter (Amicon). To prepare EDTA-compatible Ni-IMAC resin (Pierce) for protein capture, 0.5 ml of slurry for each purification was transferred into a 5-ml tube on ice. After settling, the supernatant was removed and the beads were resuspended in 1.5 ml of equilibration buffer (50 mM monosodium phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 8.0). The equilibration buffer was removed and the concentrated Expi293 supernatant was added to the washed beads. The cell supernatant was rotated end-over-end with beads for 1 hour at 4 o C. After incubation, the supernatant was run through a disposable gravity flow column (Bio-Rad) and rinsed once with 1 column volume (CV, ~10 ml) of equilibration buffer. The settled resin was then washed with 3 CV of wash buffer (50 mM monosodium phosphate, 300 mM sodium chloride, 20 mM imidazole, pH 8.0). The bound protein was eluted with 3 x 3 ml of elution buffer (50 mM monosodium phosphate, 300 mM sodium chloride, 500 mM imidazole, pH 8.0). Elutions were pooled and dialyzed overnight using a 10 kDa dialysis cassette (ThermoFisher) in 1x PBS. The following day, dialyzed protein was concentrated to ~1 mg/ml and confirmed to be >90% pure via SDS-PAGE. Aliquots were supplemented with sucrose to 5% v/v and flash frozen in liquid nitrogen, with long-term storage at -80 o C. Preparation of mouse tissues (spleen, LN, liver, PBMCs/serum) To process spleens, organs were harvested and kept in PBS on ice until processing. Spleens were manually homogenized through a 70 mm cell strainer using a 1-ml syringe plunger and subsequently washed with 10 ml of FACS buffer (PBS + 1% FBS + 2 mM EDTA). Homogenates were then spun down at 4 o C and resuspended in 3 ml of ACK lysis buffer, left at RT for 3 minutes, and topped up with cold PBS before spinning again. Cell pellets were resuspended in 10 ml of FACS buffer and passed through a 40 mm strainer to prepare a single cell suspension. To harvest Flt3l-derived cDC1s, processing was the same except for a pre-incubation of spleen pieces with 1 mg/ml Collagenase Type IV and 20 mg/ml DNase I for 30 minutes at 37 o C prior to homogenization. To process draining lymph nodes (LN, inguinal and popliteal), organs were harvested and gently stripped of excess fat before placing in PBS on ice. LNs were then manually homogenized through a 70 mM strainer, washed with 10 ml of FACS buffer, and immediately strained through a 40 mm strainer to prepare a single cell suspension. To process the liver, the gallbladder was removed, and the organ was kept on ice in 5 ml R10 media until processing. The liver was manually homogenized through a 70 mm strainer and washed with 10 ml FACS buffer. The suspension was centrifuged at RT, and the pellet was resuspended in 5 ml RT 42% isotonic Percoll (Cytiva). The suspension was then centrifuged at 800 x g for 20 minutes at RT with no brake to separate hepatocytes (top layer) and lymphocytes (pellet). After spinning, the hepatocytes and remainder of supernatant was carefully removed. ACK lysis was then performed in 5 ml final volume for 5 minutes at RT. After lysis, 5 ml of FACS buffer was added to the suspension and centrifuged at 300 x g for 3 minutes. The lymphocyte pellets were resuspended in 5 ml FACS buffer to prepare the single cell suspension. Blood collection was through the retro-orbital vein using a capillary tube. To harvest serum, blood was transferred into serum gel tubes (Sarstedt) and spun down at 10,000 x g for 5 minutes. Serum was subsequently stored at -20 o C. To collect PBMCs, blood was collected into 200 ul of PBS + 50 mM EDTA and diluted 1:1 with R10 media prior to underlaying 500 ml of Histopaque-1083 (Sigma-Aldrich). Suspensions were centrifuged at 2000 rpm x 20 minutes at RT with no brake. PBMCs were collected from the interface and transferred in a FACS tube with 4 ml of R10 media. After spinning down, cells were ACK lysed and resuspended as necessary to prepare single cell suspensions. IFN-g ELISpot assay To generate cDC1s for ELISpot, one female B6 mouse was injected i.p. with 10 mg of recombinant Flt3l diluted up to 200 ml PBS daily for 8 days. On day 9, spleens were harvested and processed into single cell suspensions. To magnetically deplete non-cDC1s, 65 x 10 6 splenocytes were resuspended to 1 x 10 8 cells/ml in MACS buffer (PBS + 0.1% BSA + 2 mM EDTA) and 65 ul of magnetic depletion master mix was added (anti-TER-119: 25 mg/ml, anti-CD64: 50 mg/ml, anti-CD19: 50 mg/ml, anti-CD3: 50 mg/ml, anti-NK1.1: 50 mg/ml, anti-CD317: 25 mg/ml, anti-Ly6G: 25 mg/ml, anti-CD31: 25 mg/ml, anti-Ly6C: 50 mg/ml, anti-CD16/CD32: 100 mg/ml, anti-CD172a: 50 mg/ml, anti-CD11b: 50 mg/ml). Of note, anti-F4/80 was found to remove Flt3l-generated cDCs, and the inclusion of this antibody is not recommended. The cells and antibodies were incubated on ice for 20 minutes and subsequently diluted up to 4 ml with MACS buffer before centrifugation. Splenocytes were resuspended back to 1 x 10 8 cells/ml in MACS buffer, and 65 ul of streptavidin nanobeads (Biolegend) were added. After 20 minutes on ice, bead-bound splenocytes were diluted up to 2.5 ml with MACS buffer and magnetically separated (cDC1s were untouched), repeating magnetic purification one additional time. To infect cDC1s, cells were spun down and resuspended to 5 x 10 6 cells/ml in PBS + 1% FBS. WT ECTV or ECTVDC15 was added to an MOI of 1, and cells were infected at 37 o C for 1 hour, with gentle resuspension every 20 minutes. After incubation, cells were washed with R10 media and resuspended to 1.5 x 10 5 cells/ml. Two hours prior to T cell addition, 100 ul of cDC1s were added to an ELISpot plate (Millipore) precoated with an IFNg capture antibody according to manufacturer protocols (BD Biosciences) and incubated at 37 o C. To generated ECTV-specific T cells, 2 female B6 mice were infected with WT ECTV for 8 days prior to spleen harvest. After spleen processing, splenocytes were pooled and CD4+ and CD8+ T cells were isolated using corresponding Mojosort isolation kits (Biolegend). The magnetic negative selection process was identical to that of cDC1s above. CD8+ and CD4+ T cells were resuspended to 1.5 x 10 5 cells/ml and 3 x 10 5 cells/ml, respectively, in R10 prior to plating. To corresponding wells, 100 ul of diluted T cells were added. The ELISpot plates were allowed to incubate at 37 o C for 16-18 hours. ELISpot plates were developed according to manufacturer protocols and IFNg spots were quantified using a CTL Immunospot S6 Universal Analyzer. Flow cytometry and tetramer For flow cytometry, viable cells were first discriminated using either Live/Dead Fixable Aqua dye (ThermoFisher) at 1:500 or Zombie UV Fixable dye (Biolegend) at 1:1000 for 10 minutes at RT. Alongside all surface stains, anti-CD16/CD32 (BioXCell) was added to a final concentration of 10 mg/ml to block Fc receptors. Surface stains were performed for 30 minutes at 4 o C in FACS buffer. In panels involving transcription factors (e.g., T-bet, TCF-1), cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer Set (Invitrogen) for 1 hour at RT. For all other panels, cells were fixed and permeabilized using the Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences) for 20 minutes at 4 o C. All intracellular staining was performed at RT for 30 minutes. For ECTV A33R detection, unconjugated anti-MPXV A35R was included in intracellular stains, and a BV711 anti-human secondary was subsequently added for an additional 30 minutes at RT. Samples were analyzed on the BD Fortessa or Symphony A5 cytometers, and data were processed using FlowJo (BD Biosciences). B8R tetramers were included in the extracellular stain at 2 mg/ml where applicable. Notably, the B8R tetramer is most compatible with the anti-CD8 clone KT15, as clone 53-6.7 was found to cause antigen-non-specific tetramer binding. I1L tetramer staining was performed separately for 1 hour at 37 o C at 2 mg/ml prior to viability staining. Intracellular cytokine and degranulation assay Six hours prior to restimulation, DC2.4 cells were harvested, and two aliquots of 5 x 10 6 cells were resuspended to 50 x 10 6 cells/ml in PBS + 1% FBS. Cells were subsequently left uninfected or infected with DC15 at an MOI of 1 for 1 hour at 37 o C, with gentle resuspension every 20 minutes. After 1 hour, cells were diluted in a 15-ml conical vial up to 15 ml with R10 supplemented with 10 mM HEPES and rotated end-over-end for five hours. For cytokine and CD107a staining, 2 x 10 6 splenocytes were added to a 96-well U-bottom plate in 100 ml R10 medium and allowed to equilibrate for 30 minutes at 37 o C. During incubation, DC2.4 cells were spun down and resuspended to 2 x 10 6 cells/ml in R10. To corresponding wells, 50 ml of uninfected or infected DC2.4 cells were added. For peptide stimulation, 50 ml of 40 mg/ml peptide (B8R or 963) and 8 mg/ml anti-CD28 (Biolegend) in R10 were added to corresponding wells (final concentrations 10 mg/ml and 2 mg/ml, respectively). Splenocyte suspensions were then incubated at 37 o C for 1 hour. After 1 hour, 50 ml of 20 mg/ml brefeldin A, 8 mM monensin, and 8 mg/ml anti-CD107a (BD Biosciences) were added to each well (final concentrations 4 mg/ml, 2 mM, and 2 mg/ml, respectively), and splenocytes were left at 37 o C for 5 additional hours. After restimulation, cells were then stained for flow cytometry as described above. Naïve splenocytes were used as a negative control. FACS sorting and bulk sequencing preparation For T eff and B8R+ T eff sorting, 25 x 10 6 splenocytes were viability and surface stained for CD44, CD4, CD8a, B8R tetramer, CD3, and CD62L. Samples were then sorted using an Aurora CS-2 Cell Sorter (Cytek). For bulk TCR sequencing, 4 x 10 3 B8R+ CD8+ T eff were sorted into FACS buffer. For T eff bulk mRNA sequencing, between 4 x 10 4 and 1.5 x 10 5 CD4+ or CD8+ T eff were sorted into FACS buffer. After sorting, cells were centrifuged at 400 x g for 5 minutes and washed in PBS. For TCR sequencing, B8R+ CD8+ T eff were directly lysed and subjected to first-strand synthesis using the SMART-Seq Mouse TCR (with UMIs) kit (Takara) according to manufacturer instructions. Initial TCR a/b chain amplifications were performed according to manufacturer instructions. For amplification during PCR #2 (UDI addition), 24 cycles gave the best yield across all samples. Amplified libraries were then pooled (equimolar) and concentrated using NucleoMag NGS Clean-up and Size Select beads (Takara). cDNA concentrations were quantified using a Qubit 4 Fluorometer, and size analysis was performed using an Agilent TapeStation. For bulk T eff mRNA sequencing, cells were lysed in 200 ml TRI Reagent (Zymo) and vortexed at 1000 rpm for 60 seconds. RNA was isolated using a Direct-zol RNA Microprep kit (Zymo) according to manufacturer instructions, eluting in 8 ml of nuclease-free water. mRNA quality was assessed using an Agilent Bioanalyzer. RNA was converted into cDNA libraries using the Zymo-Seq SwitchFree 3’ mRNA Library Kit (Zymo) according to the manufacturer protocol. Based on RNA concentrations, library amplification PCR reactions were performed with 19 cycles for 100 ng input RNA, 20 cycles for 75 ng input RNA, and 21 cycles for 50 ng input RNA. Sample groups (based on dpi and T cell type) were pooled and concentrated using SPRIselect Beads (Beckman Coulter). cDNA concentrations were quantified using a Qubit 4 Fluorometer, and size analysis was performed using an Agilent TapeStation. For popliteal LN mRNA sequencing, LNs were prepared as described above. Cell pellets were resuspended in 200 ml TRI Reagent and vortexed at 1000 rpm for 60 seconds. RNA was isolated using a Direct-zol RNA Miniprep kit (Zymo) according to manufacturer instructions, eluting in 20 ml of nuclease-free water. mRNA quality was assessed using an Agilent Bioanalyzer. RNA was converted into cDNA libraries as above, using 100 ng input RNA. Samples were pooled and concentrated using SPRIselect beads. cDNA concentrations were quantified using a Qubit 4 Fluorometer, and size analysis was performed using an Agilent TapeStation. Bulk TCR sequencing and analysis Pooled TCR libraries were sent to Novogene and sequenced using the NovaSeq X Plus with paired-end 150 bp sequencing. A total of 50 GB were sequenced across sub-libraries. For all sub-libraries, the average Q30 was 90%. FASTQ files were processed and analyzed using the Cogent NGS Immune Profiler Software (Takara) according to manufacturer recommendations, with >95% of all reads mapping to either the TCR a or b chain. A UMI cutoff of 8 was used to ensure only high quality UMI groups were included in clonality analyses. To calculate Simpson Clonality, the proportion of individual clonotypes (on the nucleotide level) was squared, the squared proportions were then summated, and the square root of this sum was calculated as the final clonality parameter. V and J gene usage was calculated as an output of Cogent NGS Immune Profiler Software. Bulk RNA sequencing and analysis Pooled 3’ mRNA libraries were sent to Novogene and sequenced using the NovaSeq X Plus with paired-end 150 bp sequencing. A total of 350 GB were sequenced across sub-libraries, for a sequencing depth of ~30 x 10 6 paired-end reads per sample. Due to low sequence diversity, 17% PhiX was spiked in to improve run quality. All sub-libraries had a Q30 > 78%, with an average of 82%. To pre-process sequencing data, umi_tools 141 was used to extract the UMI from read 1 and assign to corresponding read 2 (UMI-tagged). Afterwards, UMI-tagged reads were trimmed to remove polyT tracts and Illumina adapter sequence. A genome index was generated with STAR (version 2.7.10a) 142 using the GRCm39 mouse reference genome. Trimmed, UMI-tagged reads were then aligned against the genome index to generate BAM files. BAM files were indexed, and UMIs were subsequently deduplicated using umi_tools . Prior to differential expression analysis, count matrices were generated using featureCounts 143 . Gene labels were mapped to Ensembl gene IDs, and samples were then analyzed using DESeq2 144 , identifying significant genes as those with an adjusted p-value 0.5. Principal component plots were generated using rlog transformed counts. Where applicable, ambient RNA content was highlighted in volcano plots, manually identified by a high abundance of erythrocyte-associated genes. To perform gene ontology (GO) term enrichment, differentially expressed genes were analyzed using Metascape 145 . The most significantly enriched terms (defined by a -log 10 (q-score) > 1.3), and their corresponding q-scores, were plotted in GraphPad prism. Gene set enrichment analysis (GSEA) was performed using software distributed by the Broad Institute 146 . Relevant gene sets were downloaded from the Molecular Signatures Database available through the GSEA website ( https://www.gsea-msigdb.org/gs=a/msigdb/index.jsp ). When applicable, genes strongly associated with ambient RNA (i.e., hemoglobin-associated genes) were excluded from GSEA analysis to prevent confounding outputs. In vivo antibody and antiviral treatment For in vivo antibody treatments, 200 mg of antibody were diluted up to 200 ml in PBS and administered i.p. at specified timepoints. For antiviral treatment, CDV powder was diluted to 2 mg/ml in PBS with pulse vortexing, and the solution was 0.22-mm filtered to ensure sterility. Antiviral concentration was confirmed by A 280 absorbance prior to administration. CDV was administered in a final volume of 300 ml i.p., and the untreated mice received 300 ml of PBS only. Tetramer decay assay The tetramer decay assay was adapted from a recent publication 47 . Female B6 mice were infected with either WT or DC15 for 14 days, and spleens were subsequently harvested and processed into single cell suspensions. For each spleen, CD8+ T cells were isolated from 50 x 10 6 splenocytes using the MojoSort Mouse CD8 Isolation Kit (Biolegend) according to manufacturer instructions. For each mouse, 2-3 x 10 6 CD8+ T cells were plated in a 96-well U-bottom plate. Cells were subsequently stained for viability and surface stained for CD4, CD8a, and B8R specificity using PE and APC tetramer conjugates. After surface staining, wells were washed and split into four equal aliquots across 4 plates. Cells were then resuspended in tetramer stabilizing solution (20 mg/ml anti-H-2K b and 5 mg/ml anti-phycoerythrin (PE) in FACS buffer) and left for either 0, 15, 90 or 180 minutes at RT. After timepoint incubations, cells were fixed and left at 4 o C until running on the cytometer. In this experiment, no differences in binding kinetics were found between APC and stabilized PE tetramers. RNA isolation and qPCR in popliteal LN Female B6 mice were infected with either WT or DC15 for 24 or 32 hours. After harvesting, popliteal LNs were placed into 250 ml of RNALater (Invitrogen) and left at 4 o C until processing. LNs were then removed from RNALater and placed into 600 ml of TRI reagent in Type F homogenization tubes (Macherey-Nagel). Homogenization tubes were then vortexed at speed “4” at RT for 10 minutes. Homogenates were removed from beads and purified using the Direct-Zol RNA Miniprep kit (Zymo). RNA concentration was quantified using a Qubit 4 fluorometer and quality was evaluated using an Agilent Bioanalyzer. RNA abundance was then quantified using the ZymoScript One-Step RT-qPCR kit (Zymo), performing reactions for EVM003 and GAPDH (Table S4), according to manufacturer protocols. Technical duplicates were performed for each RNA sample. Relative RNA quantity was then calculated using the DDC t method, first normalizing to GAPDH signal prior to calculating fold-change differences between samples. Naïve LNs were used to establish the C t threshold associated with non-specific amplification (background). FACS sorting and fixation for scRNA-seq For scRNA-seq, female B6 mice were infected with either WT or DC15 for 24 or 48 hours. Sorting was performed on consecutive days to cut down time on ice during processing. Single cell suspensions of popliteal LNs were prepared as described above, except FACS buffer was spiked with RNasin Plus (Promega). Cells were viability stained and subsequently surface stained for CD19 at 4 o C for 30 minutes. After staining, live, CD19-positive and CD19-negative cells were separately sorted into LoBind tubes (USA Scientific) containing RNasin-supplemented FACS buffer. CD19-positive cells were pooled across infection conditions. Lymph nodes with minimal CD19-negative cell recovery were excluded from downstream analysis. Cell populations were subsequently fixed using the Evercode Cell Fixation kit (Parse Biosciences) according to manufacturer instructions. Fixed cells were concentrated, counted, and stored in either 50 or 10 ml aliquots at -80 o C in Cell Storage Master Mix. One day prior to scRNA library preparation, a 10 ml aliquot was thawed on ice and counted using disposable hemocytometers (Bulldog Bio). Cell counts were used to calculate the quantity of cells to load for library preparation, according to the sample loading table provided by Parse Biosciences. scRNA-seq sample processing and analysis Libraries were prepared using the Evercode WT kit (Parse Biosciences), primarily following all manufacturer instructions. When performing cDNA amplification, 8 cycles were chosen based on low RNA content cells and 12,500 cells per sub-library. For size selection, SPRIselect beads were used. To perform size analysis on cDNA, the Agilent TapeStation was used. All cDNA libraries yielded >20 ng/ul in a final volume of 20 ml. An initial 2 x 10 9 paired-end 150 bp reads were generated through a promotional program with Parse Biosciences. An additional 3 x 10 9 paired-end 150 bp reads were acquired through Novogene. Q30 values were greater than 90% for all sub-libraries with a spike-in of 10% PhiX. Across sub-libraries, a total of 69,803 cells were recovered with a total of 83,602 mean reads/cell. The median transcripts and genes per cell were 9,964 and 3,150, respectively, with a total sequencing saturation of 0.604. The Trailmaker web server (Parse Biosciences) was used for data analysis. For quality control parameters, the automatic cell size distribution filter was applied. A manual max percentage of 3% was set for the mitochondrial content filter. An automatic spline-type fit was used to select cells with good correlation of gene vs transcript numbers. A manual probability threshold of 0.4 was set for the doublet filter. Data integration was performed with Harmony 147 using automated settings set by Trailmaker. Lastly, cells were embedded into a UMAP and clustering was performed using the Leiden algorithm 148 , with a resolution of 0.15. For analysis focusing on T and NK lymphocytes, B lymphocyte clusters were excluded and re-clustering performed at a resolution of 0.13. The Trailmaker software was used to generate heatmaps and volcano plots visualizing differential gene expression analysis. Sub-clustering was similarly performed on NK cells (as defined by Ncr1 ), and a resolution of 0.1 was used to generate key clusters. Quantification and statistical analysis GraphPad Prism was used to perform all statistical tests for cell-based assays and flow cytometry data. When comparing across multiple groups in in vitro data, a two-way ANOVA with Šidák correction for multiple comparisons was performed. To compare two groups (e.g., WT vs. DC15) in vitro , a two-tailed unpaired t-test was performed. To statistically analyze in vivo parameters across multiple infection groups and time points (e.g., 5-10 dpi), a mixed-effects model was used with Šidák correction for multiple comparisons. For additional in vivo studies, two-way ANOVA with either Tukey or Šidák corrections for multiple comparisons were performed. Relevant statistical analyses are indicated within figure legends. In all experiments, results are expressed as mean ± standard deviation (SD). A p-value < 0.05 was considered significant, with significance indicated as *p < 0.05, **p < 0.01, ***p < 0.001, and **** p < 0.0001. Data availability: Lead Contact Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Laurence Eisenlohr ( [email protected] ). Reagents are available on request to the lead contact with a completed materials transfer agreement. All sequencing datasets are available on GEO as follows: bulk RNA sequencing i) CD4+ T eff 7 dpi (GSE308806), ii) CD8+ T eff 7 dpi (GSE308808), iii) CD8+ T eff 10 dpi (GSE308809), iv) dLN 48 hpi (GSE309219), TCR sequencing (GSE 309222), and single cell RNA sequencing (GSE309220). Declarations Acknowledgements: We thank members of the Eisenlohr lab for their insights and feedback throughout the development of this work; Dr. Camila Coelho and Dr. Raianna Fantin for providing the plasmids encoding the anti-A35R (i.e., anti-A33R) monoclonal antibody; Dr. Mohamed-Gabriel Alameh for providing OVA-encoding mRNA-LNPs; Keenan O’Dea for his expertise in anti-CD40L administration; Vivian Hoang for technical assistance in generating the UbC-C15-CIITA cell line. Flow cytometry data was acquired using the CHOP Flow Cytometry Core Laboratory (RRID:SCR_009726) and the Penn Cytomics and Cell Sorting Shared Resource Laboratory (RRID:SC_022376). Penn Cytomics is partially supported by the Abramson Cancer Center NCI Grant (P30 016520). RNA integrity and DNA size analysis was performed through the CHOP High Throughput Sequencing Core. We thank the NIH Tetramer Core Facility (NIH Contract 75N93020D00005 and RRID:SCR_026557) for providing B8R and I1L tetramers. Model illustrations were created using BioRender. S.D.C. was supported by an NIH F31 fellowship (F31AI183694). This work was supported by NIH grants R21AI160063 and R01AI182049 awarded to L.C.E. Author contributions S.D.C., E.M.P., and L.C.E. conceptualized the project. S.D.C. and L.C.E. conceptualized all experiments. S.D.C. performed all experiments with technical help from E.J.H., M.K.H., and C.L-S. A.R.C. provided intellectual expertise in flow cytometry methodology and panel development. H.M.S. synthesized and assisted in the characterization of anti-A33R antibodies. S.D.C. performed all formal analysis, including sequencing analysis. S.D.C. and L.C.E. wrote the manuscript, with critical review from all authors. Declaration of interests The authors declare no competing interests. References McFadden, G. (2005). Poxvirus tropism. Nat Rev Microbiol 3 , 201–213. 10.1038/nrmicro1099. MacNeill, A.L. (2022). Comparative Pathology of Zoonotic Orthopoxviruses. Pathogens 11 . 10.3390/pathogens11080892. Mitja, O., Ogoina, D., Titanji, B.K., Galvan, C., Muyembe, J.J., Marks, M., and Orkin, C.M. (2023). Monkeypox. Lancet 401 , 60–74. 10.1016/S0140-6736(22)02075-X. Gigante, C.M., Gao, J., Tang, S., McCollum, A.M., Wilkins, K., Reynolds, M.G., Davidson, W., McLaughlin, J., Olson, V.A., and Li, Y. (2019). Genome of Alaskapox Virus, A Novel Orthopoxvirus Isolated from Alaska. Viruses 11 . 10.3390/v11080708. Doty, J.B., Maghlakelidze, G., Sikharulidze, I., Tu, S.L., Morgan, C.N., Mauldin, M.R., Parkadze, O., Kartskhia, N., Turmanidze, M., Matheny, A.M., et al. (2019). Isolation and Characterization of Akhmeta Virus from Wild-Caught Rodents (Apodemus spp.) in Georgia. J Virol 93 . 10.1128/JVI.00966-19. Cardeti, G., Gruber, C.E.M., Eleni, C., Carletti, F., Castilletti, C., Manna, G., Rosone, F., Giombini, E., Selleri, M., Lapa, D., et al. (2017). Fatal Outbreak in Tonkean Macaques Caused by Possibly Novel Orthopoxvirus, Italy, January 2015 (1). Emerg Infect Dis 23 , 1941–1949. 10.3201/eid2312.162098. Deputy, N.P., Deckert, J., Chard, A.N., Sandberg, N., Moulia, D.L., Barkley, E., Dalton, A.F., Sweet, C., Cohn, A.C., Little, D.R., et al. (2023). Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med 388 , 2434–2443. 10.1056/NEJMoa2215201. Taha, A.M., Mahmoud, A.M., Abouelmagd, K., Saed, S.A.A., Khalefa, B.B., Shah, S., Satapathy, P., Shamim, M.A., Sah, S., Serhan, H.A., et al. (2024). Effectiveness of a single dose of JYNNEOS vaccine in real world: A systematic review and meta-analysis. Health Sci Rep 7 , e70069. 10.1002/hsr2.70069. Granskog, L., Saadeh, K., Lorenz, K., Quint, J., Salih, T., Lo, T., Jacobson, K., Ramos, M., Chapman, E., Snyder, R.E., and Lewnard, J.A. (2025). Effect of JYNNEOS vaccination on mpox clinical progression: a case-control study. Lancet Infect Dis 25 , 1106–1115. 10.1016/S1473-3099(25)00180-X. Phipps, K., Yates, J., Pettit, J., Bialosuknia, S., Hunt, D., DuPuis, A.P., 2nd, Payne, A., Lee, W., and McDonough, K.A. (2025). Short-Lived Neutralizing Antibody Responses to Monkeypox Virus in Smallpox Vaccine-Naive Persons after JYNNEOS Vaccination. Emerg Infect Dis 31 , 237–245. 10.3201/eid3102.241300. Garrigues, J.M., Hemarajata, P., Karan, A., Shah, N.K., Alarcon, J., Marutani, A.N., Finn, L., Smith, T.G., Gigante, C.M., Davidson, W., et al. (2023). Identification of Tecovirimat Resistance-Associated Mutations in Human Monkeypox Virus - Los Angeles County. Antimicrob Agents Chemother, e0056823. 10.1128/aac.00568-23. Smith, T.G., Gigante, C.M., Wynn, N.T., Matheny, A., Davidson, W., Yang, Y., Condori, R.E., O'Connell, K., Kovar, L., Williams, T.L., et al. (2023). Tecovirimat Resistance in Mpox Patients, United States, 2022-2023. Emerg Infect Dis 29 , 2426–2432. 10.3201/eid2912.231146. Fortier, J.C., Marsalisi, C., Cordova, E., Guo, H.J., and Verdecia, J. (2024). Challenges in Managing Treatment-Resistant Mpox Complicated by Severe Superinfection. Open Forum Infect Dis 11 , ofae138. 10.1093/ofid/ofae138. Khera, S.S., Mishra, S., Pico Espinosa, O.J., Gough, K., Tan, C., Walmsley, S., Zhabokritsky, A., Sharma, M., Chan, A.K., Leis, J.A., et al. (2025). Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials. J Antimicrob Chemother 80 , 935–940. 10.1093/jac/dkaf010. Alzhanova, D., Hammarlund, E., Reed, J., Meermeier, E., Rawlings, S., Ray, C.A., Edwards, D.M., Bimber, B., Legasse, A., Planer, S., et al. (2014). T cell inactivation by poxviral B22 family proteins increases viral virulence. PLoS Pathog 10 , e1004123. 10.1371/journal.ppat.1004123. Reynolds, S.E., Earl, P.L., Minai, M., Moore, I., and Moss, B. (2017). A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model. Virology 501 , 107–114. 10.1016/j.virol.2016.11.010. Forsyth, K.S., Roy, N.H., Peauroi, E., DeHaven, B.C., Wold, E.D., Hersperger, A.R., Burkhardt, J.K., and Eisenlohr, L.C. (2020). Ectromelia-encoded virulence factor C15 specifically inhibits antigen presentation to CD4+ T cells post peptide loading. PLoS Pathog 16 , e1008685. 10.1371/journal.ppat.1008685. Reynolds, S.E., and Moss, B. (2015). Characterization of a large, proteolytically processed cowpox virus membrane glycoprotein conserved in most chordopoxviruses. Virology 483 , 209–217. 10.1016/j.virol.2015.04.014. Peauroi, E.M., Carro, S.D., Pei, L., Reynoso, G.V., Hickman, H.D., and Eisenlohr, L.C. (2022). The ectromelia virus virulence factor C15 facilitates early viral spread by inhibiting NK cell contact. iScience 25 , 105510. 10.1016/j.isci.2022.105510. Fenner, F. (1988). Smallpox and its Eradication (World Health Organization). Garver, J., Weber, L., Vela, E.M., Anderson, M., Warren, R., Merchlinsky, M., Houchens, C., and Rogers, J.V. (2016). Ectromelia Virus Disease Characterization in the BALB/c Mouse: A Surrogate Model for Assessment of Smallpox Medical Countermeasures. Viruses 8 . 10.3390/v8070203. Sigal, L.J. (2016). The Pathogenesis and Immunobiology of Mousepox. Adv Immunol 129 , 251–276. 10.1016/bs.ai.2015.10.001. Krmpotic, A., Busch, D.H., Bubic, I., Gebhardt, F., Hengel, H., Hasan, M., Scalzo, A.A., Koszinowski, U.H., and Jonjic, S. (2002). MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol 3 , 529–535. 10.1038/ni799. Kowarz, E., Loscher, D., and Marschalek, R. (2015). Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines. Biotechnol J 10 , 647–653. 10.1002/biot.201400821. Tewari, M.K., Sinnathamby, G., Rajagopal, D., and Eisenlohr, L.C. (2005). A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. Nat Immunol 6 , 287–294. 10.1038/ni1171. Potter, L.R. (2011). Guanylyl cyclase structure, function and regulation. Cell Signal 23 , 1921–1926. 10.1016/j.cellsig.2011.09.001. Fang, M., Lanier, L.L., and Sigal, L.J. (2008). A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog 4 , e30. 10.1371/journal.ppat.0040030. Fang, M., and Sigal, L.J. (2005). Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol 175 , 6829–6836. 10.4049/jimmunol.175.10.6829. Parker, A.K., Parker, S., Yokoyama, W.M., Corbett, J.A., and Buller, R.M. (2007). Induction of natural killer cell responses by ectromelia virus controls infection. J Virol 81 , 4070–4079. 10.1128/JVI.02061-06. Gerlach, C., Moseman, E.A., Loughhead, S.M., Alvarez, D., Zwijnenburg, A.J., Waanders, L., Garg, R., de la Torre, J.C., and von Andrian, U.H. (2016). The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis. Immunity 45 , 1270–1284. 10.1016/j.immuni.2016.10.018. Zwijnenburg, A.J., Pokharel, J., Varnaite, R., Zheng, W., Hoffer, E., Shryki, I., Comet, N.R., Ehrstrom, M., Gredmark-Russ, S., Eidsmo, L., and Gerlach, C. (2023). Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. Immunity 56 , 1955–1974 e1910. 10.1016/j.immuni.2023.06.025. Wang, R., Dillon, C.P., Shi, L.Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L.L., Fitzgerald, P., Chi, H., Munger, J., and Green, D.R. (2011). The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35 , 871–882. 10.1016/j.immuni.2011.09.021. Yu, M., Lee, W.W., Tomar, D., Pryshchep, S., Czesnikiewicz-Guzik, M., Lamar, D.L., Li, G., Singh, K., Tian, L., Weyand, C.M., and Goronzy, J.J. (2011). Regulation of T cell receptor signaling by activation-induced zinc influx. J Exp Med 208 , 775–785. 10.1084/jem.20100031. Chen, B., Yu, P., Chan, W.N., Xie, F., Zhang, Y., Liang, L., Leung, K.T., Lo, K.W., Yu, J., Tse, G.M.K., et al. (2024). Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets. Signal Transduct Target Ther 9 , 6. 10.1038/s41392-023-01679-y. Heffner, M., and Fearon, D.T. (2007). Loss of T cell receptor-induced Bmi-1 in the KLRG1(+) senescent CD8(+) T lymphocyte. Proc Natl Acad Sci U S A 104 , 13414–13419. 10.1073/pnas.0706040104. Wedel, J., Kochupurakkal, N., Kong, S.W., Bose, S., Lee, J.W., Maslyar, M., Alsairafi, B., MacLeod, K., Liu, K., Zhang, H., et al. (2025). Neuropilin-2 functions as a coinhibitory receptor to regulate antigen-induced inflammation and allograft rejection. J Clin Invest 135 . 10.1172/JCI172218. Palmer, D.C., Guittard, G.C., Franco, Z., Crompton, J.G., Eil, R.L., Patel, S.J., Ji, Y., Van Panhuys, N., Klebanoff, C.A., Sukumar, M., et al. (2015). Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med 212 , 2095–2113. 10.1084/jem.20150304. Kosugi, A., Sakakura, J., Yasuda, K., Ogata, M., and Hamaoka, T. (2001). Involvement of SHP-1 tyrosine phosphatase in TCR-mediated signaling pathways in lipid rafts. Immunity 14 , 669–680. 10.1016/s1074-7613(01)00146-7. Sridaran, D., Chouhan, S., Mahajan, K., Renganathan, A., Weimholt, C., Bhagwat, S., Reimers, M., Kim, E.H., Thakur, M.K., Saeed, M.A., et al. (2022). Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nat Commun 13 , 6929. 10.1038/s41467-022-34724-5. van Spriel, A.B., Puls, K.L., Sofi, M., Pouniotis, D., Hochrein, H., Orinska, Z., Knobeloch, K.P., Plebanski, M., and Wright, M.D. (2004). A regulatory role for CD37 in T cell proliferation. J Immunol 172 , 2953–2961. 10.4049/jimmunol.172.5.2953. Shah, K., Al-Haidari, A., Sun, J., and Kazi, J.U. (2021). T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther 6 , 412. 10.1038/s41392-021-00823-w. Collins, S., Lutz, M.A., Zarek, P.E., Anders, R.A., Kersh, G.J., and Powell, J.D. (2008). Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. Eur J Immunol 38 , 528–536. 10.1002/eji.200737157. Preiss, N.K., Kamal, Y., Wilkins, O.M., Li, C., Kolling, F.W.t., Trask, H.W., Usherwood, Y.K., Cheng, C., Frost, H.R., and Usherwood, E.J. (2023). Characterizing control of memory CD8 T cell differentiation by BTB-ZF transcription factor Zbtb20. Life Sci Alliance 6 . 10.26508/lsa.202201683. Roychoudhuri, R., Clever, D., Li, P., Wakabayashi, Y., Quinn, K.M., Klebanoff, C.A., Ji, Y., Sukumar, M., Eil, R.L., Yu, Z., et al. (2016). BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. Nat Immunol 17 , 851–860. 10.1038/ni.3441. Sun, Y., Preiss, N.K., Valenteros, K.B., Kamal, Y., Usherwood, Y.K., Frost, H.R., and Usherwood, E.J. (2020). Zbtb20 Restrains CD8 T Cell Immunometabolism and Restricts Memory Differentiation and Antitumor Immunity. J Immunol 205 , 2649–2666. 10.4049/jimmunol.2000459. Dzutsev, A.H., Belyakov, I.M., Isakov, D.V., Margulies, D.H., and Berzofsky, J.A. (2007). Avidity of CD8 T cells sharpens immunodominance. Int Immunol 19 , 497–507. 10.1093/intimm/dxm016. Singhaviranon, S., Dempsey, J.P., Hagymasi, A.T., Mandoiu, II, and Srivastava, P.K. (2025). Low-avidity T cells drive endogenous tumor immunity in mice and humans. Nat Immunol 26 , 240–251. 10.1038/s41590-024-02044-z. Caserta, S., Kleczkowska, J., Mondino, A., and Zamoyska, R. (2010). Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens. J Immunol 185 , 6545–6554. 10.4049/jimmunol.1001867. Martinez-Usatorre, A., Donda, A., Zehn, D., and Romero, P. (2018). PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells. J Immunol 201 , 792–803. 10.4049/jimmunol.1701644. Sugiyarto, G., Lau, D., Hill, S.L., Arcia-Anaya, D., Boulanger, D.S.M., Parkes, E., James, E., and Elliott, T. (2023). Reactivation of low avidity tumor-specific CD8(+) T cells associates with immunotherapeutic efficacy of anti-PD-1. J Immunother Cancer 11 . 10.1136/jitc-2023-007114. Ngiow, S.F., Manne, S., Huang, Y.J., Azar, T., Chen, Z., Mathew, D., Chen, Q., Khan, O., Wu, J.E., Alcalde, V., et al. (2024). LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell 187 , 4336–4354 e4319. 10.1016/j.cell.2024.07.018. Gupta, P.K., Godec, J., Wolski, D., Adland, E., Yates, K., Pauken, K.E., Cosgrove, C., Ledderose, C., Junger, W.G., Robson, S.C., et al. (2015). CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. PLoS Pathog 11 , e1005177. 10.1371/journal.ppat.1005177. Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., and Anderson, A.C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207 , 2187–2194. 10.1084/jem.20100643. Pace, L., Tempez, A., Arnold-Schrauf, C., Lemaitre, F., Bousso, P., Fetler, L., Sparwasser, T., and Amigorena, S. (2012). Regulatory T cells increase the avidity of primary CD8+ T cell responses and promote memory. Science 338 , 532–536. 10.1126/science.1227049. Joshi, N.S., Cui, W., Chandele, A., Lee, H.K., Urso, D.R., Hagman, J., Gapin, L., and Kaech, S.M. (2007). Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27 , 281–295. 10.1016/j.immuni.2007.07.010. Kaech, S.M., Tan, J.T., Wherry, E.J., Konieczny, B.T., Surh, C.D., and Ahmed, R. (2003). Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4 , 1191–1198. 10.1038/ni1009. Wherry, E.J., Teichgraber, V., Becker, T.C., Masopust, D., Kaech, S.M., Antia, R., von Andrian, U.H., and Ahmed, R. (2003). Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4 , 225–234. 10.1038/ni889. Hildner, K., Edelson, B.T., Purtha, W.E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B.U., Unanue, E.R., Diamond, M.S., et al. (2008). Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322 , 1097–1100. 10.1126/science.1164206. Gainey, M.D., Rivenbark, J.G., Cho, H., Yang, L., and Yokoyama, W.M. (2012). Viral MHC class I inhibition evades CD8+ T-cell effector responses in vivo but not CD8+ T-cell priming. Proc Natl Acad Sci U S A 109 , E3260–3267. 10.1073/pnas.1217111109. Kaminsky, L.W., Sei, J.J., Parekh, N.J., Davies, M.L., Reider, I.E., Krouse, T.E., and Norbury, C.C. (2015). Redundant Function of Plasmacytoid and Conventional Dendritic Cells Is Required To Survive a Natural Virus Infection. J Virol 89 , 9974–9985. 10.1128/JVI.01024-15. Christian, D.A., Adams, T.A., 2nd, Shallberg, L.A., Phan, A.T., Smith, T.E., Abraha, M., Perry, J., Ruthel, G., Clark, J.T., Pritchard, G.H., et al. (2022). cDC1 coordinate innate and adaptive responses in the omentum required for T cell priming and memory. Sci Immunol 7 , eabq7432. 10.1126/sciimmunol.abq7432. Sharma, S., Sundararajan, A., Suryawanshi, A., Kumar, N., Veiga-Parga, T., Kuchroo, V.K., Thomas, P.G., Sangster, M.Y., and Rouse, B.T. (2011). T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc Natl Acad Sci U S A 108 , 19001–19006. 10.1073/pnas.1107087108. Ferris, S.T., Durai, V., Wu, R., Theisen, D.J., Ward, J.P., Bern, M.D., Davidson, J.T.t., Bagadia, P., Liu, T., Briseno, C.G., et al. (2020). cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity. Nature 584 , 624–629. 10.1038/s41586-020-2611-3. Taraban, V.Y., Rowley, T.F., and Al-Shamkhani, A. (2004). Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol 173 , 6542–6546. 10.4049/jimmunol.173.11.6542. Liu, D., and Ford, M.L. (2020). CD11b is a novel alternate receptor for CD154 during alloimmunity. Am J Transplant 20 , 2216–2225. 10.1111/ajt.15835. Alexander, K.L., Bennion, K.B., Liu, D., and Ford, M.L. (2025). CD154:CD11b blockade enhances CD8+ T cell differentiation during infection but not transplantation. JCI Insight 10 . 10.1172/jci.insight.184843. Blair, P.J., Riley, J.L., Harlan, D.M., Abe, R., Tadaki, D.K., Hoffmann, S.C., White, L., Francomano, T., Perfetto, S.J., Kirk, A.D., and June, C.H. (2000). CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 191 , 651–660. 10.1084/jem.191.4.651. Miga, A.J., Masters, S.R., Durell, B.G., Gonzalez, M., Jenkins, M.K., Maliszewski, C., Kikutani, H., Wade, W.F., and Noelle, R.J. (2001). Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions. Eur J Immunol 31 , 959–965. 10.1002/1521-4141(200103)31:33.0.co;2-a. Fang, M., Siciliano, N.A., Hersperger, A.R., Roscoe, F., Hu, A., Ma, X., Shamsedeen, A.R., Eisenlohr, L.C., and Sigal, L.J. (2012). Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection. Proc Natl Acad Sci U S A 109 , 9983–9988. 10.1073/pnas.1202143109. McDermott, D.S., and Varga, S.M. (2011). Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think. J Immunol 187 , 5568–5576. 10.4049/jimmunol.1102104. Knudson, C.J., Ferez, M., Alves-Peixoto, P., Erkes, D.A., Melo-Silva, C.R., Tang, L., Snyder, C.M., and Sigal, L.J. (2021). Mechanisms of Antiviral Cytotoxic CD4 T Cell Differentiation. J Virol 95 , e0056621. 10.1128/JVI.00566-21. Muller, D., Koller, B.H., Whitton, J.L., LaPan, K.E., Brigman, K.K., and Frelinger, J.A. (1992). LCMV-specific, class II-restricted cytotoxic T cells in beta 2-microglobulin-deficient mice. Science 255 , 1576–1578. 10.1126/science.1347959. Kitoh, A., Ono, M., Naoe, Y., Ohkura, N., Yamaguchi, T., Yaguchi, H., Kitabayashi, I., Tsukada, T., Nomura, T., Miyachi, Y., et al. (2009). Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity 31 , 609–620. 10.1016/j.immuni.2009.09.003. Kerdiles, Y.M., Stone, E.L., Beisner, D.R., McGargill, M.A., Ch'en, I.L., Stockmann, C., Katayama, C.D., and Hedrick, S.M. (2010). Foxo transcription factors control regulatory T cell development and function. Immunity 33 , 890–904. 10.1016/j.immuni.2010.12.002. Hansen, W., Loser, K., Westendorf, A.M., Bruder, D., Pfoertner, S., Siewert, C., Huehn, J., Beissert, S., and Buer, J. (2006). G protein-coupled receptor 83 overexpression in naive CD4+CD25- T cells leads to the induction of Foxp3+ regulatory T cells in vivo. J Immunol 177 , 209–215. 10.4049/jimmunol.177.1.209. Sharma, M.D., Huang, L., Choi, J.H., Lee, E.J., Wilson, J.M., Lemos, H., Pan, F., Blazar, B.R., Pardoll, D.M., Mellor, A.L., et al. (2013). An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity 38 , 998–1012. 10.1016/j.immuni.2013.01.013. Yadav, M., Louvet, C., Davini, D., Gardner, J.M., Martinez-Llordella, M., Bailey-Bucktrout, S., Anthony, B.A., Sverdrup, F.M., Head, R., Kuster, D.J., et al. (2012). Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 209 , 1713–1722, S1711–1719. 10.1084/jem.20120822. Fantin, R.F., Yuan, M., Park, S.C., Bozarth, B., Cohn, H., Ignacio, M., Earl, P., Civljak, A., Laghlali, G., Zhang, D., et al. (2025). Human monoclonal antibodies targeting A35 protect from death caused by mpox. Cell. 10.1016/j.cell.2025.08.004. Jesus, D.M., Costa, L.T., Goncalves, D.L., Achete, C.A., Attias, M., Moussatche, N., and Damaso, C.R. (2009). Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. J Virol 83 , 11477–11490. 10.1128/JVI.01061-09. Magee, W.C., Hostetler, K.Y., and Evans, D.H. (2005). Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49 , 3153–3162. 10.1128/AAC.49.8.3153-3162.2005. Sei, J.J., Haskett, S., Kaminsky, L.W., Lin, E., Truckenmiller, M.E., Bellone, C.J., Buller, R.M., and Norbury, C.C. (2015). Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or Activation. PLoS Pathog 11 , e1004941. 10.1371/journal.ppat.1004941. Weil, R., and Israel, A. (2006). Deciphering the pathway from the TCR to NF-kappaB. Cell Death Differ 13 , 826–833. 10.1038/sj.cdd.4401856. Odagiu, L., Boulet, S., Maurice De Sousa, D., Daudelin, J.F., Nicolas, S., and Labrecque, N. (2020). Early programming of CD8(+) T cell response by the orphan nuclear receptor NR4A3. Proc Natl Acad Sci U S A 117 , 24392–24402. 10.1073/pnas.2007224117. Li, S., Miao, T., Sebastian, M., Bhullar, P., Ghaffari, E., Liu, M., Symonds, A.L., and Wang, P. (2012). The transcription factors Egr2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells. Immunity 37 , 685–696. 10.1016/j.immuni.2012.08.001. Gamper, C.J., Agoston, A.T., Nelson, W.G., and Powell, J.D. (2009). Identification of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 differentiation. J Immunol 183 , 2267–2276. 10.4049/jimmunol.0802960. DeGrendele, H.C., Kosfiszer, M., Estess, P., and Siegelman, M.H. (1997). CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J Immunol 159 , 2549–2553. Brehm, M.A., Daniels, K.A., and Welsh, R.M. (2005). Rapid production of TNF-alpha following TCR engagement of naive CD8 T cells. J Immunol 175 , 5043–5049. 10.4049/jimmunol.175.8.5043. Senda, Y., Murata-Kamiya, N., and Hatakeyama, M. (2016). C-terminal Src kinase-mediated EPIYA phosphorylation of Pragmin creates a feed-forward C-terminal Src kinase activation loop that promotes cell motility. Cancer Sci 107 , 972–980. 10.1111/cas.12962. Yu, F.X., Lin, S.C., Morrison-Bogorad, M., Atkinson, M.A., and Yin, H.L. (1993). Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J Biol Chem 268 , 502–509. Gadina, M., Sudarshan, C., Visconti, R., Zhou, Y.J., Gu, H., Neel, B.G., and O'Shea, J.J. (2000). The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. J Biol Chem 275 , 26959–26966. 10.1074/jbc.M004021200. Holmes, T.D., Pandey, R.V., Helm, E.Y., Schlums, H., Han, H., Campbell, T.M., Drashansky, T.T., Chiang, S., Wu, C.Y., Tao, C., et al. (2021). The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. Sci Immunol 6 . 10.1126/sciimmunol.abc9801. Held, W., Clevers, H., and Grosschedl, R. (2003). Redundant functions of TCF-1 and LEF-1 during T and NK cell development, but unique role of TCF-1 for Ly49 NK cell receptor acquisition. Eur J Immunol 33 , 1393–1398. 10.1002/eji.200323840. Almeida, J.S., Casanova, J.M., Santos-Rosa, M., Tarazona, R., Solana, R., and Rodrigues-Santos, P. (2023). Natural Killer T-like Cells: Immunobiology and Role in Disease. Int J Mol Sci 24 . 10.3390/ijms24032743. Ngai, H., Barragan, G.A., Tian, G., Balzeau, J.C., Zhang, C., Courtney, A.N., Guo, L., Xu, X., Wood, M.S., Drabek, J.M., et al. (2023). LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells. Cancer Immunol Res 11 , 171–183. 10.1158/2326-6066.CIR-22-0333. Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Takagi, M., Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997). Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275 , 90–94. 10.1126/science.275.5296.90. Park, K.C., Lee, D.C., and Yeom, Y.I. (2015). NDRG3-mediated lactate signaling in hypoxia. BMB Rep 48 , 301–302. 10.5483/bmbrep.2015.48.6.080. Paniagua, G., Jacob, H.K.C., Brehey, O., Garcia-Alonso, S., Lechuga, C.G., Pons, T., Musteanu, M., Guerra, C., Drosten, M., and Barbacid, M. (2022). KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. Mol Oncol 16 , 3066–3081. 10.1002/1878-0261.13213. Lo, J.Y., Chou, Y.T., Lai, F.J., and Hsu, L.J. (2015). Regulation of cell signaling and apoptosis by tumor suppressor WWOX. Exp Biol Med (Maywood) 240 , 383–391. 10.1177/1535370214566747. Sombroek, D., and Hofmann, T.G. (2009). How cells switch HIPK2 on and off. Cell Death Differ 16 , 187–194. 10.1038/cdd.2008.154. Stuchell, M.D., Garrus, J.E., Muller, B., Stray, K.M., Ghaffarian, S., McKinnon, R., Krausslich, H.G., Morham, S.G., and Sundquist, W.I. (2004). The human endosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1 budding. J Biol Chem 279 , 36059–36071. 10.1074/jbc.M405226200. Matza, D., Badou, A., Kobayashi, K.S., Goldsmith-Pestana, K., Masuda, Y., Komuro, A., McMahon-Pratt, D., Marchesi, V.T., and Flavell, R.A. (2008). A scaffold protein, AHNAK1, is required for calcium signaling during T cell activation. Immunity 28 , 64–74. 10.1016/j.immuni.2007.11.020. Morley, S.C. (2012). The actin-bundling protein L-plastin: a critical regulator of immune cell function. Int J Cell Biol 2012 , 935173. 10.1155/2012/935173. Delano, M.L., and Brownstein, D.G. (1995). Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J Virol 69 , 5875–5877. 10.1128/JVI.69.9.5875-5877.1995. Fang, M., Orr, M.T., Spee, P., Egebjerg, T., Lanier, L.L., and Sigal, L.J. (2011). CD94 is essential for NK cell-mediated resistance to a lethal viral disease. Immunity 34 , 579–589. 10.1016/j.immuni.2011.02.015. Melo-Silva, C.R., Tscharke, D.C., Lobigs, M., Koskinen, A., Wong, Y.C., Buller, R.M., Mullbacher, A., and Regner, M. (2011). The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responses. J Virol 85 , 11170–11182. 10.1128/JVI.00256-11. Chaudhri, G., Panchanathan, V., Buller, R.M., van den Eertwegh, A.J., Claassen, E., Zhou, J., de Chazal, R., Laman, J.D., and Karupiah, G. (2004). Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci U S A 101 , 9057–9062. 10.1073/pnas.0402949101. Chan, M., Audet, J., Prevost, J., Soriano, K., Doan, K., Garnett, L., Deschambault, Y., Medina, S., Stefopulos, M., Paul, J., et al. (2025). Molecular detection and isolation of clade Ib monkeypox virus, Canada, November 2024. Euro Surveill 30 . 10.2807/1560-7917.ES.2025.30.25.2500402. Koukouikila-Koussounda, F., Yinda, C.K., Mayengue, P.I., Elenga, R.G., Boussam, D.A.E., Indolo, G.D., Macosso, L.N., Munster, V.J., and Niama, F.R. (2025). Introduction of Mpox Virus Clade Ib into the Republic of the Congo. N Engl J Med 393 , 1135–1137. 10.1056/NEJMc2504089. Laurenson-Schafer, H., Sklenovska, N., Hoxha, A., Kerr, S.M., Ndumbi, P., Fitzner, J., Almiron, M., de Sousa, L.A., Briand, S., Cenciarelli, O., et al. (2023). Description of the first global outbreak of mpox: an analysis of global surveillance data. Lancet Glob Health 11 , e1012–e1023. 10.1016/S2214-109X(23)00198-5. Beiras, C.G., Malembi, E., Escrig-Sarreta, R., Ahuka, S., Mbala, P., Mavoko, H.M., Subissi, L., Abecasis, A.B., Marks, M., and Mitja, O. (2025). Concurrent outbreaks of mpox in Africa-an update. Lancet 405 , 86–96. 10.1016/S0140-6736(24)02353-5. Mitja, O., Watson-Jones, D., Choi, E.M., Jalloh, M.B., and Sahr, F. (2025). Clade IIb mpox outbreak in Sierra Leone. Lancet 405 , 2274–2275. 10.1016/S0140-6736(25)01203-6. Sun, J., Zhou, L., Wu, B., Chen, Z., He, Y., Wang, X., Lu, J., Li, D., Zhao, L., Guo, X., et al. (2025). Characteristics of the first confirmed case of human infection with mpox virus clade Ib in China. Nat Commun 16 , 4888. 10.1038/s41467-025-60217-2. Johnston, J.B., and McFadden, G. (2003). Poxvirus immunomodulatory strategies: current perspectives. J Virol 77 , 6093–6100. 10.1128/jvi.77.11.6093-6100.2003. Lodoen, M., Ogasawara, K., Hamerman, J.A., Arase, H., Houchins, J.P., Mocarski, E.S., and Lanier, L.L. (2003). NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 197 , 1245–1253. 10.1084/jem.20021973. Campbell, J.A., Trossman, D.S., Yokoyama, W.M., and Carayannopoulos, L.N. (2007). Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D. J Exp Med 204 , 1311–1317. 10.1084/jem.20062026. Alzhanova, D., Edwards, D.M., Hammarlund, E., Scholz, I.G., Horst, D., Wagner, M.J., Upton, C., Wiertz, E.J., Slifka, M.K., and Fruh, K. (2009). Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition. Cell Host Microbe 6 , 433–445. 10.1016/j.chom.2009.09.013. Chiang, S.C., Theorell, J., Entesarian, M., Meeths, M., Mastafa, M., Al-Herz, W., Frisk, P., Gilmour, K.C., Ifversen, M., Langenskiold, C., et al. (2013). Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. Blood 121 , 1345–1356. 10.1182/blood-2012-07-442558. Dustin, M.L., and Long, E.O. (2010). Cytotoxic immunological synapses. Immunol Rev 235 , 24–34. 10.1111/j.0105-2896.2010.00904.x. Kabanova, A., Zurli, V., and Baldari, C.T. (2018). Signals Controlling Lytic Granule Polarization at the Cytotoxic Immune Synapse. Front Immunol 9 , 307. 10.3389/fimmu.2018.00307. Henrickson, S.E., Perro, M., Loughhead, S.M., Senman, B., Stutte, S., Quigley, M., Alexe, G., Iannacone, M., Flynn, M.P., Omid, S., et al. (2013). Antigen availability determines CD8(+) T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity 39 , 496–507. 10.1016/j.immuni.2013.08.034. Miller, M.J., Safrina, O., Parker, I., and Cahalan, M.D. (2004). Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J Exp Med 200 , 847–856. 10.1084/jem.20041236. Huppa, J.B., Gleimer, M., Sumen, C., and Davis, M.M. (2003). Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol 4 , 749–755. 10.1038/ni951. Ueda, H., Morphew, M.K., McIntosh, J.R., and Davis, M.M. (2011). CD4+ T-cell synapses involve multiple distinct stages. Proc Natl Acad Sci U S A 108 , 17099–17104. 10.1073/pnas.1113703108. Ortega-Carrion, A., and Vicente-Manzanares, M. (2016). Concerning immune synapses: a spatiotemporal timeline. F1000Res 5 . 10.12688/f1000research.7796.1. Gu, H., and Neel, B.G. (2003). The "Gab" in signal transduction. Trends Cell Biol 13 , 122–130. 10.1016/s0962-8924(03)00002-3. Zompi, S., Gu, H., and Colucci, F. (2004). The absence of Grb2-associated binder 2 (Gab2) does not disrupt NK cell development and functions. J Leukoc Biol 76 , 896–903. 10.1189/jlb.0304179. Upshaw, J.L., Arneson, L.N., Schoon, R.A., Dick, C.J., Billadeau, D.D., and Leibson, P.J. (2006). NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol 7 , 524–532. 10.1038/ni1325. Niu, C., Li, M., Chen, Y., Zhang, X., Zhu, S., Zhou, X., Zhou, L., Li, Z., Xu, J., Hu, J.F., et al. (2022). LncRNA NCAL1 potentiates natural killer cell cytotoxicity through the Gab2-PI3K-AKT pathway. Front Immunol 13 , 970195. 10.3389/fimmu.2022.970195. Maul-Pavicic, A., Chiang, S.C., Rensing-Ehl, A., Jessen, B., Fauriat, C., Wood, S.M., Sjoqvist, S., Hufnagel, M., Schulze, I., Bass, T., et al. (2011). ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc Natl Acad Sci U S A 108 , 3324–3329. 10.1073/pnas.1013285108. Janji, B., Giganti, A., De Corte, V., Catillon, M., Bruyneel, E., Lentz, D., Plastino, J., Gettemans, J., and Friederich, E. (2006). Phosphorylation on Ser5 increases the F-actin-binding activity of L-plastin and promotes its targeting to sites of actin assembly in cells. J Cell Sci 119 , 1947–1960. 10.1242/jcs.02874. Wang, C., Morley, S.C., Donermeyer, D., Peng, I., Lee, W.P., Devoss, J., Danilenko, D.M., Lin, Z., Zhang, J., Zhou, J., et al. (2010). Actin-bundling protein L-plastin regulates T cell activation. J Immunol 185 , 7487–7497. 10.4049/jimmunol.1001424. Wabnitz, G.H., Kocher, T., Lohneis, P., Stober, C., Konstandin, M.H., Funk, B., Sester, U., Wilm, M., Klemke, M., and Samstag, Y. (2007). Costimulation induced phosphorylation of L-plastin facilitates surface transport of the T cell activation molecules CD69 and CD25. Eur J Immunol 37 , 649–662. 10.1002/eji.200636320. Sanderson, S., and Shastri, N. (1994). LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol 6 , 369–376. 10.1093/intimm/6.3.369. Miller, M.A., Ganesan, A.P., Luckashenak, N., Mendonca, M., and Eisenlohr, L.C. (2015). Endogenous antigen processing drives the primary CD4+ T cell response to influenza. Nat Med 21 , 1216–1222. 10.1038/nm.3958. Robinson, J.T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G., and Mesirov, J.P. (2011). Integrative genomics viewer. Nat Biotechnol 29 , 24–26. 10.1038/nbt.1754. Hogan, M.J., Maheshwari, N., Begg, B.E., Nicastri, A., Hedgepeth, E.J., Muramatsu, H., Pardi, N., Miller, M.A., Reilly, S.P., Brossay, L., et al. (2023). Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response. Nat Immunol 24 , 1933–1946. 10.1038/s41590-023-01644-5. Forsyth, K.S., DeHaven, B., Mendonca, M., Paul, S., Sette, A., and Eisenlohr, L.C. (2019). Poor Antigen Processing of Poxvirus Particles Limits CD4(+) T Cell Recognition and Impacts Immunogenicity of the Inactivated Vaccine. J Immunol 202 , 1340–1349. 10.4049/jimmunol.1801099. Aunins, E.A., Phan, A.T., Alameh, M.G., Dwivedi, G., Cruz-Morales, E., Christian, D.A., Tam, Y., Bunkofske, M.E., Penafiel, A.Z., O'Dea, K.M., et al. (2025). An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses. Sci Immunol 10 , eads1328. 10.1126/sciimmunol.ads1328. Baiersdorfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., and Kariko, K. (2019). A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. Mol Ther Nucleic Acids 15 , 26–35. 10.1016/j.omtn.2019.02.018. Pardi, N., Muramatsu, H., Weissman, D., and Kariko, K. (2013). In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol 969 , 29–42. 10.1007/978-1-62703-260-5_2. Smith, T., Heger, A., and Sudbery, I. (2017). UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res 27 , 491–499. 10.1101/gr.209601.116. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 , 15–21. 10.1093/bioinformatics/bts635. Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30 , 923–930. 10.1093/bioinformatics/btt656. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15 , 550. 10.1186/s13059-014-0550-8. Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10 , 1523. 10.1038/s41467-019-09234-6. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 , 15545–15550. 10.1073/pnas.0506580102. Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 16 , 1289–1296. 10.1038/s41592-019-0619-0. Traag, V.A., Waltman, L., and van Eck, N.J. (2019). From Louvain to Leiden: guaranteeing well-connected communities. Sci Rep 9 , 5233. 10.1038/s41598-019-41695-z. Additional Declarations There is NO Competing Interest. Supplementary Files TableS1.xlsx Table S1. Upregulated differentially expressed genes in WT- and DC15-derived CD8+ T eff 7 and 10 dpi, related to Figures 2 and S2. TableS2.xlsx Table S2. Differentially expressed genes in WT- and DC15-derived CD4+ T eff 7 dpi, related to Figures 5 and S5. TableS3.xlsx Table S3. Differentially expressed genes in WT- and DC15-infected dLNs 48 hpi, related to Figure S7. TableS4.xlsx Table S4. qPCR primer sequences for EVM003 and GAPDH quantification, related to Figure 7. SupplementaryFigures.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8672980","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":584697366,"identity":"a80a63bb-7d8b-4ef5-b5cd-dbd2cc19f715","order_by":0,"name":"Laurence Eisenlohr","email":"data:image/png;base64,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","orcid":"https://orcid.org/0000-0002-8475-7910","institution":"Children's Hospital of Philadelphia","correspondingAuthor":true,"prefix":"","firstName":"Laurence","middleName":"","lastName":"Eisenlohr","suffix":""},{"id":584697367,"identity":"bb89575e-3996-4285-a2be-63bf3d718e64","order_by":1,"name":"Stephen Carro","email":"","orcid":"","institution":"University of Pennsylvania","correspondingAuthor":false,"prefix":"","firstName":"Stephen","middleName":"","lastName":"Carro","suffix":""},{"id":584697368,"identity":"5580b11a-4e03-471f-8cc6-ec77d3853912","order_by":2,"name":"Emma Hedgepeth","email":"","orcid":"","institution":"Children's Hospital of Philadelphia","correspondingAuthor":false,"prefix":"","firstName":"Emma","middleName":"","lastName":"Hedgepeth","suffix":""},{"id":584697369,"identity":"0d52d5b7-f1cb-4ce9-8392-00b509c0fa8a","order_by":3,"name":"Candy Lucero-Sanchez","email":"","orcid":"https://orcid.org/0009-0007-4858-6943","institution":"Children's Hospital of Philadelphia","correspondingAuthor":false,"prefix":"","firstName":"Candy","middleName":"","lastName":"Lucero-Sanchez","suffix":""},{"id":584697370,"identity":"17dc7fff-371b-4f31-82bf-b955dadab8d6","order_by":4,"name":"Mary Heard","email":"","orcid":"https://orcid.org/0000-0002-5151-5675","institution":"Children's Hospital of Philadelphia","correspondingAuthor":false,"prefix":"","firstName":"Mary","middleName":"","lastName":"Heard","suffix":""},{"id":584697371,"identity":"fef75a14-78c2-405c-bb21-311de406f032","order_by":5,"name":"Angela Corrigan","email":"","orcid":"","institution":"University of Pennsylvania","correspondingAuthor":false,"prefix":"","firstName":"Angela","middleName":"","lastName":"Corrigan","suffix":""},{"id":584697372,"identity":"1e741236-8c26-4fa8-9126-1f0739dcb5ea","order_by":6,"name":"Heejoon Shin","email":"","orcid":"https://orcid.org/0009-0004-6621-4551","institution":"University of Pennsylvania","correspondingAuthor":false,"prefix":"","firstName":"Heejoon","middleName":"","lastName":"Shin","suffix":""},{"id":584697373,"identity":"352a1546-d000-467c-bb9e-feb1a4d7b290","order_by":7,"name":"Elise Peauroi","email":"","orcid":"","institution":"University of Pennsylvania","correspondingAuthor":false,"prefix":"","firstName":"Elise","middleName":"","lastName":"Peauroi","suffix":""}],"badges":[],"createdAt":"2026-01-22 20:10:26","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8672980/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8672980/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":101827786,"identity":"72a347df-8bbe-4569-9209-10d0ff422c7c","added_by":"auto","created_at":"2026-02-04 05:31:30","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":186931,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eC15 inhibits TCR-dependent CD4+ and CD8+ T cell activation.\u003c/u\u003e (A) Schematic for stable cell line generation and flow cytometry data for surface and intracellular HAtag expression following induction. (B) Schematic for T cell hybridoma assay and % inhibition (mean ± SD) of indicated hybrid with inducible cell lines. (C) Hybridoma activation (mean ± SD) with inducible cell lines across various T cell hybridomas, as indicated. (D) Schematic for E-F. (E and F) Spot-forming unit (SFU) counts and spot size (mean ± SD) from WT- or DC15-infected cDC1 co-cultures with ECTV-specific CD8+ (E) or CD4+ (F) T cells. G) % inhibition (mean ± SD) of I-A\u003csup\u003eb\u003c/sup\u003e-NA\u003csub\u003e437-451\u003c/sub\u003e-specific T cell hybrid with various ratios of induced MHCII-negative bystanders to MHCII+ APCs. H) Hybridoma activation (mean ± SD) by the inducible C15 cell line with or without PMA/ionomycin. (B and C) Representative of three experiments. (E-F) Data shown are pooled from four separate infections. (G) Dot represents individual experiment. (B) One-way ANOVA with Dunnett correction. (C, G, H) Two-way ANOVA with Sidak correction. (E and F) Unpaired t-test. Related to Figure S1.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/e69cc2d4e844986ede365cc4.png"},{"id":101827787,"identity":"2f5bf55b-8fb6-49fc-b902-c9023a18569a","added_by":"auto","created_at":"2026-02-04 05:31:30","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":673877,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eC15 expression promotes enhanced CD8+ T\u003c/u\u003e\u003csub\u003e\u003cu\u003eeff\u003c/u\u003e\u003c/sub\u003e\u003cu\u003e responses.\u003c/u\u003e (A) Schematic for B-D and J-L. (B) Representative flow gating for CD8+ T\u003csub\u003eeff\u003c/sub\u003e and the proportion of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (of total CD8+ T) (mean ± SD) over time in the spleen for indicated infection conditions. (C) %+ (CD25 or CD69) or normalized MFI (PD-1) of B8R+ CD8+ T\u003csub\u003eeff\u003c/sub\u003e (mean ± SD) over time for WT or DC15 infection. (D) Normalized MFI (perforin or GzmB) of B8R+ CD8+ T\u003csub\u003eeff\u003c/sub\u003e (mean ± SD) over time for WT or DC15 infection. (E-H) % cytokine-producing CD8+ T cells (mean ± SD) following restimulation of splenocytes with infected DC2.4 cells (E/G) or peptide pulsing with B8R peptide (F/H) at 7 (E/F) or 9 (G/H) dpi. (I) %CD107+ CD8+ T cells (mean ± SD) following restimulation of splenocytes 9 dpi as indicated. (J) Proportion of B8R+ CD8+ (mean ± SD) over time for WT or DC15 infection. (K/L) Quantification of CX3CR1hi (K) and CX3CR1int (L) B8R+ CD8+ T\u003csub\u003eeff\u003c/sub\u003e (mean ± SD) over time in WT- or DC15-infected mice. (M) DEGs in CD8+ T\u003csub\u003eeff\u003c/sub\u003e between WT and DC15 infection. (B-D, J-L) Data pooled across 1-3 independent experiments with n=4-15 for each group. (E-F) Data derived from 4-5 mice per group. (G-I) Data pooled across two independent experiments with n=10-11 per group. (I) Dot represents one mouse. (M) Sequencing data derived from n=4-5 per group. (B-D, J-L) Mixed-effects model with Sidak correction. (E-H) Unpaired t-test. (I) Two-way ANOVA with Fisher’s LSD test. Related to Figure S2.\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/fc44fc42b5b266d0f1089aeb.png"},{"id":101827789,"identity":"523a6aee-4e2e-4e8f-9abf-1b5beadfce05","added_by":"auto","created_at":"2026-02-04 05:31:30","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":602692,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eCD8+ T cell clonality, avidity and memory following WT or DC15 infection.\u003c/u\u003e (A) Simpson clonality (mean ± SD) of B8R+ CD8+ T\u003csub\u003eeff\u003c/sub\u003e at indicated dpi for WT or DC15. (B) Schematic for C-E. (C) Survival curve for mice infected with WT or DC15 either untreated or depleted of CD4+ T cells. (D) % PD-1+, CD39/TIM-3+, TOX/TIM-3+, or LAG-3/TIM-3+ of B8R+ CD8+ T\u003csub\u003eeff\u003c/sub\u003e (mean ± SD) at 30 dpi with WT or DC15 either untreated or depleted of CD4+ T cells. (E) Representative flow cytometry plots for values quantified in (D). (F) Markers of memory populations and representative flow cytometry plots from each key timepoint. (G) %SLEC, DPEC, or MPEC (mean ± SD) of B8R+ CD8+ T cells over time in WT- or DC15-infected mice. (A, D) Dot represents individual mouse. (G) Data derived from 5 mice per group. (A) Two-way ANOVA with Fisher’s LSD test. (C) Mantel-Cox test. (D) Two-way ANOVA with Tukey correction. (G) Unpaired t-test for each timepoint. Related to Figure S3.\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/145f4fc7de228eee22be87b3.png"},{"id":101827797,"identity":"681a220b-8fd8-4e21-9548-0c4bbf567e6d","added_by":"auto","created_at":"2026-02-04 05:31:30","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":116016,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eCross-presentation compensates for inhibition of CD8+ T cells by C15.\u003c/u\u003e (A) Schematic for C-L. (B-E) %T\u003csub\u003eeff\u003c/sub\u003e of total splenic CD8+ T cells (B), %PD-1+CD25+ of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (C), %CX3CR1hi of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (D), %B8R+ of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (E) (mean ± SD) at 7 dpi with WT or DC15 in B6 or \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e\u003cem\u003e \u003c/em\u003emice. (F) Schematic for G-I. (G) CD4/CD8 ratio of CD3+ splenocytes (G), %T\u003csub\u003eeff\u003c/sub\u003e of splenic CD8+ T cells (H), and %T\u003csub\u003eeff\u003c/sub\u003e of splenicCD4+ T cells (mean ± SD) from WT-infected B6 or \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e-/-\u003c/sup\u003e mice untreated or treated with CD40L blocking antibody 7 dpi. (B-E) Data pooled across 3 independent experiments. (B-E, G-I) Dot represents one mouse. (B-E) Two-way ANOVA with Tukey correction. (G-I) Two-way ANOVA with Fisher’s LSD test. Related to Figure S4.\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/8b300c539b00f5036fb8a884.png"},{"id":101881269,"identity":"c64adc83-6329-41ea-a2ee-cb619985bbc0","added_by":"auto","created_at":"2026-02-04 15:11:15","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":662483,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eCD4 T\u003c/u\u003e\u003csub\u003e\u003cu\u003eeff\u003c/u\u003e\u003c/sub\u003e\u003cu\u003e, CD4-CTL and T\u003c/u\u003e\u003csub\u003e\u003cu\u003efh\u003c/u\u003e\u003c/sub\u003e\u003cu\u003e responses are enhanced during WT infection.\u003c/u\u003e (A-B) %T\u003csub\u003eeff\u003c/sub\u003e (A) and CD11a+CD49d+ (B) (mean ± SD) of total splenic CD4+ T cells in WT- or DC15-infected mice. (C) Representative flow plot of I1L+ CD4+ T cells and quantification of splenic I1L+ CD4+ T cells (mean ± SD) over time in WT- or DC15-infected mice. (D) Representative flow cytometry gating for the identification of CD4-CTLs. (E) %GzmB+ of CD4+ T\u003csub\u003eeff\u003c/sub\u003e (mean ± SD) over time in WT- or DC15-infected mice. (F) %GzmB+ perforin+ (mean ± SD) of CD4+ T\u003csub\u003eeff\u003c/sub\u003e for each infection condition in indicated mouse strains. (G) DEGs in CD4+ T\u003csub\u003eeff\u003c/sub\u003e between WT and DC15 infection. (H) Enriched GO terms in CD8+ T\u003csub\u003eeff\u003c/sub\u003e from each infection condition. (I-J) %T\u003csub\u003efh\u003c/sub\u003e (I) of %T\u003csub\u003efr\u003c/sub\u003e (J) (mean ± SD) of total splenic CD4+ T cells or CD4+ T\u003csub\u003eeff\u003c/sub\u003e at 7 and 10 dpi in different infection conditions. (A-C, E) Data pooled across 1-3 independent experiments with n=4-15 for each group. (F, I-J) Dot represents individual mouse. (G-H) Sequencing data derived from n=5 for each group. (A-C, E) Mixed-effects model with Sidak correction. (F, I-J) Two-way ANOVA with Sidak correction. Related to Figure S5.\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/4c32000a364436029993d937.png"},{"id":101881231,"identity":"dc80ef41-fa55-4566-93c3-269701f29cf8","added_by":"auto","created_at":"2026-02-04 15:10:59","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":722494,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eNK cells restrict antigen load during DC15 infection to dampen T cell responses.\u003c/u\u003e (A) #Infected iMOs per 1 x 10\u003csup\u003e6\u003c/sup\u003e CD3-NK1.1-Ly6G- splenocytes (mean ± SD) 7 dpi with WT or DC15 in each corresponding mouse strain, with representative flow cytometry plots below. (B) Schematic for C-H. (C-F) %GzmB+perforin+ and GzmB+ only of CD4+ T\u003csub\u003eeff\u003c/sub\u003e (C), %CX3CR1+ and CX3CR1int of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (D), %PD-1+CD25+ of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (E), and %T\u003csub\u003eeff\u003c/sub\u003e of total splenic CD8+ T cells (F) (mean ± SD) at 7 dpi across infection conditions. (G-H) Representative histograms and quantified MFI of GzmB (G) and perforin (H) for CD8+ T\u003csub\u003eeff\u003c/sub\u003e (mean ± SD) at 7 dpi across infection conditions. (I) Schematic for J-L. (J-L) %T\u003csub\u003eeff\u003c/sub\u003e of total CD8+ T cells (J), %PD-1+CD25+ of CD8+ T\u003csub\u003eeff\u003c/sub\u003e\u003csup\u003e \u003c/sup\u003e(K), and %GzmB+perforin+ and GzmB+ only of CD4+ T\u003csub\u003eeff\u003c/sub\u003e (L) (mean ± SD) at 7 dpi across infection conditions. (M-O) %T\u003csub\u003eeff\u003c/sub\u003e of total splenic CD8+ T cells (M), %PD-1+CD25+ of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (N), %TIM-3 of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (O) (mean ± SD) at 7 dpi across infection conditions in B6 or \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e\u003cem\u003e \u003c/em\u003emice. (C-H, J-O) Data pooled across 2 independent experiments. (A, C-H, J-O) Each dot represents one mouse. (A) Unpaired t-test. (C-H, J-O) Ordinary one-way ANOVA with Tukey correction. Related to Figure S6.\u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/e2c213ef638500acdb0dea3d.png"},{"id":101880910,"identity":"aaef62d2-42f5-45b9-ab36-c160263fb581","added_by":"auto","created_at":"2026-02-04 15:07:46","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":657458,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eNK cells undergo distinct transcriptional changes during DC15 infection.\u003c/u\u003e (A) Fold change of \u003cem\u003eEVM003\u003c/em\u003eexpression (mean ± SD) in WT- or DC15-infected dLNs at 24 or 32 hpi. (B-E) %KLRG1+ (B), %CD137+ (C), normalized GzmB MFI (D), and %IFNg+ (E) (mean ± SD) of NK cells in WT or DC15-infected dLNs at 48 hpi. (F) UMAP of scRNA-seq data from dLN 24 or 48 hpi with WT or DC15. (G) Heatmap of DEGs across Leiden clusters at 48 hpi with WT or DC15. (H) Volcano plot of DEGs in NK cells 24 hpi with WT or DC15. (I) UMAP of subset NK cell clusters. (J) Volcano plot of DEGs between NK-1 and NK-2 subset clusters. (K) Volcano plot of DEGs in in the NK-2 sub-cluster 48 hpi with WT or DC15. (A-E) Dot represents individual mouse. (B-E) Data pooled across 2-3 independent experiments. (F-K) Sequencing data derived from n=4-5 for each group. (A) Two-way ANOVA with Fisher’s LSD test. (B-E) Unpaired t-test. Related to Figure S7.\u003c/p\u003e","description":"","filename":"7.png","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/9bb319e99da844f5d2b668b2.png"},{"id":101827793,"identity":"f4c3a87d-c042-4b70-becc-fd92d7e17ae5","added_by":"auto","created_at":"2026-02-04 05:31:30","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":103527,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eC15 antagonizes NK or T cells depending on host immunocompetence.\u003c/u\u003e (A) Survival curve of C57Bl/6 mice infected with WT or DC15 pre-treated with isotype or NK1.1-depleting antibody. (B) Survival curve of BALB/c mice infected DC15 pre-treated with isotype or NK1.1-depleting antibody. (C) Schematic for D. (D) %A33R+ (mean ± SD) of splenic iMOs, DCs, and B cells 7 dpi with WT or DC15. (E-I) %T\u003csub\u003eeff\u003c/sub\u003e of total splenic CD8+ T cells (E), %Ki67+ of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (F), %PD-1+CD25+ of CD8+ T\u003csub\u003eeff\u003c/sub\u003e (G), %T\u003csub\u003eeff\u003c/sub\u003e of total splenic CD4+ T cells (H), and %GzmB+ only of CD4+ T\u003csub\u003eeff\u003c/sub\u003e (I) (mean ± SD) at 7 dpi with WT or DC15. (A) Data derived from n=10 mice per group. (B) Data derived from n=5 mice per group. (D-I) Each dot represents an individual mouse. (A) Mantel-Cox test. (D) Two-way ANOVA with Fisher’s LSD test. (E-I) Unpaired t-test.\u003c/p\u003e","description":"","filename":"8.png","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/2bf433f32e638d6354a17de4.png"},{"id":107144197,"identity":"e604e0e3-eab0-4aac-a709-5be7f52a6996","added_by":"auto","created_at":"2026-04-17 09:29:01","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":4644373,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/656bd0b3-5273-4249-8aa4-4d0f7318c177.pdf"},{"id":101827796,"identity":"d3c49a05-78b3-40e4-8cc0-9e44fa6aeb8b","added_by":"auto","created_at":"2026-02-04 05:31:30","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":64402,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eTable S1. Upregulated differentially expressed genes in WT- and DC15-derived CD8+ T\u003c/u\u003e\u003csub\u003e\u003cu\u003eeff\u003c/u\u003e\u003c/sub\u003e\u003cu\u003e 7 and 10 dpi, related to Figures 2 and S2.\u003c/u\u003e\u003c/p\u003e","description":"","filename":"TableS1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/a38c625d4456f0947b1a2853.xlsx"},{"id":101880987,"identity":"cadd0b7d-6b2c-4e0e-b435-848b2fd7b3aa","added_by":"auto","created_at":"2026-02-04 15:08:40","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":58645,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eTable S2. Differentially expressed genes in WT- and DC15-derived CD4+ T\u003c/u\u003e\u003csub\u003e\u003cu\u003eeff\u003c/u\u003e\u003c/sub\u003e\u003cu\u003e 7 dpi, related to Figures 5 and S5.\u003c/u\u003e\u003c/p\u003e","description":"","filename":"TableS2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/2401acc062ee51305d3e99e8.xlsx"},{"id":101827791,"identity":"cec60ecf-e19e-4fe3-880d-4e33ba8fa8be","added_by":"auto","created_at":"2026-02-04 05:31:30","extension":"xlsx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":26631,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eTable S3. Differentially expressed genes in WT- and DC15-infected dLNs 48 hpi, related to Figure S7.\u003c/u\u003e\u003c/p\u003e","description":"","filename":"TableS3.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/6b34a98e20db5bcf4eeb53e6.xlsx"},{"id":101881211,"identity":"5292553a-3e27-4141-bcbb-a96533afd00e","added_by":"auto","created_at":"2026-02-04 15:10:45","extension":"xlsx","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":9354,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eTable S4. qPCR primer sequences for EVM003 and GAPDH quantification, related to Figure 7.\u003c/u\u003e\u003c/p\u003e","description":"","filename":"TableS4.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/d3a83d738f4d03f75c8dab71.xlsx"},{"id":101881350,"identity":"c6f5e008-3b12-4630-9018-fed1c0750b56","added_by":"auto","created_at":"2026-02-04 15:11:40","extension":"docx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":4069359,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryFigures.docx","url":"https://assets-eu.researchsquare.com/files/rs-8672980/v1/4e29ca9703625c837232239c.docx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"Conditional T and NK cell antagonism by a giant and highly conserved orthopoxvirus virulence factor","fulltext":[{"header":"Main","content":"\u003cp\u003eOrthopoxviruses (OPXVs) are a genus of mammalian-tropic viruses that exhibit a broad host range, induce severe pathology, and are a significant public health burden\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. Although the most prominent OPXV, variola (the causative agent of smallpox), was eradicated in 1980, the global human-to-human spread of mpox (MPXV)\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e as well as the emergence of novel OPXV species\u003csup\u003e\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e highlight the substantial risk OPXVs continue to pose to the general population. Furthermore, the 2022-23 outbreak of Clade IIB mpox revealed significant limitations of current anti-OPXV therapeutics, including sub-optimal vaccine efficacy\u003csup\u003e\u003cspan additionalcitationids=\"CR8 CR9\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e and ineffectiveness of current FDA-approved antivirals\u003csup\u003e\u003cspan additionalcitationids=\"CR12 CR13\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. Generally, OPXV virulence is attributed to the abundant immunomodulatory proteins encoded within their genomes, but many of these proteins are understudied and are also not shared across the entire genus, creating barriers to the establishment of general principles of OPXV virulence.\u003c/p\u003e \u003cp\u003eNotable among OPXV immunomodulatory proteins is the B22 family of proteins\u003csup\u003e\u003cspan additionalcitationids=\"CR16 CR17 CR18\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. Encoded by the largest open reading frames (ORFs) in OPXV genomes, B22 proteins are highly conserved in all OPXVs except for vaccinia\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e, which was used to develop the smallpox and mpox vaccines due to its dampened virulence\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e. Initial \u003cem\u003ein vitro\u003c/em\u003e studies found that B22 proteins, including those from monkeypox, cowpox (CPXV), and variola, are potent inhibitors of T cell receptor (TCR)-dependent activation\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. Furthermore, studies in non-human primates demonstrated that infection with MPXV lacking its B22 homolog (MPXVΔ197) was severely attenuated in its pathogenesis, both in viral replication over time as well as morbidity and mortality\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. These findings as well as the large size and high conservation of B22 family members strongly imply a major and indispensable role in OPXV biology. In line with this, studies using ectromelia (ECTV) infection in mice found that the insertion of a stop codon before its B22 ORF (corresponding protein termed \u0026ldquo;C15\u0026rdquo; in ECTV) largely prevents mortality in BALB/c mice\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e, which are highly susceptible to wild-type (WT) ECTV infection\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. Together, these studies demonstrated conserved and prominent contributions to virulence by B22 proteins in diverse mammalian hosts and highlight their strong candidacy as potential targets for anti-OPXV therapeutics. However, the immunological consequences of B22 protein expression \u003cem\u003ein vivo\u003c/em\u003e have been poorly defined.\u003c/p\u003e \u003cp\u003eECTV infection of mice exemplifies a natural host-pathogen relationship with notable similarities to the disease progression of smallpox\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e, and alongside the high conservation of its B22 protein with those of MPXV and variola\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e, this model offers a broadly relevant avenue to study the critical contributions of B22 proteins to OPXV virulence. Using ECTV, we previously demonstrated that C15 is capable of potently inhibiting mouse CD4\u0026thinsp;+\u0026thinsp;T cells, but not CD8\u0026thinsp;+\u0026thinsp;T cells, post-peptide loading onto antigen-presenting cells (APCs)\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e, in contrast to other B22 family members, which had been demonstrated to inhibit both CD4\u0026thinsp;+\u0026thinsp;and CD8\u0026thinsp;+\u0026thinsp;T cells\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. Furthermore, preliminary \u003cem\u003ein vitro\u003c/em\u003e findings suggested that C15 functions by inhibiting the formation of APC-T cell synapses\u003csup\u003e\u003cem\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/em\u003e\u003c/sup\u003e. Further complicating the picture is the discovery that C15 contributes to viral dissemination \u003cem\u003ein vivo\u003c/em\u003e as early as two days post-infection in C57Bl/6 (B6) mice\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e, well before the establishment of an adaptive immune response. Whole lymph node imaging revealed that C15 inhibits natural killer (NK) cell engagement of infected cells, resulting in much greater viral replication and dissemination at early time points in WT ECTV infection compared to ECTVΔC15\u003csup\u003e19\u003c/sup\u003e. These findings place C15, and B22 proteins by extension, into an extremely limited category of viral virulence factors that can inhibit both the innate and adaptive immune system through the targeting of separate immune cell populations\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Nevertheless, the consequences of C15 on the development of antiviral T cell responses and the dynamic interplay between C15 and NK cells \u003cem\u003ein vivo\u003c/em\u003e has not been explored. Furthermore, whether C15 is capable of unequivocally inhibiting CD8\u0026thinsp;+\u0026thinsp;T cells, like other B22 proteins, has not been thoroughly investigated.\u003c/p\u003e \u003cp\u003eHere, using a novel \u003cem\u003ein vitro\u003c/em\u003e expression system, we demonstrate that, indeed, C15 potently inhibits CD8\u0026thinsp;+\u0026thinsp;T cells, uncovering a third inhibitory activity of this enigmatic virulence factor. Counterintuitively, during \u003cem\u003ein vivo\u003c/em\u003e infection of C57Bl/6 (B6) mice, in the face of C15, WT ECTV induced larger and more functional CD8\u0026thinsp;+\u0026thinsp;T cell responses compared to ECTVΔC15, with phenotypic and transcriptomic analyses indicating stronger TCR signaling in WT-derived CD8\u0026thinsp;+\u0026thinsp;T cells. Experiments in \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice identified cDC1-mediated cross-presentation as the primary host workaround to CD8\u0026thinsp;+\u0026thinsp;T cell inhibition by C15, but CD4\u0026thinsp;+\u0026thinsp;T cell responses were similarly enhanced with C15 expression. Considering previous findings that NK cells heavily restrict ECTVΔC15 replication early in the draining lymph node, we determined that antigen load differences, driven by C15-mediated antagonism of NK cells, were the defining factors in the T cell responses to WT and ECTVΔC15. Using single cell RNA sequencing, we identified a candidate signaling scaffold that may be upstream of C15-mediated NK cell inhibition. Finally, we demonstrated that in BALB/c mice, which bear deficiencies in NK cell responses against ECTV, C15 more prominently targets CD4\u0026thinsp;+\u0026thinsp;and CD8\u0026thinsp;+\u0026thinsp;T cell responses, establishing the principle of conditional immune antagonism by C15.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eThe ECTV C15 protein inhibits both CD4\u0026thinsp;+\u0026thinsp;and CD8\u0026thinsp;+\u0026thinsp;T cells\u003c/h2\u003e \u003cp\u003eTo evaluate the breadth of T cell inhibition by C15, we established an inducible expression system that utilizes the Sleeping Beauty transposase to deliver a doxycycline-controlled C15-(HA tag) gene cassette into C57Bl/6 (B6)-derived skin fibroblasts (B6-C15) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA)\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e. We validated the expression and membrane trafficking of C15 via flow cytometry, demonstrating dose-dependent increases in HA-tag+ cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). In previous work, we demonstrated that C15 inhibits CD4\u0026thinsp;+\u0026thinsp;T cell activation\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. To confirm this activity in our inducible expression system, we transduced B6-C15 cells with lentivirus encoding the class II transactivator (CIITA) (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eA), induced overnight, and performed a T cell hybridoma assay (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB)\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e. As controls, we included an uninduced condition and an inducible cell line expressing the comparably large transmembrane protein guanylyl cyclase C (GC-C) (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eB)\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e. In line with our previous findings, C15 expression significantly reduced activation of MHCII-restricted T cell hybridomas (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB).\u003c/p\u003e \u003cp\u003eInitial publications on B22 family proteins reported that these proteins inhibit both CD4\u0026thinsp;+\u0026thinsp;and CD8\u0026thinsp;+\u0026thinsp;T cell activation\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. In contrast, we previously demonstrated that C15 inhibits only CD4\u0026thinsp;+\u0026thinsp;T cells\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. We speculated this selective effect was due to low C15 expression levels in our previous systems, and, indeed, this is supported by the demonstration that inhibition of CD4\u0026thinsp;+\u0026thinsp;T cell hybridomas by C15 is reduced when expression is driven by a weaker promoter (UbC) (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eC). We investigated the inhibition of various CD8\u0026thinsp;+\u0026thinsp;T cell hybridomas using our inducible cell line, finding that C15 inhibited all CD8\u0026thinsp;+\u0026thinsp;T cell hybridomas similarly to CD4\u0026thinsp;+\u0026thinsp;T cell hybridomas (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC). To ensure inhibition was not an artifact of our \u003cem\u003ein vitro\u003c/em\u003e system, we infected FMS-like tyrosine kinase 3 ligand (Flt3l)-derived type 1 conventional dendritic cells (cDC1s) (Figures \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eD-G) with ECTV-eGFP (WT)\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e or ECTVΔC15 (ΔC15)\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eH-I) for co-culture with ECTV-specific primary CD8\u0026thinsp;+\u0026thinsp;or CD4\u0026thinsp;+\u0026thinsp;T cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD). Restimulation of CD8+ (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE) and CD4+ (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF) T cells by ΔC15-infected cDC1s was significantly greater compared to WT-infected cDC1s, although the relative inhibition was much more potent in the CD4\u0026thinsp;+\u0026thinsp;T cell co-culture. Furthermore, CD4\u0026thinsp;+\u0026thinsp;T cell IFNγ spots were significantly larger when co-cultured with ΔC15-infected cDC1s compared to WT-infected cDC1s (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF).\u003c/p\u003e \u003cp\u003eC15-mediated inhibition was not due to downregulation of any MHC or co-stimulatory molecule (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eJ), suggesting that the mechanism of C15 inhibition is either MHC-independent or fundamental to all antigen-specific APC-T cell interactions. Previous data indicated that C15 functions post-peptide loading\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e, but it has not yet been shown whether C15 modulates the number of peptide-MHC (pMHC) complexes on the cell surface. Using TCR-like antibodies that recognize either pMHCI (H-2K\u003csup\u003eb\u003c/sup\u003e-SIINFEKL) or pMHCII (I-A\u003csup\u003eb\u003c/sup\u003e-Ea\u003csub\u003e52-68\u003c/sub\u003e) complexes, we found that C15 does not alter the abundance of pMHC complexes on the cell surface, derived from either mRNA lipid nanoparticle-encoded protein (Figures \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eK-M) or pulsed peptide (Figures \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eN-O). Taken together, our data indicate that, in addition to its impact on NK cells, C15 can inhibit CD4\u0026thinsp;+\u0026thinsp;and CD8\u0026thinsp;+\u0026thinsp;T cells without disrupting pMHC complex presentation at the cell surface.\u003c/p\u003e \u003cp\u003eTo gain additional insights into C15 inhibitory activity, we asked whether C15 could inhibit T cell hybridoma activation from a \u0026ldquo;bystander\u0026rdquo; cell. To accomplish this, we induced MHCII-negative C15-HA-tag cells (bystander) and co-incubated them with MHCII+ B6 fibroblasts (APCs) in the presence CD4\u0026thinsp;+\u0026thinsp;T cell hybridomas and exogenous peptide. Here, C15 inhibited hybridoma activation in a dose-dependent manner (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG), but this was not mediated by a secreted fragment since supernatant from high density cell cultures did not have an inhibitory effect (Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eP). To ask whether C15 antagonizes TCR-independent calcium flux or intracellular signaling, we treated hybridomas with ionomycin and phorbol 12-myristate 13-acetate (PMA). In this context, C15 was unable to inhibit hybridoma activation (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eH), suggesting TCR-dependent inhibition like other B22 protein members\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. Thus, our data indicate that C15 is cell-associated and can inhibit TCR-dependent CD4\u0026thinsp;+\u0026thinsp;and CD8\u0026thinsp;+\u0026thinsp;T cell activation without necessarily being expressed by the APC.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eCD8 + T cell responses are enhanced in the face of C15\u003c/h3\u003e\n\u003cp\u003eGiven the importance of CD8\u0026thinsp;+\u0026thinsp;T cells in protective immunity against ECTV\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e, we footpad infected B6 mice with either WT or ΔC15 and evaluated splenic CD8\u0026thinsp;+\u0026thinsp;T cell responses (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). Contrary to expectations, CD8\u0026thinsp;+\u0026thinsp;effector T cell (CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e) responses to infection were significantly greater as a percentage of total CD8\u0026thinsp;+\u0026thinsp;T cells during WT infection, with differences being apparent as early as 7 days post-infection (dpi) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB). To probe antigen-specific CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e, we stained splenic CD8\u0026thinsp;+\u0026thinsp;T cells with an H-2K\u003csup\u003eb\u003c/sup\u003e tetramer loaded with the immunodominant B8R\u003csub\u003e20-27\u003c/sub\u003e epitope (B8R+) (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eA). Notably, at 6 dpi, WT-derived B8R+ T\u003csub\u003eeff\u003c/sub\u003e had greater expression of the activating markers CD69 and CD25, which persisted through 7 dpi (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC). Furthermore, PD-1, perforin, and granzyme B (GzmB) were upregulated starting at 7 dpi, and PD-1 expression was maintained through 10 dpi (Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC-D). Together, these data suggest that WT infection (C15-expressing), counterintuitively, induced a larger and more activated CD8\u0026thinsp;+\u0026thinsp;T cell response to infection compared to ΔC15.\u003c/p\u003e \u003cp\u003eTo further investigate whether CD8\u0026thinsp;+\u0026thinsp;T cell responses are, in fact, enhanced in the face of C15, we assessed cytokine production by and cytolytic potential of CD8\u0026thinsp;+\u0026thinsp;T cells from either WT or ΔC15-infected mice at 7 or 9 dpi. This was done via restimulation of splenocytes with ΔC15-infected DC2.4 cells or B8R peptide (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eB). While there were no significant differences in the proportion of cytokine-producing CD8\u0026thinsp;+\u0026thinsp;T cells with either restimulation condition at 7 dpi (Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eE-F), by 9 dpi, a substantially greater proportion of WT-derived CD8\u0026thinsp;+\u0026thinsp;T cells were cytokine-producing and exhibited higher cytotoxic potential compared to ΔC15-infected mice from both restimulation conditions (Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eG-I). The greater functionality of WT-derived total CD8\u0026thinsp;+\u0026thinsp;T cells can be attributed to the larger population of CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e in WT-infected mice at 9 dpi (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB), but the lower functionality of B8R peptide-stimulated T cells in ΔC15-infected mice indicate less cytokine-producing capacity on a per cell basis, as the proportion of B8R+ CD8\u0026thinsp;+\u0026thinsp;T cells is equivalent between WT and ΔC15 at this timepoint (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eJ). In line with decreased functionality, a significantly greater proportion of ΔC15-derived B8R+ T\u003csub\u003eeff\u003c/sub\u003e highly expressed CX3CR1 (CX3CR1\u003csup\u003ehi\u003c/sup\u003e) (Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eK and \u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003eS2\u003c/span\u003eC-D), a marker of terminal differentiation that has been negatively associated with polyfunctionality\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. Furthermore, at 9 dpi, there were more CX3CR1\u003csup\u003eint\u003c/sup\u003e B8R+ T\u003csub\u003eeff\u003c/sub\u003e in WT-infected mice compared to in ΔC15-infected mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eL). Together, these data indicate that B8R+ T\u003csub\u003eeff\u003c/sub\u003e in WT-infected mice are more polyfunctional and less terminally differentiated than those from ΔC15 infection.\u003c/p\u003e \u003cp\u003eLastly, to couple phenotypic and functional differences with transcriptional changes, we performed bulk RNA-sequencing on splenic CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e at 7 and 10 dpi (Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eM and \u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003eS2\u003c/span\u003eE and Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e). At 7 dpi, differentially expressed genes (DEGs) within CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e from WT-infected mice were enriched for targets of MYC \u0026ndash; a prominent regulator downstream of T cell activation (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eF)\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e, IL-2 signaling (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eG), and zinc ion binding (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eH), which has been positively associated with TCR engagement\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e,\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e. Gene ontology (GO) analysis further demonstrated enrichment in genes related to mRNA processing, RNA localization, ribosome biogenesis, and DNA metabolism (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eI). In contrast, ΔC15-derived CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e were strongly enriched for genes downstream of type I interferon (IFN) (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eJ), genes associated with an NK cell-like phenotype (Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eK), and genes implicated in negative regulation of TCR signaling (\u003cem\u003eCd37\u003c/em\u003e, \u003cem\u003eCish\u003c/em\u003e, \u003cem\u003eKlr1g\u003c/em\u003e, \u003cem\u003eNrp2\u003c/em\u003e, \u003cem\u003ePtpn6\u003c/em\u003e, \u003cem\u003eTnk2\u003c/em\u003e)\u003csup\u003e\u003cspan additionalcitationids=\"CR36 CR37 CR38 CR39\" citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. At 10 dpi, WT-derived CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e maintained greater expression of several AP-1-associated factors (\u003cem\u003eFos\u003c/em\u003e, \u003cem\u003eJun\u003c/em\u003e, \u003cem\u003eEgr1\u003c/em\u003e)\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e while ΔC15-derived CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e had greater expression of \u003cem\u003eBach2\u003c/em\u003e and \u003cem\u003eZbtb20\u003c/em\u003e, which restrain chromatin accessibility of AP-1 factors\u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e,\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e and limit the metabolic capacity of CD8\u0026thinsp;+\u0026thinsp;T cells\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e, indicating the persistence of T cell phenotypes from earlier infection timepoints (Figures \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eL-M and Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e). These transcriptional data support the findings that WT infection drives larger and functionally enhanced CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e compared to ΔC15-derived CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e, in line with our direct assessments of CD8\u0026thinsp;+\u0026thinsp;T cell phenotype.\u003c/p\u003e\n\u003ch3\u003eCD8 + T cells have higher avidity during WT infection\u003c/h3\u003e\n\u003cp\u003eWe speculated that WT infection induced larger CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e responses than ΔC15 infection due to broader T cell priming from a more diverse array of epitopes. Consistent with this, by 10 dpi, there were significantly less B8R\u0026thinsp;+\u0026thinsp;T cells among T\u003csub\u003eeff\u003c/sub\u003e during WT infection compared to ΔC15 (Figure \u003cspan refid=\"MOESM3\" class=\"InternalRef\"\u003eS3\u003c/span\u003eA). This suggests that antigen-specific responses during WT infection are more antigenically diverse and less dominated by the B8R epitope than those during ΔC15 infection. Conversely, a significantly greater proportion of B8R+ T\u003csub\u003eeff\u003c/sub\u003e during ΔC15 infection suggests that there may be differences in clonal diversity among B8R+ CD8\u0026thinsp;+\u0026thinsp;T cells. To investigate this, we performed bulk TCR sequencing on B8R+ T\u003csub\u003eeff\u003c/sub\u003e cells from WT- or ΔC15-infected mice at 7 and 10 dpi (Figure \u003cspan refid=\"MOESM3\" class=\"InternalRef\"\u003eS3\u003c/span\u003eB). However, there were no differences in clonal diversity between WT- or ΔC15-infected mice at either timepoint (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA). Furthermore, there were not major differences in either V or J gene usage between infection conditions (Figures \u003cspan refid=\"MOESM3\" class=\"InternalRef\"\u003eS3\u003c/span\u003eC-D). Therefore, C15 expression does not alter the TCR repertoire of B8R\u0026thinsp;+\u0026thinsp;T cells, and there is no evidence for selective clonal expansion in either infection condition.\u003c/p\u003e \u003cp\u003eAn alternative explanation for the enhanced CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e responses during WT infection is greater T cell avidity, as higher avidity T cells have been shown to proliferate more efficiently \u003cem\u003ein vivo\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e. Therefore, we tested the relative avidity of B8R+ CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e from WT- or ΔC15-infected mice using a tetramer decay assay (Figure \u003cspan refid=\"MOESM3\" class=\"InternalRef\"\u003eS3\u003c/span\u003eE)\u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e. We found no differences in the rate of tetramer decay between infection conditions, suggesting similar avidities (Figure \u003cspan refid=\"MOESM3\" class=\"InternalRef\"\u003eS3\u003c/span\u003eF), but the B8R tetramer-TCR affinity may be too high for a meaningful investigation of T cell avidity. As an orthogonal approach, we evaluated the phenotype of WT- or ΔC15-derived CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e over time in a model of chronic antigen stimulation, as high avidity T cells have been shown to undergo greater exhaustion in these contexts\u003csup\u003e\u003cspan additionalcitationids=\"CR48 CR49\" citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e. To generate a model of chronic antigen stimulation during ECTV infection, we depleted B6 mice of CD4\u0026thinsp;+\u0026thinsp;T cells prior to infection with WT and ΔC15 (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB), as previous work suggested CD4\u0026thinsp;+\u0026thinsp;T cells are required to promote efficient CD8\u0026thinsp;+\u0026thinsp;T cell contraction post-infection\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. WT-infected mice began succumbing to infection by approximately 35 dpi, with 80% deceased by 70 dpi, whereas ΔC15-infected mice largely survived throughout this timeline (80% survival) (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC). By 30 dpi, CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e in CD4-depleted mice generally had elevated PD-1 expression, but WT-derived CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e exhibited higher expression of the terminal exhaustion markers CD39, TOX, and LAG-3 compared to those from ΔC15-infected mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD)\u003csup\u003e\u003cspan additionalcitationids=\"CR52\" citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e, which were enriched within B8R\u0026thinsp;+\u0026thinsp;T cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eE). CD8\u0026thinsp;+\u0026thinsp;T cell exhaustion was highly progressive, with systemic upregulation of terminal exhaustion markers in the days prior to death (Figure \u003cspan refid=\"MOESM3\" class=\"InternalRef\"\u003eS3\u003c/span\u003eG). Together, these findings suggest that WT-derived CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e have greater avidity that drives enhanced proliferation and functionality \u003cem\u003ein vivo\u003c/em\u003e.\u003c/p\u003e\n\u003ch3\u003eCD8 + T cells exhibit similar memory trajectories during WT and ΔC15 infection\u003c/h3\u003e\n\u003cp\u003eGreater avidity of CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e during WT infection suggests that CD8\u0026thinsp;+\u0026thinsp;T cell memory may be enhanced compared to ΔC15 infection\u003csup\u003e\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e\u003c/sup\u003e. To investigate this, we tracked B8R\u0026thinsp;+\u0026thinsp;T cells over the course of 6 months post-WT or -ΔC15 infection and monitored short-lived effector cells (SLEC), memory precursor effector cells (MPEC), and \u0026ldquo;double positive\u0026rdquo; (KLRG1\u0026thinsp;+\u0026thinsp;CD127+) effector cells (DPEC) (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eF), which are thought to be the primary source of \u0026ldquo;exKLRG1\u0026rdquo; long-lived memory cells\u003csup\u003e\u003cspan additionalcitationids=\"CR56\" citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e\u003c/sup\u003e. SLEC and DPEC were the dominant populations at 14 dpi in all mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eG), while DPEC and MPEC were dominant at 181 dpi, with roughly equal proportions. Notably, the trajectories of memory development were similar following WT and ΔC15 infection (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eG). Therefore, despite C15 expression substantially enhancing the magnitude and function of the acute CD8\u0026thinsp;+\u0026thinsp;T cell response, there does not appear to be long-term effects on the development of CD8\u0026thinsp;+\u0026thinsp;T cell memory against the B8R epitope.\u003c/p\u003e\n\u003ch3\u003eCross-presentation compensates for C15-mediated inhibition of direct presentation to CD8 + T cells\u003c/h3\u003e\n\u003cp\u003eThe juxtaposition of potent CD8\u0026thinsp;+\u0026thinsp;T cell inhibition by C15 \u003cem\u003ein vitro\u003c/em\u003e and the greater CD8\u0026thinsp;+\u0026thinsp;T cell responses during WT infection suggests compensatory mechanisms \u003cem\u003ein vivo\u003c/em\u003e. While C15 can effectively block antigen presentation from a bystander cell (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG), we speculated that cross-presentation drives enhanced CD8\u0026thinsp;+\u0026thinsp;T cell responses during WT infection compared to ΔC15. Therefore, we used the \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mouse model, which is deficient in the development of CD8α\u0026thinsp;+\u0026thinsp;cDC1s \u0026ndash; the primary mediators of cross-presentation during poxviral infections\u003csup\u003e\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e,\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e \u0026ndash; while allowing for ECTV viral replication\u003csup\u003e\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e\u003c/sup\u003e. We infected either B6 or \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice with WT or ΔC15 and investigated their splenic CD8\u0026thinsp;+\u0026thinsp;T cell responses at 7 dpi (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). Similar to other reports\u003csup\u003e\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e\u003c/sup\u003e, we found that the ratio of splenic CD4+/CD8\u0026thinsp;+\u0026thinsp;T cells 7 dpi was significantly higher in \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice compared to B6 counterparts, highlighting an intrinsic deficit in CD8\u0026thinsp;+\u0026thinsp;T cell proliferation independent of infection condition (Figure \u003cspan refid=\"MOESM4\" class=\"InternalRef\"\u003eS4\u003c/span\u003eA). However, the development of CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e was significantly reduced in WT-infected \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice compared to their B6 counterparts, while CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e were unchanged in ΔC15-infected mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB). While CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e did not differ in their expression of CD25 or CX3CR1 between B6 and \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice (Figs.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC-D), the proportion of B8R+ T\u003csub\u003eeff\u003c/sub\u003e was significantly upregulated in \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice independent of infection condition (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eE), suggesting that B8R is more abundantly presented when cross-presentation is stunted. CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e also trended towards or exhibited greater expression of TIM-3 in \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice (Figure \u003cspan refid=\"MOESM4\" class=\"InternalRef\"\u003eS4\u003c/span\u003eB), which may explain the lower capacity for \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e to proliferate\u003csup\u003e\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eCD40-CD40L signaling between cDC1s and CD4\u0026thinsp;+\u0026thinsp;T cells has been suggested as critical in the \u0026ldquo;licensing\u0026rdquo; of cDC1s for CD8\u0026thinsp;+\u0026thinsp;T cell priming\u003csup\u003e\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e\u003c/sup\u003e. To exclude the possibility that the differences observed with WT and \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice could be explained by differences in CD40-CD40L signaling, we treated B6 and \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice with αCD40L blocking antibody during WT infection (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eF). CD70 expression, a response downstream of CD40 ligation\u003csup\u003e\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e\u003c/sup\u003e, on cDC1s was downregulated in B6 mice treated with αCD40L, indicating successful blockade (Figures \u003cspan refid=\"MOESM4\" class=\"InternalRef\"\u003eS4\u003c/span\u003eC-D). Batf3-independent cDC1s responded with limited CD70 upregulation but greater overall CD40 expression (Figures \u003cspan refid=\"MOESM4\" class=\"InternalRef\"\u003eS4\u003c/span\u003eE), and αCD40L treatment expanded cDC1s in \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice (Figure \u003cspan refid=\"MOESM4\" class=\"InternalRef\"\u003eS4\u003c/span\u003eF). CD40L blockade did not dampen CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e responses to WT infection in B6 mice, but it increased the induction of CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e in \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice (Figs.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG-H), implicating non-canonical CD40L signaling in negatively regulating CD8\u0026thinsp;+\u0026thinsp;T cell responses in \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice during ECTV infection\u003csup\u003e\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e,\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e\u003c/sup\u003e. In B6 mice, there was a decrease in CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e following αCD40L treatment (Figs.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eI), which was expected given the role for CD40L in activation of CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e\u003csup\u003e67,68\u003c/sup\u003e. Together, these data demonstrate that phenotypes in WT-infected \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice are not due to a lack of CD40-CD40L engagement, and that T cell responses during WT infection are more sensitive to deficits in cross-presentation compared to ΔC15 infection, in line with inhibition of direct presentation to CD8\u0026thinsp;+\u0026thinsp;T cells by C15.\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eCD4\u0026thinsp;+\u0026thinsp;T cell responses are similarly enhanced during WT infection compared to ΔC15\u003c/h2\u003e \u003cp\u003eInhibition of CD4\u0026thinsp;+\u0026thinsp;T cells by C15 has been previously reported \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003eex vivo\u003c/em\u003e\u003csup\u003e\u003cem\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/em\u003e\u003c/sup\u003e. Furthermore, here, C15 demonstrated enhanced potency against CD4\u0026thinsp;+\u0026thinsp;T cells \u003cem\u003eex vivo\u003c/em\u003e compared to CD8\u0026thinsp;+\u0026thinsp;T cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF). We therefore speculated that CD4\u0026thinsp;+\u0026thinsp;T cell responses may be more sensitive to C15 inhibition \u003cem\u003ein vivo\u003c/em\u003e. However, like CD8\u0026thinsp;+\u0026thinsp;T cells, we found that the induction of CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e (CD62L-CD44+) was greater during WT infection compared to ΔC15 (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA). Furthermore, the development of antigen-experienced CD4\u0026thinsp;+\u0026thinsp;T cells (CD11a+CD49d+)\u003csup\u003e69,70\u003c/sup\u003e, which correlate with CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e (Figure S5A), and antigen-specific (I-A\u003csup\u003eb\u003c/sup\u003e-I1L\u003csub\u003e7-21\u003c/sub\u003e-specific, I1L+)\u003csup\u003e69\u003c/sup\u003e CD4\u0026thinsp;+\u0026thinsp;T cells was greater in spleens of WT-infected mice by 7 dpi (Figs.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eB-C), without an impact to immunodominance over time (Figure S5B).\u003c/p\u003e \u003cp\u003eA hallmark of ECTV infection is the development of cytotoxic CD4\u0026thinsp;+\u0026thinsp;T cells (CD4-CTLs, GzmB\u0026thinsp;+\u0026thinsp;and/or perforin+)\u003csup\u003e69,71\u003c/sup\u003e. As previously described\u003csup\u003e\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e,\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e\u003c/sup\u003e, WT infection induced a substantial population of CD4-CTLs (Figs.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eD-E). In contrast, there was little to no CD4-CTL induction during ΔC15 infection (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eE). To determine whether CD4-CTL induction is strictly dependent on C15, we compared CD4-CTL development during ΔC15 infection of β2m\u003csup\u003e-/-\u003c/sup\u003e mice, as the absence of CD8\u0026thinsp;+\u0026thinsp;T cells in these mice (Figure S5C) induces a compensatory increase in CD4-CTLs\u003csup\u003e\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e\u003c/sup\u003e. Notably, the induction of CD4-CTLs was rescued in β2m\u003csup\u003e-/-\u003c/sup\u003e mice following ΔC15 infection (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eF), suggesting that CD4-CTL responses are not intrinsically linked to C15 expression.\u003c/p\u003e \u003cp\u003eTo gain broader insights into the impact of C15 on CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e cell responses, we performed bulk RNA-sequencing on sorted splenic CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e 7 dpi (Figs.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eG, \u003cspan refid=\"Fig13\" class=\"InternalRef\"\u003eS5\u003c/span\u003eD and Table \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003e). WT-derived CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e, like CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e, had increased expression of transcriptional modules downstream of IL-2 signaling (Figure S5E) and MYC expression (Figure S5F), as well as upregulation of genes related to oxidative phosphorylation (Figure S5G) and the unfolded protein response (Figure S5H). GO term enrichment further identified an upregulation of genes associated with the cell cycle in WT-derived CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eH). The transcriptional phenotype of CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e during ΔC15 infection was similar to that of CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e (Figs.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eG and \u003cspan refid=\"Fig13\" class=\"InternalRef\"\u003eS5\u003c/span\u003eI-J), but there was also greater expression of regulatory T cells (T\u003csub\u003ereg\u003c/sub\u003e)-associated genes (\u003cem\u003eRunx1, Foxo1, Foxo3, Foxp3, Gpr83, Ikzf4, Nrp1\u003c/em\u003e)\u003csup\u003e\u003cspan additionalcitationids=\"CR74 CR75 CR76\" citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e\u003c/sup\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eG), suggesting that ΔC15-derived CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e are more skewed towards immunosuppressive phenotypes.\u003c/p\u003e \u003cp\u003eLastly, we asked whether CD4\u0026thinsp;+\u0026thinsp;T follicular helper cell (T\u003csub\u003efh\u003c/sub\u003e) responses recapitulated our findings in CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e, examining the balance of T\u003csub\u003efh\u003c/sub\u003e and CD4\u0026thinsp;+\u0026thinsp;T follicular regulatory cells (T\u003csub\u003efr\u003c/sub\u003e), as antibodies are a critical determinant of protection against ECTV\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. We measured the induction of T\u003csub\u003efh\u003c/sub\u003e and T\u003csub\u003efr\u003c/sub\u003e cells in the spleen and inguinal lymph node (iLN) at 7 and 10 dpi (Figure S5K). WT-infected mice had a significantly greater proportion of T\u003csub\u003efh\u003c/sub\u003e within both splenic CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e and total CD4\u0026thinsp;+\u0026thinsp;T cells 7 dpi, but this difference was not apparent at 10 dpi (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eI). In contrast, ΔC15-infected mice had greater proportions of T\u003csub\u003efr\u003c/sub\u003e in splenic CD4\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e at 7 and 10 dpi and within total CD4\u0026thinsp;+\u0026thinsp;T cells 10 dpi (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eJ). Between infection conditions, we found no significant differences in the induction of T\u003csub\u003efh\u003c/sub\u003e or T\u003csub\u003efr\u003c/sub\u003e cells within the iLN (Figures S5L-M). Notably, these differences in T\u003csub\u003efh\u003c/sub\u003e did not change anti-ECTV IgG antibody titers 28 dpi (Figure S5N). Overall, as with CD8\u0026thinsp;+\u0026thinsp;T cell responses, CD4\u0026thinsp;+\u0026thinsp;T cell responses to ECTV infection are enhanced in the presence of C15 \u0026ndash; at odds with the potent inhibition observed \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003eex vivo\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eCross-protective immunity is maintained in the absence of C15\u003c/h3\u003e\n\u003cp\u003eGiven WT- and ΔC15-infected mice displayed similar CD8\u0026thinsp;+\u0026thinsp;T cell memory trajectories and equivalent anti-ECTV IgG development, we asked whether significant deficits in acute T cell responses during ΔC15 infection impacted the establishment of cross-protective immunity. Therefore, we challenged WT- or ΔC15-immunized mice 30 dpi with a lethal dose of the related orthopoxvirus, cowpox (CPXV) (Figure S5O). All ECTV-immunized (WT or ΔC15) mice survived (Figure S5P), with increases in the CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e population following challenge (Figure S5Q). Together, these data demonstrate that the transcriptional, phenotypic and functional differences in CD8\u0026thinsp;+\u0026thinsp;and CD4\u0026thinsp;+\u0026thinsp;responses during WT or ΔC15 infection, under the specified conditions, do not hinder the establishment of cross-protective immunity.\u003c/p\u003e\n\u003ch3\u003eT cell differences between WT and ΔC15 infection are driven by antigen load\u003c/h3\u003e\n\u003cp\u003eWhile cDC1-mediated cross-presentation explains the enhanced CD8\u0026thinsp;+\u0026thinsp;T cell responses in the face of C15 expression, this mechanism does not explain the deficiencies in CD8\u0026thinsp;+\u0026thinsp;and CD4\u0026thinsp;+\u0026thinsp;T cell responses during ΔC15 infection, which should be significantly enhanced compared to WT according to \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003eex vivo\u003c/em\u003e findings (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e)\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. We next considered the possibility that the interaction between C15 and its third cellular target, NK cells, impacts T cell responses. We have previously demonstrated that ΔC15 replication in B6 mice is heavily restricted in the draining lymph node due to NK cell-mediated control, which is effectively antagonized by C15\u003csup\u003e19\u003c/sup\u003e. Therefore, we hypothesized that decreased antigen load during ΔC15 infection may underlie the differences in T cell responses described above, and this notion is further supported by the association between CD4-CTL induction and viral replication\u003csup\u003e\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e\u003c/sup\u003e, both of which are markedly reduced during ΔC15 infection.\u003c/p\u003e \u003cp\u003eThe finding that ΔC15 infection of β2m\u003csup\u003e-/-\u003c/sup\u003e mice rescued the induction of CD4-CTLs (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eF) implies that ΔC15 infection replication is enhanced in the absence of a functional CD8\u0026thinsp;+\u0026thinsp;T cell compartment. Indeed, B6 mice pretreated with anti-CD8 depleting antibody succumbed to both WT and ΔC15 infection (Figure S6A). To directly quantify viral burden in β2m\u003csup\u003e-/-\u003c/sup\u003e mice \u003cem\u003eex vivo\u003c/em\u003e, we used an anti-MPXV A35R (A33R in ECTV) monoclonal antibody\u003csup\u003e\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e\u003c/sup\u003e, which displayed strong cross-reactivity with ECTV (Figures S6B-C). Notably, inflammatory monocytes (iMOs, Figure S6D) from ΔC15-infected β2m\u003csup\u003e-/-\u003c/sup\u003e mice were more highly infected than their B6 counterparts (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA). Thus, differences in viral load may explain the impairment of T cell responses during ΔC15 infection.\u003c/p\u003e \u003cp\u003eTo explicitly test the relationship between antigen load and T cell phenotype, we first infected B6 mice with WT ECTV and treated with cidofovir (CDV) 3 dpi to limit late viral replication (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eB)\u003csup\u003e\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e,\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e\u003c/sup\u003e. In line with previous reports\u003csup\u003e\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e\u003c/sup\u003e, CDV treatment significantly dampened the induction of CD4-CTLs (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eC). Furthermore, CDV treatment also increased the proportion of CX3CR1\u0026thinsp;+\u0026thinsp;and CX3CR1\u003csup\u003eint\u003c/sup\u003e CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eD) and reduced PD-1\u0026thinsp;+\u0026thinsp;CD25+ CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eE). CDV treatment did not impact the magnitude of CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e generation among total CD8\u0026thinsp;+\u0026thinsp;T cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eF), but the expression of granzyme B and perforin was reduced to a level equal to ΔC15 infection (Figs.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eG-H). To directly implicate NK cells as the mediator of key antigen restrictions during ΔC15 infection, we compared T cell responses to WT or ΔC15 infection in untreated mice with that of NK-depleted, ΔC15-infected mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eI). NK cell depletion restored CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e induction to levels equivalent to WT infection (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eJ) and increased CD25 and PD-1 expression above that of WT infection (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eK). Furthermore, NK cell depletion rescued CD4-CTL induction (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eL). Together, these data demonstrate that NK cell-infected cell interactions and their subsequent impact on antigen load are the defining factors in the CD4\u0026thinsp;+\u0026thinsp;and CD8\u0026thinsp;+\u0026thinsp;T cell response to WT and ΔC15 infection in B6 mice.\u003c/p\u003e \u003cp\u003eAs a proof-of-principle, we revisited ΔC15 infection of \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice, where the proportion of CD8\u0026thinsp;+\u0026thinsp;T cells that developed into T\u003csub\u003eeff\u003c/sub\u003e by 7 dpi was equivalent to B6 counterparts (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB). In this model, we speculated that lower antigen load in combination with deficiencies in cross-presentation synergize to ablate CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e expansion during ΔC15 infection in \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice, and this notion is supported by the finding that the proportion of CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e at 9 dpi is unchanged during ΔC15 infection compared to WT infection, which underwent a modest expansion (Figures S6E).\u003c/p\u003e \u003cp\u003eGiven findings thus far, we reasoned that increases in antigen load during ΔC15 infection of \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice should propel CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e expansion beyond that of WT infection, as direct presentation is more efficient than cross-presentation\u003csup\u003e\u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e81\u003c/span\u003e\u003c/sup\u003e. We depleted NK cells in \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice prior to ΔC15 infection, and in line with our hypothesis, NK cell depletion pushed CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e expansion beyond that of WT-infected \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eM) and enhanced CD25 (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eN) and TIM-3 expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eO). Thus, restoration of antigen load during ΔC15 infection of \u003cem\u003eBatf3\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/-\u003c/em\u003e\u003c/sup\u003e mice, which has unobstructed direct priming due to the absence of C15, led to enhanced CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e responses compared to WT infection. This further supports early antigen load restriction of ΔC15 by NK cells as the critical bottleneck in the establishment of robust antiviral T cell responses.\u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eNK and T cells undergo distinct transcriptional changes in the dLN during ΔC15 infection\u003c/h2\u003e \u003cp\u003eEarly engagement and antagonism of NK cell-mediated control by C15 is critical to permit efficient viral replication in the dLN\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e, ultimately driving enhanced CD8\u0026thinsp;+\u0026thinsp;and CD4\u0026thinsp;+\u0026thinsp;T cell responses to infection. To investigate the mechanistic basis, we first assessed the transcriptional differences in the dLN during WT and ΔC15 infection at 48 hpi, a time point prior to measurable differences in viral titer\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. We performed bulk RNA sequencing on dLNs harvested 48 hpi (Figures S7A-B and Table \u003cspan refid=\"MOESM3\" class=\"InternalRef\"\u003eS3\u003c/span\u003e). GO term enrichment of DEGs identified a handful of terms that were different between infection conditions (Figure S7C). Most notable terms were production of reactive oxygen species in WT-infected and macroautophagy in ΔC15-infected dLNs. To more precisely identify transcriptional differences, we performed single cell RNA sequencing (scRNA-seq). To ensure we captured the earliest points of divergence between WT and ΔC15 infection, we performed qPCR for viral RNA at 24 and 32 hpi as well as probed NK cell phenotypes at 48 hpi. There was significantly more viral RNA by 32 hpi in WT-infected dLNs (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eA). Additionally, by 48 hpi, NK cells from WT-infected dLNs had significantly greater expression of KLRG1 (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eB), CD137 (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eC), GzmB (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eD), and IFNγ (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eE), suggesting that the initial impact of C15 on NK function occurs prior to 48 hpi. Therefore, we chose 24 and 48 hpi as timepoints for scRNA-seq, specifically probing transcriptional changes within T and NK cell (CD19-negative) populations (Figure S7D).\u003c/p\u003e \u003cp\u003eWe recovered eight Leiden clusters, named according to key marker genes (Figs.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eF and \u003cspan refid=\"Fig15\" class=\"InternalRef\"\u003eS7\u003c/span\u003eE). Across timepoints, IFN-responsive T cells and NK cells increased in proportion for both infection conditions (Figures S7F-G). Notably, a cluster of T cells (annotated \u0026ldquo;Activated T cells\u0026rdquo;) defined by TCR-associated genes (\u003cem\u003eNfkb1\u003c/em\u003e, \u003cem\u003eNr4a3\u003c/em\u003e, \u003cem\u003eEgr3\u003c/em\u003e, \u003cem\u003eRelb\u003c/em\u003e, \u003cem\u003eDnmt3a\u003c/em\u003e, \u003cem\u003eMyc\u003c/em\u003e)\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e,\u003cspan additionalcitationids=\"CR83 CR84\" citationid=\"CR82\" class=\"CitationRef\"\u003e82\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e\u003c/sup\u003e had greater representation in ΔC15-infected dLNs at 48 hpi (Figure S7G). Cluster-specific expression analysis did not identify DEGs 24 hpi infection across T cell clusters, but by 48 hpi, several genes downstream of TCR engagement (\u003cem\u003eTox, Cd44, Tnf, Egr1\u003c/em\u003e)\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e,\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e,\u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e\u003c/sup\u003e and those associated with cytoskeleton remodeling (\u003cem\u003ePrag1, Tmsb10\u003c/em\u003e)\u003csup\u003e\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e,\u003cspan citationid=\"CR89\" class=\"CitationRef\"\u003e89\u003c/span\u003e\u003c/sup\u003e were upregulated during ΔC15 infection (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eG). In contrast, T cell clusters from WT-infected mice mainly upregulated genes associated with IFN signaling (\u003cem\u003eMx1\u003c/em\u003e, \u003cem\u003eIfit3b\u003c/em\u003e, \u003cem\u003eSocs3\u003c/em\u003e). Together, these data are consistent with earlier TCR engagement in ΔC15-infected dLNs.\u003c/p\u003e \u003cp\u003eWhen investigating NK cells at 24 hpi, only a single DEG, \u003cem\u003eGab2\u003c/em\u003e (a signaling scaffold)\u003csup\u003e\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e\u003c/sup\u003e, was upregulated in ΔC15 dLNs (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eH), and there were no DEGs at 48 hpi (Figure S7H), in contrast with phenotypic differences seen by flow cytometry (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eB-E). Therefore, we performed sub-clustering on NK cells to investigate key NK cell subsets. This yielded two primary clusters (NK-1 and NK-2) (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eI), with NK-1 enriched for conventional NK cell marker genes (\u003cem\u003eNcr1\u003c/em\u003e, \u003cem\u003eKlrk1\u003c/em\u003e, \u003cem\u003eGzma\u003c/em\u003e, \u003cem\u003eItga2\u003c/em\u003e) and NK-2 enriched for genes associated with transcriptional regulation as well as NKT-like markers (\u003cem\u003eTcf7\u003c/em\u003e, \u003cem\u003eLef\u003c/em\u003e, \u003cem\u003eBcl11b\u003c/em\u003e)\u003csup\u003e\u003cspan additionalcitationids=\"CR92 CR93\" citationid=\"CR91\" class=\"CitationRef\"\u003e91\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e\u003c/sup\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eJ). At 48 hpi, DEGs were only found within NK-2 (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eK). WT-derived NK-2 cells had greater expression of \u003cem\u003eKlrg1\u003c/em\u003e as well as several genes related to MAPK-ERK signaling (\u003cem\u003eKsr1\u003c/em\u003e, \u003cem\u003eMap3k5\u003c/em\u003e, \u003cem\u003eNdrg3\u003c/em\u003e)\u003csup\u003e\u003cspan additionalcitationids=\"CR96\" citationid=\"CR95\" class=\"CitationRef\"\u003e95\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e\u003c/sup\u003e, regulation of apoptosis (\u003cem\u003eHipk2\u003c/em\u003e, \u003cem\u003eWwox\u003c/em\u003e)\u003csup\u003e\u003cspan citationid=\"CR98\" class=\"CitationRef\"\u003e98\u003c/span\u003e,\u003cspan citationid=\"CR99\" class=\"CitationRef\"\u003e99\u003c/span\u003e\u003c/sup\u003e and vesicle transport (\u003cem\u003eVps37b\u003c/em\u003e)\u003csup\u003e\u003cspan citationid=\"CR100\" class=\"CitationRef\"\u003e100\u003c/span\u003e\u003c/sup\u003e. In contrast, ΔC15-derived NK-2 cells had increased expression of three genes associated with regulation of calcium signaling (\u003cem\u003eAhnak\u003c/em\u003e)\u003csup\u003e\u003cspan citationid=\"CR101\" class=\"CitationRef\"\u003e101\u003c/span\u003e\u003c/sup\u003e, glycerol-3-phosphate shuttling (\u003cem\u003eGpd2\u003c/em\u003e), and actin bundling (\u003cem\u003eLcp1\u003c/em\u003e)\u003csup\u003e\u003cspan citationid=\"CR102\" class=\"CitationRef\"\u003e102\u003c/span\u003e\u003c/sup\u003e. Together, these data identify transcriptional differences in NK cells from WT- and ΔC15-infected dLNs that may point to the key function of C15 during early infection, including a potential signaling scaffold (\u003cem\u003eGab2\u003c/em\u003e) downstream of C15-associated inhibition of NK cell function.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eC15 antagonizes NK or T cells depending on host immunocompetence\u003c/h2\u003e \u003cp\u003eThe genetic factors underlying the resistance of B6 mice to lethal ECTV infection, compared to other mouse strains, have been directly mapped to the natural killer complex (NKC)\u003csup\u003e\u003cspan citationid=\"CR103\" class=\"CitationRef\"\u003e103\u003c/span\u003e,\u003cspan citationid=\"CR104\" class=\"CitationRef\"\u003e104\u003c/span\u003e\u003c/sup\u003e. The essential role of C15-mediated NK cell inhibition to permit enhanced viral dissemination suggests that C15-NK cell engagement is the predominant NK-dependent host-pathogen interaction governing ECTV pathogenesis in B6 mice. To directly test this notion, we evaluated mortality of B6 mice infected with WT or ΔC15 that had been pre-treated with anti-NK1.1 depleting antibody, a treatment that induces significant mortality during WT infection\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. By 9 dpi, 60% of WT-infected mice succumbed to infection (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eA). However, NK-depleted mice had significantly less mortality following ΔC15 infection, with only a single mouse succumbing to infection 9 dpi (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eA). Thus, NK cell-mediated control of infection in B6 mice is significantly less critical for protection in the absence of C15.\u003c/p\u003e \u003cp\u003eOther mouse strains, such as BALB/c mice, are not protected from lethal ECTV infection, with differences in susceptibility thought to be strongly driven by deficiencies in NK cell responses to infection\u003csup\u003e\u003cspan citationid=\"CR105\" class=\"CitationRef\"\u003e105\u003c/span\u003e,\u003cspan citationid=\"CR106\" class=\"CitationRef\"\u003e106\u003c/span\u003e\u003c/sup\u003e. This suggests that C15 engagement of NK cells may have less importance in driving pathogenesis, as NK cell responses are naturally impaired. Furthermore, previous work in BALB/c mice demonstrated that at 4 dpi, which is past the critical timepoints of early NK cell engagement, viral loads of WT and ΔC15 are equivalent in the dLN, spleen, and liver\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. To evaluate the importance of C15-NK cell interactions to ECTV pathogenesis, we similarly treated BALB/c mice with anti-NK1.1 antibody prior to infection with ΔC15. Here, in contrast to B6 mice, NK cell depletion prior to infection of BALB/c mice with ΔC15 resulted in 100% mortality (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eB), indicating that, in this case, NK cell engagement by C15 is not the primary form of antagonism to host immunity. We therefore hypothesized that C15 may have a more pronounced inhibitory impact on the development of T cell responses in BALB/c mice compared to B6 mice. To test this, we infected BALB/c mice with either WT or ΔC15 and quantified infected cells within the spleen at 5 and 7 dpi as well as T cell responses at 7 dpi (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eC). In line with previous reports demonstrating lower viral titers by 6 and 8 dpi during ΔC15 infection\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e, inflammatory monocytes (iMOs), DCs, and B cells were either trending or significantly less infected 7 dpi in ΔC15-infected mice (Figs.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eD and \u003cspan refid=\"Fig14\" class=\"InternalRef\"\u003eS6\u003c/span\u003eD). However, the magnitude of CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e responses were comparable between infection conditions at 7 dpi (Figs.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eE), with some ΔC15-infected mice having levels of CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e greater than WT-infected mice. While proliferation among CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e was similar as measured via %Ki67+ (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eF), ΔC15-derived CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eeff\u003c/sub\u003e had lower CD25 expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eG). Within the CD4\u0026thinsp;+\u0026thinsp;T cell compartment, T\u003csub\u003eeff\u003c/sub\u003e as well as CD4-CTL responses were similar between infection conditions at 7 dpi (Figs.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eH-I). Collectively, these data indicate that in hosts where C15-mediated antagonism of NK cells is not the primary mode of immunomodulation, C15 does, in fact, meaningfully inhibit T cell responses, as evidenced by the equal (trending towards greater) magnitude of T\u003csub\u003eeff\u003c/sub\u003e responses during ΔC15 infection but lower viral load at 7 dpi. Furthermore, these data demonstrate the ability of C15 to exhibit \u0026ldquo;conditional antagonism\u0026rdquo;, where different inhibitory activities are exhibited, depending upon the immunological capabilities of the host.\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe continued global persistence of OPXVs, post-eradication of variola, highlights an incomplete understanding of their biology and a critical need for innovative antiviral strategies\u003csup\u003e107-112\u003c/sup\u003e. The immunomodulatory proteins encoded by OPXVs ultimately determine pathogenesis\u003csup\u003e113\u003c/sup\u003e, but there is much to be learned about how these proteins contribute to pathogenesis. To date, there have been limited studies on both the function and \u003cem\u003ein vivo\u003c/em\u003e significance of B22 proteins\u003csup\u003e15-17,19\u003c/sup\u003e, despite their conservation, extreme size notwithstanding, in all highly virulent OPXVs. Our studies on the ECTV B22 protein, C15, have demonstrated its capacity to antagonize three immune cell populations: CD4+ T cells\u003csup\u003e17\u003c/sup\u003e, NK cells\u003csup\u003e19\u003c/sup\u003e, and, as shown here, CD8+ T cells. While C15 potently inhibited CD4+ and CD8+ T cells \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003eex vivo\u003c/em\u003e (Figure 1), in B6 mice, WT (C15-expressing) ECTV infection generated significantly more robust T cell responses, as indicated by phenotypic, functional and transcriptomic analyses (Figures 2, 3 and 5). We determined this was partially explained by compensatory cDC1-mediated cross-presentation (Figure 4) but primarily driven by antigen load differences from differential restriction of viral replication by NK cells (Figure 6). Specifically, early restriction of DC15 viral replication by NK cells, which is antagonized by C15, dampened T cell responses, and this deficiency could be restored through the depletion of NK cells prior to DC15 infection. Single cell RNA sequencing analysis identified a candidate signaling adapter, \u003cem\u003eGab2\u003c/em\u003e, that may be downstream of C15-mediated antagonism of NK cells (Figure 7). Lastly, we found that in BALB/c mice, which have genetic deficiencies in NK cell responses to ECTV, C15 more prominently inhibited T cell responses (Figure 8). \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eUnlike other viral virulence factors that have been described to inhibit both T cells and NK cells\u003csup\u003e23,114\u003c/sup\u003e, C15 does not appear to modulate the expression of key ligands critical for effector cell engagement (e.g., MHC molecules)\u003csup\u003e23,114-116\u003c/sup\u003e, setting it apart. All current evidence suggests that C15 inhibits cell-cell contacts\u003csup\u003e17,19\u003c/sup\u003e, though this has yet to be explicitly demonstrated. While parallels can be drawn between the function of synaptic events for CD8+ T cells and NK cells\u003csup\u003e117-119\u003c/sup\u003e, CD4+ T cells are more distinct, both kinetically\u003csup\u003e120-123\u003c/sup\u003e and in post-synaptic function\u003csup\u003e124\u003c/sup\u003e. This raises the question of whether C15 inhibitory functions map to a single domain or are spatially separated. B22 proteins are unusually large (e.g., C15 is 1924 amino acids), and previous studies have identified two cleavage-dependent fragments\u003csup\u003e15,18\u003c/sup\u003e, leading to speculation that one fragment mediates each respective inhibitory activity (i.e., NK cells and T cells). Our lab is actively investigating the molecular mechanisms and structure-function relationships of C15.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Many viral virulence factors have been described to have multiple functions, and in many cases, multi-functionality is a necessity due to limited genome size. However, OPXVs are some of the largest mammalian viruses by genome size (~170-230 kb). The integration of multiple immune-targeting functions coupled with the maintenance of a very large ORF raises key questions about the evolutionary benefit of B22 proteins. Here, our findings in B6 and BALB/c mice offer a potential explanation. In B6 mice, the NK cell-targeting function of C15 is the critical host-pathogen interaction, which permits enhanced viral replication and dissemination. However, the consequence to this replication is more robust antiviral T cell responses. In BALB/c mice, where NK cells have intrinsic deficits in control of viral replication, C15 more prominently antagonizes the early development of T cell responses, which likely underlies its enhanced replication at later timepoints during infection\u003csup\u003e16\u003c/sup\u003e. These points suggest that the conditional antagonism of NK cells or T cells allows ECTV to robustly replicate in genetically diverse hosts, using differences in host immunocompetence to enhance viral fitness. Furthermore, our data imply that enhanced T cell responses during WT infection in B6 mice is a \u0026ldquo;trade-off\u0026rdquo; for the virus, where early viral replication is more critical for spread to uninfected hosts rather than having enhanced fitness during the adaptive immune responses. In BALB/c mice, where early viral replication is not heavily restricted by NK cells, antagonism of T cells is likely more critical for viral fitness. Thus, the evolutionary benefit of B22 proteins may stem from their adaptability against host immune defenses, though this topic requires further exploration.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eOur previous work highlighting the relationship between C15 and NK cells was inferential, using whole lymph node imaging to quantify the proximity of infected cells and NK cells\u003csup\u003e19\u003c/sup\u003e. Here, using scRNA-seq, we were able to identify a signaling scaffold, Gab2, that may be associated with C15 antagonism of NK cells. Gab2 (Grb2-associated binder 2) or its binding partner, Grb2, are involved in the regulation of lymphocyte PI3K signaling downstream of various receptors\u003csup\u003e125\u003c/sup\u003e, including Fcg\u0026nbsp;receptors\u003csup\u003e126\u003c/sup\u003e, activating receptors\u003csup\u003e127\u003c/sup\u003e, and cytokine receptors\u003csup\u003e90\u003c/sup\u003e. Gab2 expression has been demonstrated in both mouse and human NK cells\u003csup\u003e126,128\u003c/sup\u003e, but its role in NK cell signal transduction is largely unknown. Prior work suggested that Gab2 is not required for NK cell function in mice\u003csup\u003e126\u003c/sup\u003e, but additional studies in human NK92MI cells implicate Gab2 as a primary regulator of NK cell PI3K signaling\u003csup\u003e128\u003c/sup\u003e. Thus, further studies on the role of Gab2 and PI3K signaling in NK cell activation during ECTV infection and its relationship with C15 antagonism are required. At 48 hpi, DC15-derived NK-2 cells had greater expression of three genes of interest: \u003cem\u003eAhnak\u003c/em\u003e, \u003cem\u003eGpd2\u003c/em\u003e, and \u003cem\u003eLcp1\u003c/em\u003e. Previous work in T cells has identified a critical role for AHNAK in regulating calcium signaling, specifically maintaining the membrane expression of calcium channels and permitting NFAT translocation into the nucleus\u003csup\u003e101\u003c/sup\u003e. Given that calcium flux is required for functional NK cell cytotoxicity\u003csup\u003e129\u003c/sup\u003e, DC15-derived NK-2 cells may have an enhanced capacity for cytolysis. Further supporting this notion is the greater expression of \u003cem\u003eLcp1\u003c/em\u003e, which encodes for the actin cross-linker L-plastin (LPL)\u003csup\u003e102,130\u003c/sup\u003e. LPL plays a significant role in the regulation of T cell activation through the stabilization of immunological synapses\u003csup\u003e131\u003c/sup\u003e as well as transport of activating receptors\u003csup\u003e132\u003c/sup\u003e. Together, these upregulated genes suggest that DC15-derived NK-2 cells may be functionally enhanced at this timepoint relative to WT-derived cells, in line with an inhibition of NK cells by C15.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eOverall, our findings underscore the complexity of B22 proteins and their diverse engagement of the host immune response. The significant homology between C15 and the mpox B22 protein\u003csup\u003e17\u003c/sup\u003e, as well as other human-tropic OPXVs, necessitates investigation into the conservation of function across homologs, which could reinforce the establishment of B22 proteins as next-generation OPXV antiviral targets. Moreover, the differences in host response to infection in B6 and BALB/c mice suggest that in a genetically diverse human population, the presence or absence of potential B22 protein targets in individuals (e.g., NK receptors) may significantly impact the outcome to infection, defining whether B22 proteins primarily function to inhibit innate or adaptive immune responses.\u0026nbsp;\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eMice\u003c/p\u003e\n\u003cp\u003eFemale and male C57Bl/6J (strain #000664) and BALB/cJ (strain #000651) (8-10 weeks old) were purchased from The Jackson Laboratory. \u003cem\u003eBatf3\u003csup\u003e-/-\u003c/sup\u003e\u003c/em\u003e mice (strain #013755) were initially purchased form The Jackson Laboratory and subsequently bred in-house. In all experiments, mice were age and sex-matched across infection groups, and mice ranged between 8-12 weeks old in all infection experiments. Mice were maintained in a specific pathogen-free facility at the Children\u0026rsquo;s Hospital of Philadelphia (CHOP). All experiments and procedures were approved by the Institutional Animal Care and Use Committees at CHOP.\u003c/p\u003e\n\u003cp\u003eECTV and CPXV Infections\u003c/p\u003e\n\u003cp\u003eECTV-eGFP (Strain Moscow) was a kind gift from Dr. Luis Sigal\u003csup\u003e27\u003c/sup\u003e. ECTVDC15 was previously constructed using standard homologous recombination\u003csup\u003e17\u003c/sup\u003e. CPXV strain Brighton Red cell lysate was ordered from BEI Resources (NR-88) and approved under USDA Veterinary Permit #611-24-185-96159. All viruses were propagated and titered as previously described\u003csup\u003e16-18\u003c/sup\u003e. Briefly, ECTV viruses were seeded on 143B (TK\u003csup\u003e-\u003c/sup\u003e) osteosarcoma cells at a multiplicity of infection (MOI) of 3 for 72 hours. Cells were then harvested and subjected to 3x freeze-thaw-vortex cycles prior to re-seeding. After scaling up (8 x T175 flask), virus was purified by ultracentrifugation at 20,000 rpm x 1 hour on a 36% sucrose cushion. Viral stocks were resuspended in 10 mM Tris pH 9.0. CPXV was purified similarly, except viral stocks were grown using BS-C-1 cells. Purified virus was titered by plaque assay on BS-C-1 cells under an overlay of 1% methylcellulose/complete DMEM media. For mouse infection with ECTV, C57Bl/6J and\u0026nbsp;\u003cem\u003eBatf3\u003csup\u003e-/-\u003c/sup\u003e\u003c/em\u003e mice were infected with 3 x 10\u003csup\u003e3\u003c/sup\u003e plaque-forming units (PFU) by injection of 15\u0026nbsp;ml volume in PBS into the hind footpad. Alternatively, BALB/cJ mice were infected with 3 x 10\u003csup\u003e2\u003c/sup\u003e PFU into the hind footpad. For mouse infection with CPXV, C57Bl/6J mice were infected intraperitoneally (i.p.) with 2 x 10\u003csup\u003e5\u003c/sup\u003e PFU. All infections were performed in the morning between 8-10 AM. Cellular analyses during infection were performed in the spleen, liver or popliteal lymph node, as indicated.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCell lines\u003c/p\u003e\n\u003cp\u003eAll fibroblast (e.g., B6-C15, B6-GCC, UbC-C15) cell lines were derived from in-house C57Bl/6 (B6) skin fibroblasts. B6 parental fibroblasts (MHCII-) were used to generate inducible cell lines. B6 fibroblasts expressing human CIITA and BALB/c-derived I-E\u003csup\u003ed\u003c/sup\u003e were used to generate the UbC-C15 cell line. These cell lines and derivative cell lines (see below) were maintained in Dulbecco\u0026rsquo;s modified eagle medium (DMEM) containing 5% (D5) or 10% (D10) fetal bovine serum, 2 mM L-glutamine, and 1x penicillin and streptomycin. 143B and BS-C-1 cell lines were cultured in D5 and D10, respectively. Where applicable, cell lines were also cultured in the presence of 2\u0026nbsp;mg/ml blasticidin to maintain purity of inducible cell lines. The generation and characterization of T cell hybridomas (NP\u003csub\u003e366-374\u003c/sub\u003e, OVA\u003csub\u003e257-264\u003c/sub\u003e, M-SL9, and NA\u003csub\u003e437-451\u003c/sub\u003e) was previously described\u003csup\u003e133,134\u003c/sup\u003e. Briefly, antigen-specific T cells were fused with the partner cell line, BWZ.36/CD8a, which contained an NFAT-inducible \u003cem\u003elacZ\u003c/em\u003e cassette to readout activation. T cell hybridomas were maintained in Roswell Park Memorial Institute (RPMI) medium containing 10% FBS, 2 mM L-glutamine, 1x penicillin and streptomycin and 50\u0026nbsp;mM 2-mercaptoethanol (R10). Similarly, DC2.4 cells were grown and maintained in R10 medium. All cells were grown at 37 \u003csup\u003eo\u003c/sup\u003eC in a 5% CO\u003csub\u003e2\u003c/sub\u003e incubator.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eLentivirus generation and transduction\u003c/p\u003e\n\u003cp\u003eThe C15-HAtag encoding lentiviral vector was generated by performing fragmented in-fusion cloning to insert the C15-HAtag cassette in between the XbaI and SalI restriction sites of the pUltra lentiviral vector (Addgene, plasmid #24129), downstream of an eGFP reporter. The CIITA-encoding lentiviral vector was generated by removing the eGFP cassette from the pUltra vector by restriction digest and inserting a gene block for human CIITA (Uniprot P33076) with an N-terminal FLAG (DYKDDDDK) tag between the AgeI and SalI restriction sites. For lentivirus production, 6 x 10\u003csup\u003e6\u003c/sup\u003e 293T cells were plated in a 10-cm dish in D5 media overnight. The following day, 22\u0026nbsp;mg total of endotoxin-free plasmid preparations of the glycoprotein (VSV-G, Addgene plasmid #8454), packaging components (psPAX2, Addgene plasmid #12260), and transfer vector (pUltra-derived vector) were transfected with Lipofectamine 2000 (Invitrogen) at a 0.2:1:1 ratio. To generate lipid complexes, 50 ul of Lipofectamine 2000 was added to the plasmid mixture and complexed for 15 minutes. Five ml of pre-warmed antibiotic-free D5 media was add to cells prior to complexes. After complex addition, cells were cultured for 16 hours. The next day, media was replaced with 10 ml of complete D5 media and left for 24 hours. Lentivirus was collected at 24 and 48 hours, pooled, filtered through a 0.22-mm filter, precipitated using Lenti-X Concentrator (Takara Bio) according to manufacturer protocols, and resuspended in 50\u0026nbsp;ml aliquots.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo transduce cells, 1 x 10\u003csup\u003e5\u003c/sup\u003e cells were resuspended in 3 ml of D5 media containing 8\u0026nbsp;mg/ml polybrene (Sigma-Aldrich). One 50\u0026nbsp;ml aliquot of lentivirus was then added to the cell suspension, mixed by gentle pipetting, and left to complex for 5 minutes at room temperature (RT). After 5 minutes, cells were plated in individual wells of a 6-well plate and cultured overnight. Transductants were expanded up to a T75 flask prior to cell sorting for either eGFP+ (UbC-C15) or MHCII+ (CIITA) cells. A total of three sorts were performed to recover a pure, but polyclonal, population.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eGeneration of stable cell lines and induction\u003c/p\u003e\n\u003cp\u003eTo generate inducible expression vectors, codon-optimized C15\u003csup\u003e17\u003c/sup\u003e and guanylyl cyclase C (GC-C, kind gift from Dr. Scott Waldman) were subcloned into the pSBtet-Bla vector (Addgene, plasmid #60510) between the SfiI restriction sites. For stable cell line generation, 2 x 10\u003csup\u003e6\u003c/sup\u003e B6 parental fibroblasts were plated into a 10-cm dish with D5 media and cultured overnight. The next day, 1\u0026nbsp;mg of inducible, gene-of-interest vectors (C15 or GC-C) were co-transfected alongside 2\u0026nbsp;mg of the pCMV(CAT)T7-SB100 vector (Addgene plasmid #34879) using 9\u0026nbsp;ml of X-tremeGENE HP DNA transfection reagent (Roche). Complexes were formed at room temperature for 30 minutes, replacing culture media before addition to cells. Transfections were left in the incubator for 48 hours. After incubation, cells were trypsinized, spun down, and resuspended in 10 ml of D10-Bla (D10 + 2\u0026nbsp;mg/ml blasticidin) media. For each cell line, either 1 ml, 400\u0026nbsp;ml, 200\u0026nbsp;ml, 100\u0026nbsp;ml, 50\u0026nbsp;ml, or 20\u0026nbsp;ml of cell suspension was plated in a final volume of 2 ml D10-Bal in a 6-well plate. Cells were left in the incubator for 1-2 weeks, replacing every 2-3 days and monitoring the development of cell \u0026ldquo;islands\u0026rdquo;. Individual cell islands were marked using a light microscope and subsequently scraped using a p200 tip into 1 ml of D10-Bla media in individual wells of a 24-well plate. Colonies were expanded from a 24-well plate into a 6-well plate and subsequently screened by flow cytometry for protein expression.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo screen clones for protein expression, clones were trypsinized and duplicated into another 6-well plate. The duplicate plate media was supplemented with 1\u0026nbsp;mg/ml doxycycline hyclate (Sigma-Aldrich), and cells were induced overnight. The following day, cells were recovered from each well using a calcium-magnesium free medium and scraping, followed by gentle resuspension. Clones were then stained, using an antibody specific for the HAtag expression, either by surface staining (C15) or intracellular staining (GC-C) and analyzed using a flow cytometer. The top clone(s) from the original plate were expanded and frozen down for further use.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo induce cells for T cell hybridoma assays (see below), cell lines were trypsinized, spun down, and resuspended in complete D5 media (no blasticidin). Between 2-3 x 10\u003csup\u003e6\u003c/sup\u003e cells of each cell line were transferred into two duplicate 15-ml conical vials and topped up with D5 media to ~14.5 ml. To both tubes, 150\u0026nbsp;ml of 1M HEPES pH 7.4 (Gibco) was added, but to only one tube, 150 ul of 100\u0026nbsp;mg/ml doxycycline (diluted 1:100 from a 10 mg/ml stock) was added for the induced condition. Conicals were then parafilmed and rotated at 37 \u003csup\u003eo\u003c/sup\u003eC end-over-end for 16-20 hours.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eViral genome sequencing\u003c/p\u003e\n\u003cp\u003eTo prepare DNA from ECTV viruses for sequencing, genomic DNA was isolated from 0.5 ml of sucrose-cushion purified viral stock using the DNeasy Blood and Tissue Kits (Qiagen) according to manufacturer protocols. Two\u0026nbsp;mg of genomic DNA was sent to Genewiz for library preparation and short read whole genome sequencing, collecting a total of 1 GB sequencing data for each viral sample. Reads were mapped to the ECTV Moscow (GenBank AF012825.2) genome. Genomic variants were visualized using the Integrative Genomics Viewer (IGV Version 2.19.1)\u003csup\u003e135\u003c/sup\u003e. ECTV-eGFP and ECTVDC15 were determined to be \u0026gt;99.997% identical to the reference genome.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWhole virion ELISA and anti-A33R antibody validation\u003c/p\u003e\n\u003cp\u003eTo quantify the development of anti-ECTV antibodies, high-capacity ELISA plates were coated with 2 x 10\u003csup\u003e5\u003c/sup\u003e PFU ECTV Moscow in 100\u0026nbsp;ml PBS overnight at 4 \u003csup\u003eo\u003c/sup\u003eC. The following day, the plates were blocked (3% goat serum, 0.5 % dehydrated milk powder, 0.1% Tween-20 in PBS) for 1.5 hours at RT with 150 rpm shaking. Plates were washed with PBS-T (PBS + 0.05% Tween-20) and 100\u0026nbsp;ml of serum serial dilutions were added for 2 hours at RT with 150 rpm shaking. Serial dilutions of the human anti-A35R antibody were also added to test cross-reactivity with ECTV. After removing and washing serum/antibody dilutions, plates were stained with 100\u0026nbsp;ml goat anti-mouse IgG (H+L) HRP secondary antibody at 1:5000 or goat anti-human IgG (H+L) HRP secondary antibody at 1:2500 in blocking buffer for 1 hour at RT with 150 rpm shaking. Afterwards, plates were washed and 100\u0026nbsp;ml of TMB SureBlue substrate (1:1 mixture of solutions A and B, SeraCare) were added to each well without shaking for 10 minutes at RT in the dark. After 10 minutes, 50\u0026nbsp;ml of 2M hydrochloric acid (HCl) was added to each well, and plates were gently tapped to distribute HCl. Immediately after neutralization, plate absorbance was measured at 450 nm.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo validate cross-reactivity of anti-A35R monoclonal with ECTV A33R, B6 parental fibroblasts were infected \u003cem\u003ein vitro\u003c/em\u003e with ECTV-eGFP. Briefly, two aliquots of 5 x 10\u003csup\u003e5\u003c/sup\u003e cells were spun down in 1.7-ml microfuge tubes and resuspended in 100 ul PBS + 1% FBS. To one tube, 5 x 10\u003csup\u003e5\u003c/sup\u003e PFU of ECTV-eGFP were added, and the tubes were left to incubate at 37 \u003csup\u003eo\u003c/sup\u003eC for 1 hour, gently resuspending with a p200 every 20 minutes. After the incubation, tubes were topped up with D5 media and spun down. Cells were resuspended in 1 ml of D5 media and subsequently plated in a 6-well plate in a final volume of 2 ml of D5 media overnight. The next day, cells were trypsinized, spun down, and transferred to a 96-well U-bottom plate for flow cytometry staining.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eSynthetic peptides\u003c/p\u003e\n\u003cp\u003eThe following synthetic peptides were used: OVA\u003csub\u003e257-264\u003c/sub\u003e (SIINFEKL), M-SL9 (SLQGRTLIL)\u003csup\u003e136\u003c/sup\u003e, NP\u003csub\u003e366-374\u003c/sub\u003e (ASNENMETM), NA\u003csub\u003e437-451\u003c/sub\u003e (TVDWSWPDGAELPFT)\u003csup\u003e134\u003c/sup\u003e, B8R\u003csub\u003e20-27\u003c/sub\u003e (TSYKFESV), and EVM153\u003csub\u003e46-60\u003c/sub\u003e (VKNKYMWCYSQVNKR)\u003csup\u003e137\u003c/sup\u003e. All peptides were obtained lyophilized from Genscript at \u0026gt;85% purify. Stock concentrations were made to 10 mg/ml in DMSO. \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eT cell hybridoma assay\u003c/p\u003e\n\u003cp\u003eThe day before a T cell hybridoma assay, cells were induced as described above. In some instances, 1\u0026nbsp;mg of mRNA-LNP/1 x 10\u003csup\u003e6\u003c/sup\u003e cells was added to the 15-ml conical prior to end-over-end rotation overnight. The following day, fibroblasts (APCs) were spun down and resuspended to 2.5 x 10\u003csup\u003e5\u003c/sup\u003e cells/ml in R10 media. T cell hybrids were harvested from their respective flasks and resuspended to 2.78 x 10\u003csup\u003e5\u003c/sup\u003e cells/ml in R10 media. To a 96-well black flat-bottom plate, 100 ul of APCs and 90 ul of T cell hybrids were plated into respective wells. When adding peptide, 10 ul of 200\u0026nbsp;mg/ml synthetic peptide diluted in 0.1% BSA/PBS was added to each corresponding well (10\u0026nbsp;mg/ml final concentration). In negative control wells, 10 ul of 0.1% BSA/PBS was added in absence of peptide. Co-cultures were incubated at 37 \u003csup\u003eo\u003c/sup\u003eC for 16-20 hours. After incubation, co-cultures were lysed with a substrate buffer containing 1.25% Triton X-100, 22\u0026nbsp;mg/ml 4-methyl-umbelliferyl-b-D-galactopyranoside (Sigma-Aldrich), 38.5\u0026nbsp;mM 2-mercaptoethanol and 9 mM MgCl\u003csub\u003e2\u003c/sub\u003e in PBS for 3 hours at 37 \u003csup\u003eo\u003c/sup\u003eC. After incubation, fluorescence was quantified at 365/445 nm using a microplate reader. Hybridoma assays consisted of at least three technical replicates and were performed several independent times where indicated. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFor hybridoma assays with phorbol 12-myristate 13-acetate (PMA) and ionomycin, APC-hybrid co-cultures in the presence of exogenous peptide were allowed to incubate for 1 hour at 37 \u003csup\u003eo\u003c/sup\u003eC prior to addition of 50 ng/ml PMA and 1\u0026nbsp;mg/ml ionomycin.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTrans and supernatant inhibition assay\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTrans\u003c/em\u003e inhibition assays were performed the same as other T cell hybridoma assays with a few modifications. Briefly, bystander cells (MHCII-negative, B6-C15 or B6-GC-C) were spun down and resuspended to 1 x 10\u003csup\u003e6\u003c/sup\u003e in R10 media. A serial dilution of bystander cells was made such that concentrations were 5 x 10\u003csup\u003e4\u003c/sup\u003e cells/50\u0026nbsp;ml, 2.5 x 10\u003csup\u003e4\u003c/sup\u003e cells/50\u0026nbsp;ml, and 1.25 x 10\u003csup\u003e4\u003c/sup\u003e cells/50\u0026nbsp;ml. To corresponding wells, 50\u0026nbsp;ml of diluted bystanders or 50\u0026nbsp;ml R10 medium alone were added. APCs (MHCII-positive, B6-CIITA) were resuspended to 5 x 10\u003csup\u003e5\u003c/sup\u003e cells/ml, and 50\u0026nbsp;ml were added to each well. Peptide was added to a final concentration of 10\u0026nbsp;mg/ml, as above, and co-cultures were incubated at 37 \u003csup\u003eo\u003c/sup\u003eC for 16-20 hours. Assay readout was performed according to standard protocols.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo test inhibitory capacity of supernatant, 5 x 10\u003csup\u003e6\u003c/sup\u003e B6-C15-CIITA or B6-GC-C-CIITA cells were induced overnight in a 15-ml conical vial. The next day, induced cells were spun down and supernatant isolated. B6-CIITA cells were then resuspended to 2.5 x 10\u003csup\u003e5\u003c/sup\u003e cells in either R10, B6-C15-CIITA supernatant, or B6-GC-C-CIITA supernatant. A standard T cell hybridoma assay was then setup and readout the following day.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eGeneration of mRNA-LNPs\u003c/p\u003e\n\u003cp\u003eOVA mRNA-LNPs were a kind gift of Dr. Mohamed-Gabriel Alameh and are described elsewhere.\u003csup\u003e138\u003c/sup\u003e Preclinical-grade mRNA encoding the\u0026nbsp;a\u0026nbsp;and\u0026nbsp;b\u0026nbsp;chains of I-E\u003csup\u003ed\u003c/sup\u003e were made using previously published methods.\u003csup\u003e139,140\u003c/sup\u003e The\u0026nbsp;b\u0026nbsp;chain was modified to encode a covalently linked epitope (\u0026ldquo;S1\u0026rdquo;, FERFEIFPK) to ensure proper folding of I-E\u003csup\u003ed\u003c/sup\u003e. To maximize translation of mRNA molecules, the sequence was codon-optimized to enrich for GC content. Optimized DNA sequences were inserted into an mRNA expression vector that was a kind gift of Dr. Drew Weissman. Expression vectors were first linearized prior to \u003cem\u003ein vitro\u003c/em\u003e transcription using the MEGAscript T7 Transcription Kit (ThermoFisher), substituting N1-methylpsuedouridine (TriLink) in place of uridine and co-translationally capping with the CleanCap reagent (TriLink). Synthesized mRNA was purified using cellulose to remove dsRNA byproducts, and the quality evaluated by agarose gel electrophoresis.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEqual molar ratios of I-E\u003csup\u003ed\u003c/sup\u003e a\u0026nbsp;and\u0026nbsp;b\u0026nbsp;chains were co-encapsulated into LNPs. The lipid mixture was composed of the SM-102 (BroadPharm), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, Avanti), cholesterol (Avanti), and 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG-2000, Avanti) at a 50:38.5:10:1.5 molar ratio. Lipids were dissolved in ethanol and buffered in 10% v/v citric acid, pH 4.0. Subsequently, 150\u0026nbsp;mg of total mRNA were diluted in citric acid buffer. The total lipid mass to RNA mass ratio was 17.5:1. Lipids were then added into diluted mRNA and rapidly mixed via P1000 pipet 15-17 times. LNPs were then immediately neutralized with an equal volume of PBS and dialyzed in PBS overnight using a 10 kDa dialysis cassette (Thermo). The following day, mRNA-LNPs were concentrated using a 10 kDa centrifugal filter (Amicon) to 0.2-0.3 mg/ml.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eSynthesis of recombinant Flt3l\u003c/p\u003e\n\u003cp\u003eFor recombinant Flt3l generation, a codon-optimized (Twist Biosciences) DNA sequence for the ectodomain of human Flt3l (Met1-Ala181, Uniprot P49771) fused to a C-terminal 6x-His tag was inserted into a CMV promoter-driven expression vector via in-fusion cloning. Endotoxin-free plasmid preparations were then transfected into Expi293 cells (ThermoFisher) according to manufacturer recommendations. Briefly, 20\u0026nbsp;mg of pCMV-hFtl3l-6xHis and 80\u0026nbsp;ml of Expifectamine 293 were diluted into 1.5 and 1.4 ml of Opti-MEM I Reduced Serum Media, respectively (Gibco). After incubation for 5 minutes at RT, the diluted Expifectamine 293 was added into the diluted DNA, gently mixing with a p1000 pipet. Complexes were allowed to form at RT for 15 minutes. During complexation, Expi293 cells were diluted to 3 x 10\u003csup\u003e6\u003c/sup\u003e cells/ml in 25 ml of Expi293 Expression Medium (Gibco). After the incubation, formed complexes were added dropwise to Expi293 cells while gently shaking to distribute. Cells were placed back into the incubator at 37 \u003csup\u003eo\u003c/sup\u003eC while shaking on an orbital shaker at 125 rpm for 18-20 hours. The following day, 150\u0026nbsp;ml of Enhancer 1 and 1.5 ml of Enhancer 2 were added to the transfected cells. The cells were then placed back into the incubator and grown for an additional 4 days (5 days total expression).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo purify recombinant protein, cell cultures were spun down at 2500 x g for 10 minutes at 4 \u003csup\u003eo\u003c/sup\u003eC. The supernatant was subsequently filtered through a 0.22\u0026nbsp;mm filter and concentrated down to ~10 ml using a 10 kDa centrifugal filter (Amicon). To prepare EDTA-compatible Ni-IMAC resin (Pierce) for protein capture, 0.5 ml of slurry for each purification was transferred into a 5-ml tube on ice. After settling, the supernatant was removed and the beads were resuspended in 1.5 ml of equilibration buffer (50 mM monosodium phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 8.0). The equilibration buffer was removed and the concentrated Expi293 supernatant was added to the washed beads. The cell supernatant was rotated end-over-end with beads for 1 hour at 4 \u003csup\u003eo\u003c/sup\u003eC. After incubation, the supernatant was run through a disposable gravity flow column (Bio-Rad) and rinsed once with 1 column volume (CV, ~10 ml) of equilibration buffer. The settled resin was then washed with 3 CV of wash buffer (50 mM monosodium phosphate, 300 mM sodium chloride, 20 mM imidazole, pH 8.0). The bound protein was eluted with 3 x 3 ml of elution buffer (50 mM monosodium phosphate, 300 mM sodium chloride, 500 mM imidazole, pH 8.0). Elutions were pooled and dialyzed overnight using a 10 kDa dialysis cassette (ThermoFisher) in 1x PBS. The following day, dialyzed protein was concentrated to ~1 mg/ml and confirmed to be \u0026gt;90% pure via SDS-PAGE. Aliquots were supplemented with sucrose to 5% v/v and flash frozen in liquid nitrogen, with long-term storage at -80 \u003csup\u003eo\u003c/sup\u003eC. \u0026nbsp; \u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePreparation of mouse tissues (spleen, LN, liver, PBMCs/serum)\u003c/p\u003e\n\u003cp\u003eTo process spleens, organs were harvested and kept in PBS on ice until processing. Spleens were manually homogenized through a 70\u0026nbsp;mm cell strainer using a 1-ml syringe plunger and subsequently washed with 10 ml of FACS buffer (PBS + 1% FBS + 2 mM EDTA). Homogenates were then spun down at 4 \u003csup\u003eo\u003c/sup\u003eC and resuspended in 3 ml of ACK lysis buffer, left at RT for 3 minutes, and topped up with cold PBS before spinning again. Cell pellets were resuspended in 10 ml of FACS buffer and passed through a 40\u0026nbsp;mm strainer to prepare a single cell suspension. To harvest Flt3l-derived cDC1s, processing was the same except for a pre-incubation of spleen pieces with 1 mg/ml Collagenase Type IV and 20\u0026nbsp;mg/ml DNase I for 30 minutes at 37 \u003csup\u003eo\u003c/sup\u003eC prior to homogenization.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo process draining lymph nodes (LN, inguinal and popliteal), organs were harvested and gently stripped of excess fat before placing in PBS on ice. LNs were then manually homogenized through a 70\u0026nbsp;mM strainer, washed with 10 ml of FACS buffer, and immediately strained through a 40\u0026nbsp;mm strainer to prepare a single cell suspension.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo process the liver, the gallbladder was removed, and the organ was kept on ice in 5 ml R10 media until processing. The liver was manually homogenized through a 70\u0026nbsp;mm strainer and washed with 10 ml FACS buffer. The suspension was centrifuged at RT, and the pellet was resuspended in 5 ml RT 42% isotonic Percoll (Cytiva). The suspension was then centrifuged at 800 x g for 20 minutes at RT with no brake to separate hepatocytes (top layer) and lymphocytes (pellet). After spinning, the hepatocytes and remainder of supernatant was carefully removed. ACK lysis was then performed in 5 ml final volume for 5 minutes at RT. After lysis, 5 ml of FACS buffer was added to the suspension and centrifuged at 300 x g for 3 minutes. The lymphocyte pellets were resuspended in 5 ml FACS buffer to prepare the single cell suspension.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eBlood collection was through the retro-orbital vein using a capillary tube. To harvest serum, blood was transferred into serum gel tubes (Sarstedt) and spun down at 10,000 x g for 5 minutes. Serum was subsequently stored at -20 \u003csup\u003eo\u003c/sup\u003eC. To collect PBMCs, blood was collected into 200 ul of PBS + 50 mM EDTA and diluted 1:1 with R10 media prior to underlaying 500\u0026nbsp;ml of Histopaque-1083 (Sigma-Aldrich). Suspensions were centrifuged at 2000 rpm x 20 minutes at RT with no brake. PBMCs were collected from the interface and transferred in a FACS tube with 4 ml of R10 media. After spinning down, cells were ACK lysed and resuspended as necessary to prepare single cell suspensions.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIFN-g\u0026nbsp;ELISpot assay\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo generate cDC1s for ELISpot, one female B6 mouse was injected i.p. with 10\u0026nbsp;mg of recombinant Flt3l diluted up to 200\u0026nbsp;ml PBS daily for 8 days. On day 9, spleens were harvested and processed into single cell suspensions. To magnetically deplete non-cDC1s, 65 x 10\u003csup\u003e6\u003c/sup\u003e splenocytes were resuspended to 1 x 10\u003csup\u003e8\u003c/sup\u003e cells/ml in MACS buffer (PBS + 0.1% BSA + 2 mM EDTA) and 65 ul of magnetic depletion master mix was added (anti-TER-119: 25\u0026nbsp;mg/ml, anti-CD64: 50\u0026nbsp;mg/ml, anti-CD19: 50\u0026nbsp;mg/ml, anti-CD3: 50\u0026nbsp;mg/ml, anti-NK1.1: 50\u0026nbsp;mg/ml, anti-CD317: 25\u0026nbsp;mg/ml, anti-Ly6G: 25\u0026nbsp;mg/ml, anti-CD31: 25\u0026nbsp;mg/ml, anti-Ly6C: 50\u0026nbsp;mg/ml, anti-CD16/CD32: 100\u0026nbsp;mg/ml, anti-CD172a: 50\u0026nbsp;mg/ml, anti-CD11b: 50\u0026nbsp;mg/ml). Of note, anti-F4/80 was found to remove Flt3l-generated cDCs, and the inclusion of this antibody is not recommended. The cells and antibodies were incubated on ice for 20 minutes and subsequently diluted up to 4 ml with MACS buffer before centrifugation. Splenocytes were resuspended back to 1 x 10\u003csup\u003e8\u003c/sup\u003e cells/ml in MACS buffer, and 65 ul of streptavidin nanobeads (Biolegend) were added. After 20 minutes on ice, bead-bound splenocytes were diluted up to 2.5 ml with MACS buffer and magnetically separated (cDC1s were untouched), repeating magnetic purification one additional time. To infect cDC1s, cells were spun down and resuspended to 5 x 10\u003csup\u003e6\u003c/sup\u003e cells/ml in PBS + 1% FBS. WT ECTV or ECTVDC15 was added to an MOI of 1, and cells were infected at 37 \u003csup\u003eo\u003c/sup\u003eC for 1 hour, with gentle resuspension every 20 minutes. After incubation, cells were washed with R10 media and resuspended to 1.5 x 10\u003csup\u003e5\u003c/sup\u003e cells/ml. Two hours prior to T cell addition, 100 ul of cDC1s were added to an ELISpot plate (Millipore) precoated with an IFNg\u0026nbsp;capture antibody according to manufacturer protocols (BD Biosciences) and incubated at 37 \u003csup\u003eo\u003c/sup\u003eC.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo generated ECTV-specific T cells, 2 female B6 mice were infected with WT ECTV for 8 days prior to spleen harvest. After spleen processing, splenocytes were pooled and CD4+ and CD8+ T cells were isolated using corresponding Mojosort isolation kits (Biolegend). The magnetic negative selection process was identical to that of cDC1s above. CD8+ and CD4+ T cells were resuspended to 1.5 x 10\u003csup\u003e5\u003c/sup\u003e cells/ml and 3 x 10\u003csup\u003e5\u003c/sup\u003e cells/ml, respectively, in R10 prior to plating. To corresponding wells, 100 ul of diluted T cells were added. The ELISpot plates were allowed to incubate at 37 \u003csup\u003eo\u003c/sup\u003eC for 16-18 hours. ELISpot plates were developed according to manufacturer protocols and IFNg\u0026nbsp;spots were quantified using a CTL Immunospot S6 Universal Analyzer.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFlow cytometry and tetramer\u003c/p\u003e\n\u003cp\u003eFor flow cytometry, viable cells were first discriminated using either Live/Dead Fixable Aqua dye (ThermoFisher) at 1:500 or Zombie UV Fixable dye (Biolegend) at 1:1000 for 10 minutes at RT. Alongside all surface stains, anti-CD16/CD32 (BioXCell) was added to a final concentration of 10\u0026nbsp;mg/ml to block Fc receptors. Surface stains were performed for 30 minutes at 4 \u003csup\u003eo\u003c/sup\u003eC in FACS buffer. In panels involving transcription factors (e.g., T-bet, TCF-1), cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer Set (Invitrogen) for 1 hour at RT. For all other panels, cells were fixed and permeabilized using the Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences) for 20 minutes at 4 \u003csup\u003eo\u003c/sup\u003eC. All intracellular staining was performed at RT for 30 minutes. For ECTV A33R detection, unconjugated anti-MPXV A35R was included in intracellular stains, and a BV711 anti-human secondary was subsequently added for an additional 30 minutes at RT. Samples were analyzed on the BD Fortessa or Symphony A5 cytometers, and data were processed using FlowJo (BD Biosciences).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eB8R tetramers were included in the extracellular stain at 2\u0026nbsp;mg/ml where applicable. Notably, the B8R tetramer is most compatible with the anti-CD8 clone KT15, as clone 53-6.7 was found to cause antigen-non-specific tetramer binding. I1L tetramer staining was performed separately for 1 hour at 37 \u003csup\u003eo\u003c/sup\u003eC at 2\u0026nbsp;mg/ml prior to viability staining.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIntracellular cytokine and degranulation assay\u003c/p\u003e\n\u003cp\u003eSix hours prior to restimulation, DC2.4 cells were harvested, and two aliquots of 5 x 10\u003csup\u003e6\u003c/sup\u003e cells were resuspended to 50 x 10\u003csup\u003e6\u003c/sup\u003e cells/ml in PBS + 1% FBS. Cells were subsequently left uninfected or infected with\u0026nbsp;DC15 at an MOI of 1 for 1 hour at 37 \u003csup\u003eo\u003c/sup\u003eC, with gentle resuspension every 20 minutes. After 1 hour, cells were diluted in a 15-ml conical vial up to 15 ml with R10 supplemented with 10 mM HEPES and rotated end-over-end for five hours. For cytokine and CD107a staining, 2 x 10\u003csup\u003e6\u003c/sup\u003e splenocytes were added to a 96-well U-bottom plate in 100\u0026nbsp;ml R10 medium and allowed to equilibrate for 30 minutes at 37 \u003csup\u003eo\u003c/sup\u003eC. During incubation, DC2.4 cells were spun down and resuspended to 2 x 10\u003csup\u003e6\u003c/sup\u003e cells/ml in R10. To corresponding wells, 50\u0026nbsp;ml of uninfected or infected DC2.4 cells were added. For peptide stimulation, 50\u0026nbsp;ml of 40\u0026nbsp;mg/ml peptide (B8R or 963) and 8\u0026nbsp;mg/ml anti-CD28 (Biolegend) in R10 were added to corresponding wells (final concentrations 10\u0026nbsp;mg/ml and 2\u0026nbsp;mg/ml, respectively). Splenocyte suspensions were then incubated at 37 \u003csup\u003eo\u003c/sup\u003eC for 1 hour. After 1 hour, 50\u0026nbsp;ml of 20\u0026nbsp;mg/ml brefeldin A, 8\u0026nbsp;mM monensin, and 8\u0026nbsp;mg/ml anti-CD107a (BD Biosciences) were added to each well (final concentrations 4\u0026nbsp;mg/ml, 2\u0026nbsp;mM, and 2\u0026nbsp;mg/ml, respectively), and splenocytes were left at 37 \u003csup\u003eo\u003c/sup\u003eC for 5 additional hours. After restimulation, cells were then stained for flow cytometry as described above. Na\u0026iuml;ve splenocytes were used as a negative control.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFACS sorting and bulk sequencing preparation\u003c/p\u003e\n\u003cp\u003eFor T\u003csub\u003eeff\u003c/sub\u003e and B8R+ T\u003csub\u003eeff\u003c/sub\u003e sorting, 25 x 10\u003csup\u003e6\u003c/sup\u003e splenocytes were viability and surface stained for CD44, CD4, CD8a, B8R tetramer, CD3, and CD62L. Samples were then sorted using an Aurora CS-2 Cell Sorter (Cytek). For bulk TCR sequencing, 4 x 10\u003csup\u003e3\u003c/sup\u003e B8R+ CD8+ T\u003csub\u003eeff\u003c/sub\u003e were sorted into FACS buffer. For T\u003csub\u003eeff\u003c/sub\u003e bulk mRNA sequencing, between 4 x 10\u003csup\u003e4\u003c/sup\u003e and 1.5 x 10\u003csup\u003e5\u003c/sup\u003e CD4+ or CD8+ T\u003csub\u003eeff\u003c/sub\u003e were sorted into FACS buffer. After sorting, cells were centrifuged at 400 x g for 5 minutes and washed in PBS.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFor TCR sequencing, B8R+ CD8+ T\u003csub\u003eeff\u003c/sub\u003e were directly lysed and subjected to first-strand synthesis using the SMART-Seq Mouse TCR (with UMIs) kit (Takara) according to manufacturer instructions. Initial TCR\u0026nbsp;a/b\u0026nbsp;chain amplifications were performed according to manufacturer instructions. For amplification during PCR #2 (UDI addition), 24 cycles gave the best yield across all samples. Amplified libraries were then pooled (equimolar) and concentrated using NucleoMag NGS Clean-up and Size Select beads (Takara). cDNA concentrations were quantified using a Qubit 4 Fluorometer, and size analysis was performed using an Agilent TapeStation.\u003c/p\u003e\n\u003cp\u003eFor bulk T\u003csub\u003eeff\u003c/sub\u003e mRNA sequencing, cells were lysed in 200\u0026nbsp;ml TRI Reagent (Zymo) and vortexed at 1000 rpm for 60 seconds. RNA was isolated using a Direct-zol RNA Microprep kit (Zymo) according to manufacturer instructions, eluting in 8\u0026nbsp;ml of nuclease-free water. mRNA quality was assessed using an Agilent Bioanalyzer. RNA was converted into cDNA libraries using the Zymo-Seq SwitchFree 3\u0026rsquo; mRNA Library Kit (Zymo) according to the manufacturer protocol. Based on RNA concentrations, library amplification PCR reactions were performed with 19 cycles for 100 ng input RNA, 20 cycles for 75 ng input RNA, and 21 cycles for 50 ng input RNA. Sample groups (based on dpi and T cell type) were pooled and concentrated using SPRIselect Beads (Beckman Coulter). cDNA concentrations were quantified using a Qubit 4 Fluorometer, and size analysis was performed using an Agilent TapeStation.\u003c/p\u003e\n\u003cp\u003eFor popliteal LN mRNA sequencing, LNs were prepared as described above. Cell pellets were resuspended in 200\u0026nbsp;ml TRI Reagent and vortexed at 1000 rpm for 60 seconds. RNA was isolated using a Direct-zol RNA Miniprep kit (Zymo) according to manufacturer instructions, eluting in 20\u0026nbsp;ml of nuclease-free water. mRNA quality was assessed using an Agilent Bioanalyzer. RNA was converted into cDNA libraries as above, using 100 ng input RNA. Samples were pooled and concentrated using SPRIselect beads. cDNA concentrations were quantified using a Qubit 4 Fluorometer, and size analysis was performed using an Agilent TapeStation.\u003c/p\u003e\n\u003cp\u003eBulk TCR sequencing and analysis\u003c/p\u003e\n\u003cp\u003ePooled TCR libraries were sent to Novogene and sequenced using the NovaSeq X Plus with paired-end 150 bp sequencing. A total of 50 GB were sequenced across sub-libraries. For all sub-libraries, the average Q30 was 90%. FASTQ files were processed and analyzed using the Cogent NGS Immune Profiler Software (Takara) according to manufacturer recommendations, with \u0026gt;95% of all reads mapping to either the TCR\u0026nbsp;a\u0026nbsp;or\u0026nbsp;b\u0026nbsp;chain. A UMI cutoff of 8 was used to ensure only high quality UMI groups were included in clonality analyses. To calculate Simpson Clonality, the proportion of individual clonotypes (on the nucleotide level) was squared, the squared proportions were then summated, and the square root of this sum was calculated as the final clonality parameter. V and J gene usage was calculated as an output of Cogent NGS Immune Profiler Software. \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eBulk RNA sequencing and analysis\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePooled 3\u0026rsquo; mRNA libraries were sent to Novogene and sequenced using the NovaSeq X Plus with paired-end 150 bp sequencing. A total of 350 GB were sequenced across sub-libraries, for a sequencing depth of ~30 x 10\u003csup\u003e6\u003c/sup\u003e paired-end reads per sample. Due to low sequence diversity, 17% PhiX was spiked in to improve run quality. All sub-libraries had a Q30 \u0026gt; 78%, with an average of 82%.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo pre-process sequencing data, \u003cem\u003eumi_tools\u003c/em\u003e\u003cem\u003e\u003csup\u003e141\u003c/sup\u003e\u003c/em\u003e was used to extract the UMI from read 1 and assign to corresponding read 2 (UMI-tagged). Afterwards, UMI-tagged reads were trimmed to remove polyT tracts and Illumina adapter sequence. A genome index was generated with \u003cem\u003eSTAR\u003c/em\u003e (version 2.7.10a)\u003csup\u003e142\u003c/sup\u003e using the GRCm39 mouse reference genome. Trimmed, UMI-tagged reads were then aligned against the genome index to generate BAM files. BAM files were indexed, and UMIs were subsequently deduplicated using \u003cem\u003eumi_tools\u003c/em\u003e. Prior to differential expression analysis, count matrices were generated using \u003cem\u003efeatureCounts\u003c/em\u003e\u003cem\u003e\u003csup\u003e143\u003c/sup\u003e\u003c/em\u003e. Gene labels were mapped to Ensembl gene IDs, and samples were then analyzed using \u003cem\u003eDESeq2\u003c/em\u003e\u003csup\u003e144\u003c/sup\u003e, identifying significant genes as those with an adjusted p-value \u0026lt; 0.05 and a log\u003csub\u003e2\u003c/sub\u003eFC \u0026gt; 0.5. Principal component plots were generated using rlog transformed counts. Where applicable, ambient RNA content was highlighted in volcano plots, manually identified by a high abundance of erythrocyte-associated genes.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo perform gene ontology (GO) term enrichment, differentially expressed genes were analyzed using \u003cem\u003eMetascape\u003c/em\u003e\u003cem\u003e\u003csup\u003e145\u003c/sup\u003e\u003c/em\u003e. The most significantly enriched terms (defined by a -log\u003csub\u003e10\u003c/sub\u003e(q-score) \u0026gt; 1.3), and their corresponding q-scores, were plotted in GraphPad prism. Gene set enrichment analysis (GSEA) was performed using software distributed by the Broad Institute\u003csup\u003e146\u003c/sup\u003e. Relevant gene sets were downloaded from the Molecular Signatures Database available through the GSEA website (\u003ca href=\"https://www.gsea-msigdb.org/gs=a/msigdb/index.jsp\"\u003ehttps://www.gsea-msigdb.org/gs=a/msigdb/index.jsp\u003c/a\u003e). When applicable, genes strongly associated with ambient RNA (i.e., hemoglobin-associated genes) were excluded from GSEA analysis to prevent confounding outputs.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eIn vivo\u003c/em\u003e antibody and antiviral treatment\u003c/p\u003e\n\u003cp\u003eFor \u003cem\u003ein vivo\u003c/em\u003e antibody treatments, 200\u0026nbsp;mg of antibody were diluted up to 200\u0026nbsp;ml in PBS and administered i.p. at specified timepoints. For antiviral treatment, CDV powder was diluted to 2 mg/ml in PBS with pulse vortexing, and the solution was 0.22-mm filtered to ensure sterility. Antiviral concentration was confirmed by A\u003csub\u003e280\u003c/sub\u003e absorbance prior to administration. CDV was administered in a final volume of 300\u0026nbsp;ml i.p., and the untreated mice received 300\u0026nbsp;ml of PBS only.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTetramer decay assay\u003c/p\u003e\n\u003cp\u003eThe tetramer decay assay was adapted from a recent publication\u003csup\u003e47\u003c/sup\u003e. Female B6 mice were infected with either WT or\u0026nbsp;DC15 for 14 days, and spleens were subsequently harvested and processed into single cell suspensions. For each spleen, CD8+ T cells were isolated from 50 x 10\u003csup\u003e6\u003c/sup\u003e splenocytes using the MojoSort Mouse CD8 Isolation Kit (Biolegend) according to manufacturer instructions. For each mouse, 2-3 x 10\u003csup\u003e6\u003c/sup\u003e CD8+ T cells were plated in a 96-well U-bottom plate. Cells were subsequently stained for viability and surface stained for CD4, CD8a, and B8R specificity using PE and APC tetramer conjugates. After surface staining, wells were washed and split into four equal aliquots across 4 plates. Cells were then resuspended in tetramer stabilizing solution (20\u0026nbsp;mg/ml anti-H-2K\u003csup\u003eb\u003c/sup\u003e and 5\u0026nbsp;mg/ml anti-phycoerythrin (PE) in FACS buffer) and left for either 0, 15, 90 or 180 minutes at RT. After timepoint incubations, cells were fixed and left at 4 \u003csup\u003eo\u003c/sup\u003eC until running on the cytometer. In this experiment, no differences in binding kinetics were found between APC and stabilized PE tetramers. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eRNA isolation and qPCR in popliteal LN\u003c/p\u003e\n\u003cp\u003eFemale B6 mice were infected with either WT or\u0026nbsp;DC15 for 24 or 32 hours. After harvesting, popliteal LNs were placed into 250\u0026nbsp;ml of RNALater (Invitrogen) and left at 4 \u003csup\u003eo\u003c/sup\u003eC until processing. LNs were then removed from RNALater and placed into 600\u0026nbsp;ml of TRI reagent in Type F homogenization tubes (Macherey-Nagel). Homogenization tubes were then vortexed at speed \u0026ldquo;4\u0026rdquo; at RT for 10 minutes. Homogenates were removed from beads and purified using the Direct-Zol RNA Miniprep kit (Zymo). RNA concentration was quantified using a Qubit 4 fluorometer and quality was evaluated using an Agilent Bioanalyzer.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eRNA abundance was then quantified using the ZymoScript One-Step RT-qPCR kit (Zymo), performing reactions for \u003cem\u003eEVM003\u003c/em\u003e and \u003cem\u003eGAPDH\u003c/em\u003e (Table S4), according to manufacturer protocols. Technical duplicates were performed for each RNA sample. Relative RNA quantity was then calculated using the\u0026nbsp;DDC\u003csub\u003et\u003c/sub\u003e method, first normalizing to \u003cem\u003eGAPDH\u003c/em\u003e signal prior to calculating fold-change differences between samples. Na\u0026iuml;ve LNs were used to establish the C\u003csub\u003et\u003c/sub\u003e threshold associated with non-specific amplification (background).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFACS sorting and fixation for scRNA-seq\u003c/p\u003e\n\u003cp\u003eFor scRNA-seq, female B6 mice were infected with either WT or\u0026nbsp;DC15 for 24 or 48 hours. Sorting was performed on consecutive days to cut down time on ice during processing. Single cell suspensions of popliteal LNs were prepared as described above, except FACS buffer was spiked with RNasin Plus (Promega). Cells were viability stained and subsequently surface stained for CD19 at 4 \u003csup\u003eo\u003c/sup\u003eC for 30 minutes. After staining, live, CD19-positive and CD19-negative cells were separately sorted into LoBind tubes (USA Scientific) containing RNasin-supplemented FACS buffer. CD19-positive cells were pooled across infection conditions. Lymph nodes with minimal CD19-negative cell recovery were excluded from downstream analysis. Cell populations were subsequently fixed using the Evercode Cell Fixation kit (Parse Biosciences) according to manufacturer instructions. Fixed cells were concentrated, counted, and stored in either 50 or 10\u0026nbsp;ml aliquots at -80 \u003csup\u003eo\u003c/sup\u003eC in Cell Storage Master Mix. One day prior to scRNA library preparation, a 10\u0026nbsp;ml aliquot was thawed on ice and counted using disposable hemocytometers (Bulldog Bio). Cell counts were used to calculate the quantity of cells to load for library preparation, according to the sample loading table provided by Parse Biosciences.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003escRNA-seq sample processing and analysis\u003c/p\u003e\n\u003cp\u003eLibraries were prepared using the Evercode WT kit (Parse Biosciences), primarily following all manufacturer instructions. When performing cDNA amplification, 8 cycles were chosen based on low RNA content cells and 12,500 cells per sub-library. For size selection, SPRIselect beads were used. To perform size analysis on cDNA, the Agilent TapeStation was used. All cDNA libraries yielded \u0026gt;20 ng/ul in a final volume of 20\u0026nbsp;ml. An initial 2 x 10\u003csup\u003e9\u003c/sup\u003e paired-end 150 bp reads were generated through a promotional program with Parse Biosciences. An additional 3 x 10\u003csup\u003e9\u003c/sup\u003e paired-end 150 bp reads were acquired through Novogene. Q30 values were greater than 90% for all sub-libraries with a spike-in of 10% PhiX. Across sub-libraries, a total of 69,803 cells were recovered with a total of 83,602 mean reads/cell. The median transcripts and genes per cell were 9,964 and 3,150, respectively, with a total sequencing saturation of 0.604. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe Trailmaker web server (Parse Biosciences) was used for data analysis. For quality control parameters, the automatic cell size distribution filter was applied. A manual max percentage of 3% was set for the mitochondrial content filter. An automatic spline-type fit was used to select cells with good correlation of gene vs transcript numbers. A manual probability threshold of 0.4 was set for the doublet filter. Data integration was performed with Harmony\u003csup\u003e147\u003c/sup\u003e using automated settings set by Trailmaker. Lastly, cells were embedded into a UMAP and clustering was performed using the Leiden algorithm\u003csup\u003e148\u003c/sup\u003e, with a resolution of 0.15. For analysis focusing on T and NK lymphocytes, B lymphocyte clusters were excluded and re-clustering performed at a resolution of 0.13. The Trailmaker software was used to generate heatmaps and volcano plots visualizing differential gene expression analysis. Sub-clustering was similarly performed on NK cells (as defined by \u003cem\u003eNcr1\u003c/em\u003e), and a resolution of 0.1 was used to generate key clusters.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eQuantification and statistical analysis\u003c/p\u003e\n\u003cp\u003eGraphPad Prism was used to perform all statistical tests for cell-based assays and flow cytometry data. When comparing across multiple groups in \u003cem\u003ein vitro\u003c/em\u003e data, a two-way ANOVA with \u0026Scaron;id\u0026aacute;k correction for multiple comparisons was performed. To compare two groups (e.g., WT vs.\u0026nbsp;DC15) \u003cem\u003ein vitro\u003c/em\u003e, a two-tailed unpaired t-test was performed. To statistically analyze \u003cem\u003ein vivo\u003c/em\u003e parameters across multiple infection groups and time points (e.g., 5-10 dpi), a mixed-effects model was used with \u0026Scaron;id\u0026aacute;k correction for multiple comparisons. For additional \u003cem\u003ein vivo\u003c/em\u003e studies, two-way ANOVA with either Tukey or \u0026Scaron;id\u0026aacute;k corrections for multiple comparisons were performed. Relevant statistical analyses are indicated within figure legends. In all experiments, results are expressed as mean\u0026nbsp;\u0026plusmn;\u0026nbsp;standard deviation (SD). A p-value \u0026lt; 0.05 was considered significant, with significance indicated as *p \u0026lt; 0.05, **p \u0026lt; 0.01, ***p \u0026lt; 0.001, and **** p \u0026lt; 0.0001.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eLead Contact\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eRequests for further information and resources should be directed to and will be fulfilled by the lead contact, Laurence Eisenlohr ([email protected]). Reagents are available on request to the lead contact with a completed materials transfer agreement. All sequencing datasets are available on GEO as follows: bulk RNA sequencing i) CD4+ T\u003csub\u003eeff\u003c/sub\u003e 7 dpi (GSE308806), ii) CD8+ T\u003csub\u003eeff\u003c/sub\u003e 7 dpi (GSE308808), iii) CD8+ T\u003csub\u003eeff\u003c/sub\u003e 10 dpi (GSE308809), iv) dLN 48 hpi (GSE309219), TCR sequencing (GSE 309222), and single cell RNA sequencing (GSE309220).\u0026nbsp;\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe thank members of the Eisenlohr lab for their insights and feedback throughout the development of this work; Dr. Camila Coelho and Dr. Raianna Fantin for providing the plasmids encoding the anti-A35R (i.e., anti-A33R) monoclonal antibody; Dr. Mohamed-Gabriel Alameh for providing OVA-encoding mRNA-LNPs; Keenan O’Dea for his expertise in anti-CD40L administration; Vivian Hoang for technical assistance in generating the UbC-C15-CIITA cell line. Flow cytometry data was acquired using the CHOP Flow Cytometry Core Laboratory (RRID:SCR_009726) and the Penn Cytomics and Cell Sorting Shared Resource Laboratory (RRID:SC_022376). Penn Cytomics is partially supported by the Abramson Cancer Center NCI Grant (P30 016520). RNA integrity and DNA size analysis was performed through the CHOP High Throughput Sequencing Core. We thank the NIH Tetramer Core Facility (NIH Contract 75N93020D00005 and RRID:SCR_026557) for providing B8R and I1L tetramers. Model illustrations were created using BioRender. S.D.C. was supported by an NIH F31 fellowship (F31AI183694). This work was supported by NIH grants R21AI160063 and R01AI182049 awarded to L.C.E.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eAuthor contributions\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eS.D.C., E.M.P., and L.C.E. conceptualized the project. S.D.C. and L.C.E. conceptualized all experiments. S.D.C. performed all experiments with technical help from E.J.H., M.K.H., and C.L-S. A.R.C. provided intellectual expertise in flow cytometry methodology and panel development. H.M.S. synthesized and assisted in the characterization of anti-A33R antibodies. S.D.C. performed all formal analysis, including sequencing analysis. S.D.C. and L.C.E. wrote the manuscript, with critical review from all authors.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eDeclaration of interests\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no competing interests.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eMcFadden, G. (2005). Poxvirus tropism. Nat Rev Microbiol \u003cem\u003e3\u003c/em\u003e, 201\u0026ndash;213. 10.1038/nrmicro1099.\u003c/li\u003e\n\u003cli\u003eMacNeill, A.L. (2022). Comparative Pathology of Zoonotic Orthopoxviruses. Pathogens \u003cem\u003e11\u003c/em\u003e. 10.3390/pathogens11080892.\u003c/li\u003e\n\u003cli\u003eMitja, O., Ogoina, D., Titanji, B.K., Galvan, C., Muyembe, J.J., Marks, M., and Orkin, C.M. (2023). Monkeypox. Lancet \u003cem\u003e401\u003c/em\u003e, 60\u0026ndash;74. 10.1016/S0140-6736(22)02075-X.\u003c/li\u003e\n\u003cli\u003eGigante, C.M., Gao, J., Tang, S., McCollum, A.M., Wilkins, K., Reynolds, M.G., Davidson, W., McLaughlin, J., Olson, V.A., and Li, Y. (2019). Genome of Alaskapox Virus, A Novel Orthopoxvirus Isolated from Alaska. Viruses \u003cem\u003e11\u003c/em\u003e. 10.3390/v11080708.\u003c/li\u003e\n\u003cli\u003eDoty, J.B., Maghlakelidze, G., Sikharulidze, I., Tu, S.L., Morgan, C.N., Mauldin, M.R., Parkadze, O., Kartskhia, N., Turmanidze, M., Matheny, A.M., et al. (2019). Isolation and Characterization of Akhmeta Virus from Wild-Caught Rodents (Apodemus spp.) in Georgia. J Virol \u003cem\u003e93\u003c/em\u003e. 10.1128/JVI.00966-19.\u003c/li\u003e\n\u003cli\u003eCardeti, G., Gruber, C.E.M., Eleni, C., Carletti, F., Castilletti, C., Manna, G., Rosone, F., Giombini, E., Selleri, M., Lapa, D., et al. (2017). Fatal Outbreak in Tonkean Macaques Caused by Possibly Novel Orthopoxvirus, Italy, January 2015 (1). Emerg Infect Dis \u003cem\u003e23\u003c/em\u003e, 1941\u0026ndash;1949. 10.3201/eid2312.162098.\u003c/li\u003e\n\u003cli\u003eDeputy, N.P., Deckert, J., Chard, A.N., Sandberg, N., Moulia, D.L., Barkley, E., Dalton, A.F., Sweet, C., Cohn, A.C., Little, D.R., et al. (2023). Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med \u003cem\u003e388\u003c/em\u003e, 2434\u0026ndash;2443. 10.1056/NEJMoa2215201.\u003c/li\u003e\n\u003cli\u003eTaha, A.M., Mahmoud, A.M., Abouelmagd, K., Saed, S.A.A., Khalefa, B.B., Shah, S., Satapathy, P., Shamim, M.A., Sah, S., Serhan, H.A., et al. (2024). Effectiveness of a single dose of JYNNEOS vaccine in real world: A systematic review and meta-analysis. Health Sci Rep \u003cem\u003e7\u003c/em\u003e, e70069. 10.1002/hsr2.70069.\u003c/li\u003e\n\u003cli\u003eGranskog, L., Saadeh, K., Lorenz, K., Quint, J., Salih, T., Lo, T., Jacobson, K., Ramos, M., Chapman, E., Snyder, R.E., and Lewnard, J.A. (2025). Effect of JYNNEOS vaccination on mpox clinical progression: a case-control study. Lancet Infect Dis \u003cem\u003e25\u003c/em\u003e, 1106\u0026ndash;1115. 10.1016/S1473-3099(25)00180-X.\u003c/li\u003e\n\u003cli\u003ePhipps, K., Yates, J., Pettit, J., Bialosuknia, S., Hunt, D., DuPuis, A.P., 2nd, Payne, A., Lee, W., and McDonough, K.A. (2025). Short-Lived Neutralizing Antibody Responses to Monkeypox Virus in Smallpox Vaccine-Naive Persons after JYNNEOS Vaccination. Emerg Infect Dis \u003cem\u003e31\u003c/em\u003e, 237\u0026ndash;245. 10.3201/eid3102.241300.\u003c/li\u003e\n\u003cli\u003eGarrigues, J.M., Hemarajata, P., Karan, A., Shah, N.K., Alarcon, J., Marutani, A.N., Finn, L., Smith, T.G., Gigante, C.M., Davidson, W., et al. (2023). Identification of Tecovirimat Resistance-Associated Mutations in Human Monkeypox Virus - Los Angeles County. Antimicrob Agents Chemother, e0056823. 10.1128/aac.00568-23.\u003c/li\u003e\n\u003cli\u003eSmith, T.G., Gigante, C.M., Wynn, N.T., Matheny, A., Davidson, W., Yang, Y., Condori, R.E., O\u0026apos;Connell, K., Kovar, L., Williams, T.L., et al. (2023). Tecovirimat Resistance in Mpox Patients, United States, 2022-2023. Emerg Infect Dis \u003cem\u003e29\u003c/em\u003e, 2426\u0026ndash;2432. 10.3201/eid2912.231146.\u003c/li\u003e\n\u003cli\u003eFortier, J.C., Marsalisi, C., Cordova, E., Guo, H.J., and Verdecia, J. (2024). Challenges in Managing Treatment-Resistant Mpox Complicated by Severe Superinfection. Open Forum Infect Dis \u003cem\u003e11\u003c/em\u003e, ofae138. 10.1093/ofid/ofae138.\u003c/li\u003e\n\u003cli\u003eKhera, S.S., Mishra, S., Pico Espinosa, O.J., Gough, K., Tan, C., Walmsley, S., Zhabokritsky, A., Sharma, M., Chan, A.K., Leis, J.A., et al. (2025). Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials. J Antimicrob Chemother \u003cem\u003e80\u003c/em\u003e, 935\u0026ndash;940. 10.1093/jac/dkaf010.\u003c/li\u003e\n\u003cli\u003eAlzhanova, D., Hammarlund, E., Reed, J., Meermeier, E., Rawlings, S., Ray, C.A., Edwards, D.M., Bimber, B., Legasse, A., Planer, S., et al. (2014). T cell inactivation by poxviral B22 family proteins increases viral virulence. PLoS Pathog \u003cem\u003e10\u003c/em\u003e, e1004123. 10.1371/journal.ppat.1004123.\u003c/li\u003e\n\u003cli\u003eReynolds, S.E., Earl, P.L., Minai, M., Moore, I., and Moss, B. (2017). A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model. Virology \u003cem\u003e501\u003c/em\u003e, 107\u0026ndash;114. 10.1016/j.virol.2016.11.010.\u003c/li\u003e\n\u003cli\u003eForsyth, K.S., Roy, N.H., Peauroi, E., DeHaven, B.C., Wold, E.D., Hersperger, A.R., Burkhardt, J.K., and Eisenlohr, L.C. (2020). Ectromelia-encoded virulence factor C15 specifically inhibits antigen presentation to CD4+ T cells post peptide loading. PLoS Pathog \u003cem\u003e16\u003c/em\u003e, e1008685. 10.1371/journal.ppat.1008685.\u003c/li\u003e\n\u003cli\u003eReynolds, S.E., and Moss, B. (2015). Characterization of a large, proteolytically processed cowpox virus membrane glycoprotein conserved in most chordopoxviruses. Virology \u003cem\u003e483\u003c/em\u003e, 209\u0026ndash;217. 10.1016/j.virol.2015.04.014.\u003c/li\u003e\n\u003cli\u003ePeauroi, E.M., Carro, S.D., Pei, L., Reynoso, G.V., Hickman, H.D., and Eisenlohr, L.C. (2022). The ectromelia virus virulence factor C15 facilitates early viral spread by inhibiting NK cell contact. iScience \u003cem\u003e25\u003c/em\u003e, 105510. 10.1016/j.isci.2022.105510.\u003c/li\u003e\n\u003cli\u003eFenner, F. (1988). Smallpox and its Eradication (World Health Organization).\u003c/li\u003e\n\u003cli\u003eGarver, J., Weber, L., Vela, E.M., Anderson, M., Warren, R., Merchlinsky, M., Houchens, C., and Rogers, J.V. (2016). Ectromelia Virus Disease Characterization in the BALB/c Mouse: A Surrogate Model for Assessment of Smallpox Medical Countermeasures. Viruses \u003cem\u003e8\u003c/em\u003e. 10.3390/v8070203.\u003c/li\u003e\n\u003cli\u003eSigal, L.J. (2016). The Pathogenesis and Immunobiology of Mousepox. Adv Immunol \u003cem\u003e129\u003c/em\u003e, 251\u0026ndash;276. 10.1016/bs.ai.2015.10.001.\u003c/li\u003e\n\u003cli\u003eKrmpotic, A., Busch, D.H., Bubic, I., Gebhardt, F., Hengel, H., Hasan, M., Scalzo, A.A., Koszinowski, U.H., and Jonjic, S. (2002). MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol \u003cem\u003e3\u003c/em\u003e, 529\u0026ndash;535. 10.1038/ni799.\u003c/li\u003e\n\u003cli\u003eKowarz, E., Loscher, D., and Marschalek, R. (2015). Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines. Biotechnol J \u003cem\u003e10\u003c/em\u003e, 647\u0026ndash;653. 10.1002/biot.201400821.\u003c/li\u003e\n\u003cli\u003eTewari, M.K., Sinnathamby, G., Rajagopal, D., and Eisenlohr, L.C. (2005). A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. Nat Immunol \u003cem\u003e6\u003c/em\u003e, 287\u0026ndash;294. 10.1038/ni1171.\u003c/li\u003e\n\u003cli\u003ePotter, L.R. (2011). Guanylyl cyclase structure, function and regulation. Cell Signal \u003cem\u003e23\u003c/em\u003e, 1921\u0026ndash;1926. 10.1016/j.cellsig.2011.09.001.\u003c/li\u003e\n\u003cli\u003eFang, M., Lanier, L.L., and Sigal, L.J. (2008). A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog \u003cem\u003e4\u003c/em\u003e, e30. 10.1371/journal.ppat.0040030.\u003c/li\u003e\n\u003cli\u003eFang, M., and Sigal, L.J. (2005). Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol \u003cem\u003e175\u003c/em\u003e, 6829\u0026ndash;6836. 10.4049/jimmunol.175.10.6829.\u003c/li\u003e\n\u003cli\u003eParker, A.K., Parker, S., Yokoyama, W.M., Corbett, J.A., and Buller, R.M. (2007). Induction of natural killer cell responses by ectromelia virus controls infection. J Virol \u003cem\u003e81\u003c/em\u003e, 4070\u0026ndash;4079. 10.1128/JVI.02061-06.\u003c/li\u003e\n\u003cli\u003eGerlach, C., Moseman, E.A., Loughhead, S.M., Alvarez, D., Zwijnenburg, A.J., Waanders, L., Garg, R., de la Torre, J.C., and von Andrian, U.H. (2016). The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis. Immunity \u003cem\u003e45\u003c/em\u003e, 1270\u0026ndash;1284. 10.1016/j.immuni.2016.10.018.\u003c/li\u003e\n\u003cli\u003eZwijnenburg, A.J., Pokharel, J., Varnaite, R., Zheng, W., Hoffer, E., Shryki, I., Comet, N.R., Ehrstrom, M., Gredmark-Russ, S., Eidsmo, L., and Gerlach, C. (2023). Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. Immunity \u003cem\u003e56\u003c/em\u003e, 1955\u0026ndash;1974 e1910. 10.1016/j.immuni.2023.06.025.\u003c/li\u003e\n\u003cli\u003eWang, R., Dillon, C.P., Shi, L.Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L.L., Fitzgerald, P., Chi, H., Munger, J., and Green, D.R. (2011). The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity \u003cem\u003e35\u003c/em\u003e, 871\u0026ndash;882. 10.1016/j.immuni.2011.09.021.\u003c/li\u003e\n\u003cli\u003eYu, M., Lee, W.W., Tomar, D., Pryshchep, S., Czesnikiewicz-Guzik, M., Lamar, D.L., Li, G., Singh, K., Tian, L., Weyand, C.M., and Goronzy, J.J. (2011). Regulation of T cell receptor signaling by activation-induced zinc influx. J Exp Med \u003cem\u003e208\u003c/em\u003e, 775\u0026ndash;785. 10.1084/jem.20100031.\u003c/li\u003e\n\u003cli\u003eChen, B., Yu, P., Chan, W.N., Xie, F., Zhang, Y., Liang, L., Leung, K.T., Lo, K.W., Yu, J., Tse, G.M.K., et al. (2024). Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets. Signal Transduct Target Ther \u003cem\u003e9\u003c/em\u003e, 6. 10.1038/s41392-023-01679-y.\u003c/li\u003e\n\u003cli\u003eHeffner, M., and Fearon, D.T. (2007). Loss of T cell receptor-induced Bmi-1 in the KLRG1(+) senescent CD8(+) T lymphocyte. Proc Natl Acad Sci U S A \u003cem\u003e104\u003c/em\u003e, 13414\u0026ndash;13419. 10.1073/pnas.0706040104.\u003c/li\u003e\n\u003cli\u003eWedel, J., Kochupurakkal, N., Kong, S.W., Bose, S., Lee, J.W., Maslyar, M., Alsairafi, B., MacLeod, K., Liu, K., Zhang, H., et al. (2025). Neuropilin-2 functions as a coinhibitory receptor to regulate antigen-induced inflammation and allograft rejection. J Clin Invest \u003cem\u003e135\u003c/em\u003e. 10.1172/JCI172218.\u003c/li\u003e\n\u003cli\u003ePalmer, D.C., Guittard, G.C., Franco, Z., Crompton, J.G., Eil, R.L., Patel, S.J., Ji, Y., Van Panhuys, N., Klebanoff, C.A., Sukumar, M., et al. (2015). Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med \u003cem\u003e212\u003c/em\u003e, 2095\u0026ndash;2113. 10.1084/jem.20150304.\u003c/li\u003e\n\u003cli\u003eKosugi, A., Sakakura, J., Yasuda, K., Ogata, M., and Hamaoka, T. (2001). Involvement of SHP-1 tyrosine phosphatase in TCR-mediated signaling pathways in lipid rafts. Immunity \u003cem\u003e14\u003c/em\u003e, 669\u0026ndash;680. 10.1016/s1074-7613(01)00146-7.\u003c/li\u003e\n\u003cli\u003eSridaran, D., Chouhan, S., Mahajan, K., Renganathan, A., Weimholt, C., Bhagwat, S., Reimers, M., Kim, E.H., Thakur, M.K., Saeed, M.A., et al. (2022). Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nat Commun \u003cem\u003e13\u003c/em\u003e, 6929. 10.1038/s41467-022-34724-5.\u003c/li\u003e\n\u003cli\u003evan Spriel, A.B., Puls, K.L., Sofi, M., Pouniotis, D., Hochrein, H., Orinska, Z., Knobeloch, K.P., Plebanski, M., and Wright, M.D. (2004). A regulatory role for CD37 in T cell proliferation. J Immunol \u003cem\u003e172\u003c/em\u003e, 2953\u0026ndash;2961. 10.4049/jimmunol.172.5.2953.\u003c/li\u003e\n\u003cli\u003eShah, K., Al-Haidari, A., Sun, J., and Kazi, J.U. (2021). T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther \u003cem\u003e6\u003c/em\u003e, 412. 10.1038/s41392-021-00823-w.\u003c/li\u003e\n\u003cli\u003eCollins, S., Lutz, M.A., Zarek, P.E., Anders, R.A., Kersh, G.J., and Powell, J.D. (2008). Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. Eur J Immunol \u003cem\u003e38\u003c/em\u003e, 528\u0026ndash;536. 10.1002/eji.200737157.\u003c/li\u003e\n\u003cli\u003ePreiss, N.K., Kamal, Y., Wilkins, O.M., Li, C., Kolling, F.W.t., Trask, H.W., Usherwood, Y.K., Cheng, C., Frost, H.R., and Usherwood, E.J. (2023). Characterizing control of memory CD8 T cell differentiation by BTB-ZF transcription factor Zbtb20. Life Sci Alliance \u003cem\u003e6\u003c/em\u003e. 10.26508/lsa.202201683.\u003c/li\u003e\n\u003cli\u003eRoychoudhuri, R., Clever, D., Li, P., Wakabayashi, Y., Quinn, K.M., Klebanoff, C.A., Ji, Y., Sukumar, M., Eil, R.L., Yu, Z., et al. (2016). BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. Nat Immunol \u003cem\u003e17\u003c/em\u003e, 851\u0026ndash;860. 10.1038/ni.3441.\u003c/li\u003e\n\u003cli\u003eSun, Y., Preiss, N.K., Valenteros, K.B., Kamal, Y., Usherwood, Y.K., Frost, H.R., and Usherwood, E.J. (2020). Zbtb20 Restrains CD8 T Cell Immunometabolism and Restricts Memory Differentiation and Antitumor Immunity. J Immunol \u003cem\u003e205\u003c/em\u003e, 2649\u0026ndash;2666. 10.4049/jimmunol.2000459.\u003c/li\u003e\n\u003cli\u003eDzutsev, A.H., Belyakov, I.M., Isakov, D.V., Margulies, D.H., and Berzofsky, J.A. (2007). Avidity of CD8 T cells sharpens immunodominance. Int Immunol \u003cem\u003e19\u003c/em\u003e, 497\u0026ndash;507. 10.1093/intimm/dxm016.\u003c/li\u003e\n\u003cli\u003eSinghaviranon, S., Dempsey, J.P., Hagymasi, A.T., Mandoiu, II, and Srivastava, P.K. (2025). Low-avidity T cells drive endogenous tumor immunity in mice and humans. Nat Immunol \u003cem\u003e26\u003c/em\u003e, 240\u0026ndash;251. 10.1038/s41590-024-02044-z.\u003c/li\u003e\n\u003cli\u003eCaserta, S., Kleczkowska, J., Mondino, A., and Zamoyska, R. (2010). Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens. J Immunol \u003cem\u003e185\u003c/em\u003e, 6545\u0026ndash;6554. 10.4049/jimmunol.1001867.\u003c/li\u003e\n\u003cli\u003eMartinez-Usatorre, A., Donda, A., Zehn, D., and Romero, P. (2018). PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells. J Immunol \u003cem\u003e201\u003c/em\u003e, 792\u0026ndash;803. 10.4049/jimmunol.1701644.\u003c/li\u003e\n\u003cli\u003eSugiyarto, G., Lau, D., Hill, S.L., Arcia-Anaya, D., Boulanger, D.S.M., Parkes, E., James, E., and Elliott, T. (2023). Reactivation of low avidity tumor-specific CD8(+) T cells associates with immunotherapeutic efficacy of anti-PD-1. J Immunother Cancer \u003cem\u003e11\u003c/em\u003e. 10.1136/jitc-2023-007114.\u003c/li\u003e\n\u003cli\u003eNgiow, S.F., Manne, S., Huang, Y.J., Azar, T., Chen, Z., Mathew, D., Chen, Q., Khan, O., Wu, J.E., Alcalde, V., et al. (2024). LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell \u003cem\u003e187\u003c/em\u003e, 4336\u0026ndash;4354 e4319. 10.1016/j.cell.2024.07.018.\u003c/li\u003e\n\u003cli\u003eGupta, P.K., Godec, J., Wolski, D., Adland, E., Yates, K., Pauken, K.E., Cosgrove, C., Ledderose, C., Junger, W.G., Robson, S.C., et al. (2015). CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. PLoS Pathog \u003cem\u003e11\u003c/em\u003e, e1005177. 10.1371/journal.ppat.1005177.\u003c/li\u003e\n\u003cli\u003eSakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., and Anderson, A.C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med \u003cem\u003e207\u003c/em\u003e, 2187\u0026ndash;2194. 10.1084/jem.20100643.\u003c/li\u003e\n\u003cli\u003ePace, L., Tempez, A., Arnold-Schrauf, C., Lemaitre, F., Bousso, P., Fetler, L., Sparwasser, T., and Amigorena, S. (2012). Regulatory T cells increase the avidity of primary CD8+ T cell responses and promote memory. Science \u003cem\u003e338\u003c/em\u003e, 532\u0026ndash;536. 10.1126/science.1227049.\u003c/li\u003e\n\u003cli\u003eJoshi, N.S., Cui, W., Chandele, A., Lee, H.K., Urso, D.R., Hagman, J., Gapin, L., and Kaech, S.M. (2007). Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity \u003cem\u003e27\u003c/em\u003e, 281\u0026ndash;295. 10.1016/j.immuni.2007.07.010.\u003c/li\u003e\n\u003cli\u003eKaech, S.M., Tan, J.T., Wherry, E.J., Konieczny, B.T., Surh, C.D., and Ahmed, R. (2003). Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol \u003cem\u003e4\u003c/em\u003e, 1191\u0026ndash;1198. 10.1038/ni1009.\u003c/li\u003e\n\u003cli\u003eWherry, E.J., Teichgraber, V., Becker, T.C., Masopust, D., Kaech, S.M., Antia, R., von Andrian, U.H., and Ahmed, R. (2003). Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol \u003cem\u003e4\u003c/em\u003e, 225\u0026ndash;234. 10.1038/ni889.\u003c/li\u003e\n\u003cli\u003eHildner, K., Edelson, B.T., Purtha, W.E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B.U., Unanue, E.R., Diamond, M.S., et al. (2008). Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science \u003cem\u003e322\u003c/em\u003e, 1097\u0026ndash;1100. 10.1126/science.1164206.\u003c/li\u003e\n\u003cli\u003eGainey, M.D., Rivenbark, J.G., Cho, H., Yang, L., and Yokoyama, W.M. (2012). Viral MHC class I inhibition evades CD8+ T-cell effector responses in vivo but not CD8+ T-cell priming. Proc Natl Acad Sci U S A \u003cem\u003e109\u003c/em\u003e, E3260\u0026ndash;3267. 10.1073/pnas.1217111109.\u003c/li\u003e\n\u003cli\u003eKaminsky, L.W., Sei, J.J., Parekh, N.J., Davies, M.L., Reider, I.E., Krouse, T.E., and Norbury, C.C. (2015). Redundant Function of Plasmacytoid and Conventional Dendritic Cells Is Required To Survive a Natural Virus Infection. J Virol \u003cem\u003e89\u003c/em\u003e, 9974\u0026ndash;9985. 10.1128/JVI.01024-15.\u003c/li\u003e\n\u003cli\u003eChristian, D.A., Adams, T.A., 2nd, Shallberg, L.A., Phan, A.T., Smith, T.E., Abraha, M., Perry, J., Ruthel, G., Clark, J.T., Pritchard, G.H., et al. (2022). cDC1 coordinate innate and adaptive responses in the omentum required for T cell priming and memory. Sci Immunol \u003cem\u003e7\u003c/em\u003e, eabq7432. 10.1126/sciimmunol.abq7432.\u003c/li\u003e\n\u003cli\u003eSharma, S., Sundararajan, A., Suryawanshi, A., Kumar, N., Veiga-Parga, T., Kuchroo, V.K., Thomas, P.G., Sangster, M.Y., and Rouse, B.T. (2011). T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc Natl Acad Sci U S A \u003cem\u003e108\u003c/em\u003e, 19001\u0026ndash;19006. 10.1073/pnas.1107087108.\u003c/li\u003e\n\u003cli\u003eFerris, S.T., Durai, V., Wu, R., Theisen, D.J., Ward, J.P., Bern, M.D., Davidson, J.T.t., Bagadia, P., Liu, T., Briseno, C.G., et al. (2020). cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity. Nature \u003cem\u003e584\u003c/em\u003e, 624\u0026ndash;629. 10.1038/s41586-020-2611-3.\u003c/li\u003e\n\u003cli\u003eTaraban, V.Y., Rowley, T.F., and Al-Shamkhani, A. (2004). Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol \u003cem\u003e173\u003c/em\u003e, 6542\u0026ndash;6546. 10.4049/jimmunol.173.11.6542.\u003c/li\u003e\n\u003cli\u003eLiu, D., and Ford, M.L. (2020). CD11b is a novel alternate receptor for CD154 during alloimmunity. Am J Transplant \u003cem\u003e20\u003c/em\u003e, 2216\u0026ndash;2225. 10.1111/ajt.15835.\u003c/li\u003e\n\u003cli\u003eAlexander, K.L., Bennion, K.B., Liu, D., and Ford, M.L. (2025). CD154:CD11b blockade enhances CD8+ T cell differentiation during infection but not transplantation. JCI Insight \u003cem\u003e10\u003c/em\u003e. 10.1172/jci.insight.184843.\u003c/li\u003e\n\u003cli\u003eBlair, P.J., Riley, J.L., Harlan, D.M., Abe, R., Tadaki, D.K., Hoffmann, S.C., White, L., Francomano, T., Perfetto, S.J., Kirk, A.D., and June, C.H. (2000). CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med \u003cem\u003e191\u003c/em\u003e, 651\u0026ndash;660. 10.1084/jem.191.4.651.\u003c/li\u003e\n\u003cli\u003eMiga, A.J., Masters, S.R., Durell, B.G., Gonzalez, M., Jenkins, M.K., Maliszewski, C., Kikutani, H., Wade, W.F., and Noelle, R.J. (2001). Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions. Eur J Immunol \u003cem\u003e31\u003c/em\u003e, 959\u0026ndash;965. 10.1002/1521-4141(200103)31:3\u0026lt;959::aid-immu959\u0026gt;3.0.co;2-a.\u003c/li\u003e\n\u003cli\u003eFang, M., Siciliano, N.A., Hersperger, A.R., Roscoe, F., Hu, A., Ma, X., Shamsedeen, A.R., Eisenlohr, L.C., and Sigal, L.J. (2012). Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection. Proc Natl Acad Sci U S A \u003cem\u003e109\u003c/em\u003e, 9983\u0026ndash;9988. 10.1073/pnas.1202143109.\u003c/li\u003e\n\u003cli\u003eMcDermott, D.S., and Varga, S.M. (2011). Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think. J Immunol \u003cem\u003e187\u003c/em\u003e, 5568\u0026ndash;5576. 10.4049/jimmunol.1102104.\u003c/li\u003e\n\u003cli\u003eKnudson, C.J., Ferez, M., Alves-Peixoto, P., Erkes, D.A., Melo-Silva, C.R., Tang, L., Snyder, C.M., and Sigal, L.J. (2021). Mechanisms of Antiviral Cytotoxic CD4 T Cell Differentiation. J Virol \u003cem\u003e95\u003c/em\u003e, e0056621. 10.1128/JVI.00566-21.\u003c/li\u003e\n\u003cli\u003eMuller, D., Koller, B.H., Whitton, J.L., LaPan, K.E., Brigman, K.K., and Frelinger, J.A. (1992). LCMV-specific, class II-restricted cytotoxic T cells in beta 2-microglobulin-deficient mice. Science \u003cem\u003e255\u003c/em\u003e, 1576\u0026ndash;1578. 10.1126/science.1347959.\u003c/li\u003e\n\u003cli\u003eKitoh, A., Ono, M., Naoe, Y., Ohkura, N., Yamaguchi, T., Yaguchi, H., Kitabayashi, I., Tsukada, T., Nomura, T., Miyachi, Y., et al. (2009). Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity \u003cem\u003e31\u003c/em\u003e, 609\u0026ndash;620. 10.1016/j.immuni.2009.09.003.\u003c/li\u003e\n\u003cli\u003eKerdiles, Y.M., Stone, E.L., Beisner, D.R., McGargill, M.A., Ch\u0026apos;en, I.L., Stockmann, C., Katayama, C.D., and Hedrick, S.M. (2010). Foxo transcription factors control regulatory T cell development and function. Immunity \u003cem\u003e33\u003c/em\u003e, 890\u0026ndash;904. 10.1016/j.immuni.2010.12.002.\u003c/li\u003e\n\u003cli\u003eHansen, W., Loser, K., Westendorf, A.M., Bruder, D., Pfoertner, S., Siewert, C., Huehn, J., Beissert, S., and Buer, J. (2006). G protein-coupled receptor 83 overexpression in naive CD4+CD25- T cells leads to the induction of Foxp3+ regulatory T cells in vivo. J Immunol \u003cem\u003e177\u003c/em\u003e, 209\u0026ndash;215. 10.4049/jimmunol.177.1.209.\u003c/li\u003e\n\u003cli\u003eSharma, M.D., Huang, L., Choi, J.H., Lee, E.J., Wilson, J.M., Lemos, H., Pan, F., Blazar, B.R., Pardoll, D.M., Mellor, A.L., et al. (2013). An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity \u003cem\u003e38\u003c/em\u003e, 998\u0026ndash;1012. 10.1016/j.immuni.2013.01.013.\u003c/li\u003e\n\u003cli\u003eYadav, M., Louvet, C., Davini, D., Gardner, J.M., Martinez-Llordella, M., Bailey-Bucktrout, S., Anthony, B.A., Sverdrup, F.M., Head, R., Kuster, D.J., et al. (2012). Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med \u003cem\u003e209\u003c/em\u003e, 1713\u0026ndash;1722, S1711\u0026ndash;1719. 10.1084/jem.20120822.\u003c/li\u003e\n\u003cli\u003eFantin, R.F., Yuan, M., Park, S.C., Bozarth, B., Cohn, H., Ignacio, M., Earl, P., Civljak, A., Laghlali, G., Zhang, D., et al. (2025). Human monoclonal antibodies targeting A35 protect from death caused by mpox. Cell. 10.1016/j.cell.2025.08.004.\u003c/li\u003e\n\u003cli\u003eJesus, D.M., Costa, L.T., Goncalves, D.L., Achete, C.A., Attias, M., Moussatche, N., and Damaso, C.R. (2009). Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. J Virol \u003cem\u003e83\u003c/em\u003e, 11477\u0026ndash;11490. 10.1128/JVI.01061-09.\u003c/li\u003e\n\u003cli\u003eMagee, W.C., Hostetler, K.Y., and Evans, D.H. (2005). Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother \u003cem\u003e49\u003c/em\u003e, 3153\u0026ndash;3162. 10.1128/AAC.49.8.3153-3162.2005.\u003c/li\u003e\n\u003cli\u003eSei, J.J., Haskett, S., Kaminsky, L.W., Lin, E., Truckenmiller, M.E., Bellone, C.J., Buller, R.M., and Norbury, C.C. (2015). Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or Activation. PLoS Pathog \u003cem\u003e11\u003c/em\u003e, e1004941. 10.1371/journal.ppat.1004941.\u003c/li\u003e\n\u003cli\u003eWeil, R., and Israel, A. (2006). Deciphering the pathway from the TCR to NF-kappaB. Cell Death Differ \u003cem\u003e13\u003c/em\u003e, 826\u0026ndash;833. 10.1038/sj.cdd.4401856.\u003c/li\u003e\n\u003cli\u003eOdagiu, L., Boulet, S., Maurice De Sousa, D., Daudelin, J.F., Nicolas, S., and Labrecque, N. (2020). Early programming of CD8(+) T cell response by the orphan nuclear receptor NR4A3. Proc Natl Acad Sci U S A \u003cem\u003e117\u003c/em\u003e, 24392\u0026ndash;24402. 10.1073/pnas.2007224117.\u003c/li\u003e\n\u003cli\u003eLi, S., Miao, T., Sebastian, M., Bhullar, P., Ghaffari, E., Liu, M., Symonds, A.L., and Wang, P. (2012). The transcription factors Egr2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells. Immunity \u003cem\u003e37\u003c/em\u003e, 685\u0026ndash;696. 10.1016/j.immuni.2012.08.001.\u003c/li\u003e\n\u003cli\u003eGamper, C.J., Agoston, A.T., Nelson, W.G., and Powell, J.D. (2009). Identification of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 differentiation. J Immunol \u003cem\u003e183\u003c/em\u003e, 2267\u0026ndash;2276. 10.4049/jimmunol.0802960.\u003c/li\u003e\n\u003cli\u003eDeGrendele, H.C., Kosfiszer, M., Estess, P., and Siegelman, M.H. (1997). CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J Immunol \u003cem\u003e159\u003c/em\u003e, 2549\u0026ndash;2553.\u003c/li\u003e\n\u003cli\u003eBrehm, M.A., Daniels, K.A., and Welsh, R.M. (2005). Rapid production of TNF-alpha following TCR engagement of naive CD8 T cells. J Immunol \u003cem\u003e175\u003c/em\u003e, 5043\u0026ndash;5049. 10.4049/jimmunol.175.8.5043.\u003c/li\u003e\n\u003cli\u003eSenda, Y., Murata-Kamiya, N., and Hatakeyama, M. (2016). C-terminal Src kinase-mediated EPIYA phosphorylation of Pragmin creates a feed-forward C-terminal Src kinase activation loop that promotes cell motility. Cancer Sci \u003cem\u003e107\u003c/em\u003e, 972\u0026ndash;980. 10.1111/cas.12962.\u003c/li\u003e\n\u003cli\u003eYu, F.X., Lin, S.C., Morrison-Bogorad, M., Atkinson, M.A., and Yin, H.L. (1993). Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J Biol Chem \u003cem\u003e268\u003c/em\u003e, 502\u0026ndash;509.\u003c/li\u003e\n\u003cli\u003eGadina, M., Sudarshan, C., Visconti, R., Zhou, Y.J., Gu, H., Neel, B.G., and O\u0026apos;Shea, J.J. (2000). The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. J Biol Chem \u003cem\u003e275\u003c/em\u003e, 26959\u0026ndash;26966. 10.1074/jbc.M004021200.\u003c/li\u003e\n\u003cli\u003eHolmes, T.D., Pandey, R.V., Helm, E.Y., Schlums, H., Han, H., Campbell, T.M., Drashansky, T.T., Chiang, S., Wu, C.Y., Tao, C., et al. (2021). The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. Sci Immunol \u003cem\u003e6\u003c/em\u003e. 10.1126/sciimmunol.abc9801.\u003c/li\u003e\n\u003cli\u003eHeld, W., Clevers, H., and Grosschedl, R. (2003). Redundant functions of TCF-1 and LEF-1 during T and NK cell development, but unique role of TCF-1 for Ly49 NK cell receptor acquisition. Eur J Immunol \u003cem\u003e33\u003c/em\u003e, 1393\u0026ndash;1398. 10.1002/eji.200323840.\u003c/li\u003e\n\u003cli\u003eAlmeida, J.S., Casanova, J.M., Santos-Rosa, M., Tarazona, R., Solana, R., and Rodrigues-Santos, P. (2023). Natural Killer T-like Cells: Immunobiology and Role in Disease. Int J Mol Sci \u003cem\u003e24\u003c/em\u003e. 10.3390/ijms24032743.\u003c/li\u003e\n\u003cli\u003eNgai, H., Barragan, G.A., Tian, G., Balzeau, J.C., Zhang, C., Courtney, A.N., Guo, L., Xu, X., Wood, M.S., Drabek, J.M., et al. (2023). LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells. Cancer Immunol Res \u003cem\u003e11\u003c/em\u003e, 171\u0026ndash;183. 10.1158/2326-6066.CIR-22-0333.\u003c/li\u003e\n\u003cli\u003eIchijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Takagi, M., Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997). Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science \u003cem\u003e275\u003c/em\u003e, 90\u0026ndash;94. 10.1126/science.275.5296.90.\u003c/li\u003e\n\u003cli\u003ePark, K.C., Lee, D.C., and Yeom, Y.I. (2015). NDRG3-mediated lactate signaling in hypoxia. BMB Rep \u003cem\u003e48\u003c/em\u003e, 301\u0026ndash;302. 10.5483/bmbrep.2015.48.6.080.\u003c/li\u003e\n\u003cli\u003ePaniagua, G., Jacob, H.K.C., Brehey, O., Garcia-Alonso, S., Lechuga, C.G., Pons, T., Musteanu, M., Guerra, C., Drosten, M., and Barbacid, M. (2022). KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. Mol Oncol \u003cem\u003e16\u003c/em\u003e, 3066\u0026ndash;3081. 10.1002/1878-0261.13213.\u003c/li\u003e\n\u003cli\u003eLo, J.Y., Chou, Y.T., Lai, F.J., and Hsu, L.J. (2015). Regulation of cell signaling and apoptosis by tumor suppressor WWOX. Exp Biol Med (Maywood) \u003cem\u003e240\u003c/em\u003e, 383\u0026ndash;391. 10.1177/1535370214566747.\u003c/li\u003e\n\u003cli\u003eSombroek, D., and Hofmann, T.G. (2009). How cells switch HIPK2 on and off. Cell Death Differ \u003cem\u003e16\u003c/em\u003e, 187\u0026ndash;194. 10.1038/cdd.2008.154.\u003c/li\u003e\n\u003cli\u003eStuchell, M.D., Garrus, J.E., Muller, B., Stray, K.M., Ghaffarian, S., McKinnon, R., Krausslich, H.G., Morham, S.G., and Sundquist, W.I. (2004). The human endosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1 budding. J Biol Chem \u003cem\u003e279\u003c/em\u003e, 36059\u0026ndash;36071. 10.1074/jbc.M405226200.\u003c/li\u003e\n\u003cli\u003eMatza, D., Badou, A., Kobayashi, K.S., Goldsmith-Pestana, K., Masuda, Y., Komuro, A., McMahon-Pratt, D., Marchesi, V.T., and Flavell, R.A. (2008). A scaffold protein, AHNAK1, is required for calcium signaling during T cell activation. Immunity \u003cem\u003e28\u003c/em\u003e, 64\u0026ndash;74. 10.1016/j.immuni.2007.11.020.\u003c/li\u003e\n\u003cli\u003eMorley, S.C. (2012). The actin-bundling protein L-plastin: a critical regulator of immune cell function. Int J Cell Biol \u003cem\u003e2012\u003c/em\u003e, 935173. 10.1155/2012/935173.\u003c/li\u003e\n\u003cli\u003eDelano, M.L., and Brownstein, D.G. (1995). Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J Virol \u003cem\u003e69\u003c/em\u003e, 5875\u0026ndash;5877. 10.1128/JVI.69.9.5875-5877.1995.\u003c/li\u003e\n\u003cli\u003eFang, M., Orr, M.T., Spee, P., Egebjerg, T., Lanier, L.L., and Sigal, L.J. (2011). CD94 is essential for NK cell-mediated resistance to a lethal viral disease. Immunity \u003cem\u003e34\u003c/em\u003e, 579\u0026ndash;589. 10.1016/j.immuni.2011.02.015.\u003c/li\u003e\n\u003cli\u003eMelo-Silva, C.R., Tscharke, D.C., Lobigs, M., Koskinen, A., Wong, Y.C., Buller, R.M., Mullbacher, A., and Regner, M. (2011). The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responses. J Virol \u003cem\u003e85\u003c/em\u003e, 11170\u0026ndash;11182. 10.1128/JVI.00256-11.\u003c/li\u003e\n\u003cli\u003eChaudhri, G., Panchanathan, V., Buller, R.M., van den Eertwegh, A.J., Claassen, E., Zhou, J., de Chazal, R., Laman, J.D., and Karupiah, G. (2004). Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci U S A \u003cem\u003e101\u003c/em\u003e, 9057\u0026ndash;9062. 10.1073/pnas.0402949101.\u003c/li\u003e\n\u003cli\u003eChan, M., Audet, J., Prevost, J., Soriano, K., Doan, K., Garnett, L., Deschambault, Y., Medina, S., Stefopulos, M., Paul, J., et al. (2025). Molecular detection and isolation of clade Ib monkeypox virus, Canada, November 2024. Euro Surveill \u003cem\u003e30\u003c/em\u003e. 10.2807/1560-7917.ES.2025.30.25.2500402.\u003c/li\u003e\n\u003cli\u003eKoukouikila-Koussounda, F., Yinda, C.K., Mayengue, P.I., Elenga, R.G., Boussam, D.A.E., Indolo, G.D., Macosso, L.N., Munster, V.J., and Niama, F.R. (2025). Introduction of Mpox Virus Clade Ib into the Republic of the Congo. N Engl J Med \u003cem\u003e393\u003c/em\u003e, 1135\u0026ndash;1137. 10.1056/NEJMc2504089.\u003c/li\u003e\n\u003cli\u003eLaurenson-Schafer, H., Sklenovska, N., Hoxha, A., Kerr, S.M., Ndumbi, P., Fitzner, J., Almiron, M., de Sousa, L.A., Briand, S., Cenciarelli, O., et al. (2023). Description of the first global outbreak of mpox: an analysis of global surveillance data. Lancet Glob Health \u003cem\u003e11\u003c/em\u003e, e1012\u0026ndash;e1023. 10.1016/S2214-109X(23)00198-5.\u003c/li\u003e\n\u003cli\u003eBeiras, C.G., Malembi, E., Escrig-Sarreta, R., Ahuka, S., Mbala, P., Mavoko, H.M., Subissi, L., Abecasis, A.B., Marks, M., and Mitja, O. (2025). Concurrent outbreaks of mpox in Africa-an update. Lancet \u003cem\u003e405\u003c/em\u003e, 86\u0026ndash;96. 10.1016/S0140-6736(24)02353-5.\u003c/li\u003e\n\u003cli\u003eMitja, O., Watson-Jones, D., Choi, E.M., Jalloh, M.B., and Sahr, F. (2025). Clade IIb mpox outbreak in Sierra Leone. Lancet \u003cem\u003e405\u003c/em\u003e, 2274\u0026ndash;2275. 10.1016/S0140-6736(25)01203-6.\u003c/li\u003e\n\u003cli\u003eSun, J., Zhou, L., Wu, B., Chen, Z., He, Y., Wang, X., Lu, J., Li, D., Zhao, L., Guo, X., et al. (2025). Characteristics of the first confirmed case of human infection with mpox virus clade Ib in China. Nat Commun \u003cem\u003e16\u003c/em\u003e, 4888. 10.1038/s41467-025-60217-2.\u003c/li\u003e\n\u003cli\u003eJohnston, J.B., and McFadden, G. (2003). Poxvirus immunomodulatory strategies: current perspectives. J Virol \u003cem\u003e77\u003c/em\u003e, 6093\u0026ndash;6100. 10.1128/jvi.77.11.6093-6100.2003.\u003c/li\u003e\n\u003cli\u003eLodoen, M., Ogasawara, K., Hamerman, J.A., Arase, H., Houchins, J.P., Mocarski, E.S., and Lanier, L.L. (2003). NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med \u003cem\u003e197\u003c/em\u003e, 1245\u0026ndash;1253. 10.1084/jem.20021973.\u003c/li\u003e\n\u003cli\u003eCampbell, J.A., Trossman, D.S., Yokoyama, W.M., and Carayannopoulos, L.N. (2007). Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D. J Exp Med \u003cem\u003e204\u003c/em\u003e, 1311\u0026ndash;1317. 10.1084/jem.20062026.\u003c/li\u003e\n\u003cli\u003eAlzhanova, D., Edwards, D.M., Hammarlund, E., Scholz, I.G., Horst, D., Wagner, M.J., Upton, C., Wiertz, E.J., Slifka, M.K., and Fruh, K. (2009). Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition. Cell Host Microbe \u003cem\u003e6\u003c/em\u003e, 433\u0026ndash;445. 10.1016/j.chom.2009.09.013.\u003c/li\u003e\n\u003cli\u003eChiang, S.C., Theorell, J., Entesarian, M., Meeths, M., Mastafa, M., Al-Herz, W., Frisk, P., Gilmour, K.C., Ifversen, M., Langenskiold, C., et al. (2013). Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. Blood \u003cem\u003e121\u003c/em\u003e, 1345\u0026ndash;1356. 10.1182/blood-2012-07-442558.\u003c/li\u003e\n\u003cli\u003eDustin, M.L., and Long, E.O. (2010). Cytotoxic immunological synapses. Immunol Rev \u003cem\u003e235\u003c/em\u003e, 24\u0026ndash;34. 10.1111/j.0105-2896.2010.00904.x.\u003c/li\u003e\n\u003cli\u003eKabanova, A., Zurli, V., and Baldari, C.T. (2018). Signals Controlling Lytic Granule Polarization at the Cytotoxic Immune Synapse. Front Immunol \u003cem\u003e9\u003c/em\u003e, 307. 10.3389/fimmu.2018.00307.\u003c/li\u003e\n\u003cli\u003eHenrickson, S.E., Perro, M., Loughhead, S.M., Senman, B., Stutte, S., Quigley, M., Alexe, G., Iannacone, M., Flynn, M.P., Omid, S., et al. (2013). Antigen availability determines CD8(+) T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity \u003cem\u003e39\u003c/em\u003e, 496\u0026ndash;507. 10.1016/j.immuni.2013.08.034.\u003c/li\u003e\n\u003cli\u003eMiller, M.J., Safrina, O., Parker, I., and Cahalan, M.D. (2004). Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J Exp Med \u003cem\u003e200\u003c/em\u003e, 847\u0026ndash;856. 10.1084/jem.20041236.\u003c/li\u003e\n\u003cli\u003eHuppa, J.B., Gleimer, M., Sumen, C., and Davis, M.M. (2003). Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol \u003cem\u003e4\u003c/em\u003e, 749\u0026ndash;755. 10.1038/ni951.\u003c/li\u003e\n\u003cli\u003eUeda, H., Morphew, M.K., McIntosh, J.R., and Davis, M.M. (2011). CD4+ T-cell synapses involve multiple distinct stages. Proc Natl Acad Sci U S A \u003cem\u003e108\u003c/em\u003e, 17099\u0026ndash;17104. 10.1073/pnas.1113703108.\u003c/li\u003e\n\u003cli\u003eOrtega-Carrion, A., and Vicente-Manzanares, M. (2016). Concerning immune synapses: a spatiotemporal timeline. F1000Res \u003cem\u003e5\u003c/em\u003e. 10.12688/f1000research.7796.1.\u003c/li\u003e\n\u003cli\u003eGu, H., and Neel, B.G. (2003). The \u0026quot;Gab\u0026quot; in signal transduction. Trends Cell Biol \u003cem\u003e13\u003c/em\u003e, 122\u0026ndash;130. 10.1016/s0962-8924(03)00002-3.\u003c/li\u003e\n\u003cli\u003eZompi, S., Gu, H., and Colucci, F. (2004). The absence of Grb2-associated binder 2 (Gab2) does not disrupt NK cell development and functions. J Leukoc Biol \u003cem\u003e76\u003c/em\u003e, 896\u0026ndash;903. 10.1189/jlb.0304179.\u003c/li\u003e\n\u003cli\u003eUpshaw, J.L., Arneson, L.N., Schoon, R.A., Dick, C.J., Billadeau, D.D., and Leibson, P.J. (2006). NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol \u003cem\u003e7\u003c/em\u003e, 524\u0026ndash;532. 10.1038/ni1325.\u003c/li\u003e\n\u003cli\u003eNiu, C., Li, M., Chen, Y., Zhang, X., Zhu, S., Zhou, X., Zhou, L., Li, Z., Xu, J., Hu, J.F., et al. (2022). LncRNA NCAL1 potentiates natural killer cell cytotoxicity through the Gab2-PI3K-AKT pathway. Front Immunol \u003cem\u003e13\u003c/em\u003e, 970195. 10.3389/fimmu.2022.970195.\u003c/li\u003e\n\u003cli\u003eMaul-Pavicic, A., Chiang, S.C., Rensing-Ehl, A., Jessen, B., Fauriat, C., Wood, S.M., Sjoqvist, S., Hufnagel, M., Schulze, I., Bass, T., et al. (2011). ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc Natl Acad Sci U S A \u003cem\u003e108\u003c/em\u003e, 3324\u0026ndash;3329. 10.1073/pnas.1013285108.\u003c/li\u003e\n\u003cli\u003eJanji, B., Giganti, A., De Corte, V., Catillon, M., Bruyneel, E., Lentz, D., Plastino, J., Gettemans, J., and Friederich, E. (2006). Phosphorylation on Ser5 increases the F-actin-binding activity of L-plastin and promotes its targeting to sites of actin assembly in cells. J Cell Sci \u003cem\u003e119\u003c/em\u003e, 1947\u0026ndash;1960. 10.1242/jcs.02874.\u003c/li\u003e\n\u003cli\u003eWang, C., Morley, S.C., Donermeyer, D., Peng, I., Lee, W.P., Devoss, J., Danilenko, D.M., Lin, Z., Zhang, J., Zhou, J., et al. (2010). Actin-bundling protein L-plastin regulates T cell activation. J Immunol \u003cem\u003e185\u003c/em\u003e, 7487\u0026ndash;7497. 10.4049/jimmunol.1001424.\u003c/li\u003e\n\u003cli\u003eWabnitz, G.H., Kocher, T., Lohneis, P., Stober, C., Konstandin, M.H., Funk, B., Sester, U., Wilm, M., Klemke, M., and Samstag, Y. (2007). Costimulation induced phosphorylation of L-plastin facilitates surface transport of the T cell activation molecules CD69 and CD25. Eur J Immunol \u003cem\u003e37\u003c/em\u003e, 649\u0026ndash;662. 10.1002/eji.200636320.\u003c/li\u003e\n\u003cli\u003eSanderson, S., and Shastri, N. (1994). LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol \u003cem\u003e6\u003c/em\u003e, 369\u0026ndash;376. 10.1093/intimm/6.3.369.\u003c/li\u003e\n\u003cli\u003eMiller, M.A., Ganesan, A.P., Luckashenak, N., Mendonca, M., and Eisenlohr, L.C. (2015). Endogenous antigen processing drives the primary CD4+ T cell response to influenza. Nat Med \u003cem\u003e21\u003c/em\u003e, 1216\u0026ndash;1222. 10.1038/nm.3958.\u003c/li\u003e\n\u003cli\u003eRobinson, J.T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G., and Mesirov, J.P. (2011). Integrative genomics viewer. Nat Biotechnol \u003cem\u003e29\u003c/em\u003e, 24\u0026ndash;26. 10.1038/nbt.1754.\u003c/li\u003e\n\u003cli\u003eHogan, M.J., Maheshwari, N., Begg, B.E., Nicastri, A., Hedgepeth, E.J., Muramatsu, H., Pardi, N., Miller, M.A., Reilly, S.P., Brossay, L., et al. (2023). Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response. Nat Immunol \u003cem\u003e24\u003c/em\u003e, 1933\u0026ndash;1946. 10.1038/s41590-023-01644-5.\u003c/li\u003e\n\u003cli\u003eForsyth, K.S., DeHaven, B., Mendonca, M., Paul, S., Sette, A., and Eisenlohr, L.C. (2019). Poor Antigen Processing of Poxvirus Particles Limits CD4(+) T Cell Recognition and Impacts Immunogenicity of the Inactivated Vaccine. J Immunol \u003cem\u003e202\u003c/em\u003e, 1340\u0026ndash;1349. 10.4049/jimmunol.1801099.\u003c/li\u003e\n\u003cli\u003eAunins, E.A., Phan, A.T., Alameh, M.G., Dwivedi, G., Cruz-Morales, E., Christian, D.A., Tam, Y., Bunkofske, M.E., Penafiel, A.Z., O\u0026apos;Dea, K.M., et al. (2025). An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses. Sci Immunol \u003cem\u003e10\u003c/em\u003e, eads1328. 10.1126/sciimmunol.ads1328.\u003c/li\u003e\n\u003cli\u003eBaiersdorfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., and Kariko, K. (2019). A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. Mol Ther Nucleic Acids \u003cem\u003e15\u003c/em\u003e, 26\u0026ndash;35. 10.1016/j.omtn.2019.02.018.\u003c/li\u003e\n\u003cli\u003ePardi, N., Muramatsu, H., Weissman, D., and Kariko, K. (2013). In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol \u003cem\u003e969\u003c/em\u003e, 29\u0026ndash;42. 10.1007/978-1-62703-260-5_2.\u003c/li\u003e\n\u003cli\u003eSmith, T., Heger, A., and Sudbery, I. (2017). UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res \u003cem\u003e27\u003c/em\u003e, 491\u0026ndash;499. 10.1101/gr.209601.116.\u003c/li\u003e\n\u003cli\u003eDobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics \u003cem\u003e29\u003c/em\u003e, 15\u0026ndash;21. 10.1093/bioinformatics/bts635.\u003c/li\u003e\n\u003cli\u003eLiao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics \u003cem\u003e30\u003c/em\u003e, 923\u0026ndash;930. 10.1093/bioinformatics/btt656.\u003c/li\u003e\n\u003cli\u003eLove, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol \u003cem\u003e15\u003c/em\u003e, 550. 10.1186/s13059-014-0550-8.\u003c/li\u003e\n\u003cli\u003eZhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun \u003cem\u003e10\u003c/em\u003e, 1523. 10.1038/s41467-019-09234-6.\u003c/li\u003e\n\u003cli\u003eSubramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A \u003cem\u003e102\u003c/em\u003e, 15545\u0026ndash;15550. 10.1073/pnas.0506580102.\u003c/li\u003e\n\u003cli\u003eKorsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods \u003cem\u003e16\u003c/em\u003e, 1289\u0026ndash;1296. 10.1038/s41592-019-0619-0.\u003c/li\u003e\n\u003cli\u003eTraag, V.A., Waltman, L., and van Eck, N.J. (2019). From Louvain to Leiden: guaranteeing well-connected communities. Sci Rep \u003cem\u003e9\u003c/em\u003e, 5233. 10.1038/s41598-019-41695-z.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-8672980/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8672980/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eOrthopoxviruses, including variola and monkeypox, have long ravaged human populations for reasons that remain unclear. Members of the highly conserved B22 protein family are notable for their extreme virulence via targeting of multiple host defenses. C15, the B22 protein of ectromelia (murine model for smallpox), is known to target NK cells and CD4+ T cells, and, as shown here, also CD8+ T cells. Unexpectedly, in C57Bl/6 mice, T cell responses were larger, more functional, and phenotypically enhanced in the face of C15 expression. cDC1-mediated cross-presentation contributed to enhanced CD8+ T cell responses, but the primary contributor was C15-mediated antagonism of NK cell-dependent viral control, and single cell analysis identified a potential signaling scaffold downstream of C15 inhibitory activity. Conversely, in BALB/c mice, which mount suboptimal NK cell responses, T cells were more prominently inhibited. These studies introduce the concept of conditional immunomodulation dictated by the immunocompetence profile of the host.\u003c/p\u003e","manuscriptTitle":"Conditional T and NK cell antagonism by a giant and highly conserved orthopoxvirus virulence factor","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-02-04 05:31:25","doi":"10.21203/rs.3.rs-8672980/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"a9775ac3-dd84-4373-80c6-c983abb6bb37","owner":[],"postedDate":"February 4th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":62199663,"name":"Biological sciences/Microbiology/Virology/Pox virus"},{"id":62199664,"name":"Biological sciences/Immunology/Infectious diseases/Viral infection"},{"id":62199665,"name":"Biological sciences/Immunology/Adaptive immunity/Cellular immunity"},{"id":62199666,"name":"Biological sciences/Immunology/Lymphocytes/NK cells"}],"tags":[],"updatedAt":"2026-04-17T09:28:42+00:00","versionOfRecord":[],"versionCreatedAt":"2026-02-04 05:31:25","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8672980","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8672980","identity":"rs-8672980","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}